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13general introduction
general inTrOduCTiOn
Knowledge about the benefit-risk profile of a drug is limited at the time of drug approval and grows 
over time when the drug is increasingly used in routine daily practice. After drug approval the drug 
is used within a broader and more heterogeneous population with more comorbidities, for a longer 
period of time and under less controlled circumstances compared with the use during premarketing 
clinical trials.1 The dynamics of the benefits and the risks of a drug require a life cycle approach in which 
the benefit-risk balance is continuously evaluated.2 Proactive pharmacovigilance is part of the life cycle 
approach and is aimed at early detection and minimisation of risks.3 The World Health Organisation 
(WHO) defines pharmacovigilance as the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other possible drug-related problems.4 The 
responsible regulatory authorities at European and Dutch level are the European Medicines Agency 
(EMA) and the Dutch Medicines Evaluation Board (CBG-MEB), the Netherlands Pharmacovigilance 
Centre (LAREB) and the Dutch Health Care Inspectorate (IGZ).
Risk minimisation measures
Risk minimisation measures (RMMs) are interventions that aim to optimise the benefit-risk balance of 
a drug by minimising its risks during drug use in clinical practice. These measures intend to prevent 
or reduce the occurrence or the severity of adverse drug reactions (ADRs).5 An adverse drug reaction 
(ADR) is a response to a drug which is noxious and unintended.6 This includes events that arise from 
drug use within the terms of the marketing authorisation but also the use outside the terms of the 
marketing authorisation, including overdose, off-label use, misuse, abuse and medication errors. ADRs 
can be serious and result in hospitalisation, disablement or even death.7, 8
RMMs include conditions and restrictions to the drug use in clinical practice to enhance the safe and 
effective use of a drug. RMMs may be targeted at drug prescription, drug dispensing at the pharmacy 
as well as preparation and administration of the drug. In addition, RMMs may aim appropriate selection 
of patients to be treated, appropriate use of the drug by the patient or periodic patient monitoring 
or examination (e.g. liver function monitoring or electrocardiogram) to early recognise or detect an 
ADR to timely manage and resolve the event. RMMs are agreed between the marketing authorisation 
holder (MAH) and regulatory authorities at time of drug registration and may change during the life 
cycle of the drug for instance when new safety issues emerge. In Europe generally two types of risk 
minimisation measures can be distinguished, i.e. routine risk minimisation measures and additional risk 
minimisation measures (aRMMs). Routine RMMs are required for all drugs and include the Summary of 
Product Characteristics (SmPC), the patient information leaflet (PIL), the labelling (packaging), the pack 
size and the legal (prescription) status of a drug.5 Routine RMMs are usually sufficient; however, some 
drugs carry serious risks requiring an extra level of risk minimisation, i.e. aRMMs. Examples of aRMMs 
include educational tools for HCPs or patients, a patient alert card, a pregnancy prevention programme 
or other controlled access programmes. Controlled access programmes refer to requirements that 
need to be fulfilled before a drug can be prescribed or dispensed, e.g. specific tests or examinations 
of the patient, inclusion of the patient in a registry or an informed consent in which the HCP or patient 
confirms to be aware of certain serious risks and recommendations for use.5 Examples of drugs with 
aRMMs in the European Union (EU) are provided in Table 1.
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Dabigatran
Infliximab
Lomitapide
Insulin degludec 200 
units/ml
Bosentan
Table 1: Examples of drugs with aRMMs licensed in the EU
Active substance Therapeutic area Description of the aRMMs Risks addressed with 
aRMMs
Anticoagulation
Rheumatoid arthritis
Hypercholesterolemia
Diabetes Mellitus
Pulmonary arterial 
hypertension
Educational programme for 
HCPs; Patient alert card;
Educational programme 
for HCPs; Pre-treatment 
tuberculosis testing;
Educational programme for 
HCPs and patients; Patient 
should be included in a 
registry; Intensive liver function 
screening;
DHPC; Patient brochure; 
Poster for in pharmacy;
Educational programme for 
HCPs and patients; Patient alert 
card; Regular blood test;
Increased risk of bleeding
Reactivation of 
tuberculosis; Opportunistic 
infections
Appropriate patient 
selection; Tolerability and 
gastrointestinal effects; 
Liver toxicity; 
Potential teratogenic 
effects
Higher strength available 
with potential medication 
error 
Hepatotoxicity; 
Potential teratogenic; 
Decrease in haemoglobin
aRMM=additional risk minimisation measures; DHPC=Direct Healthcare Professional Communication; EU=European 
Union; HCPs=healthcare professionals 
Chapter 1
In the United States (US) different legal bases are in place but measures comparable to aRMMs in 
the EU can be required to minimise drug related risks. On a case-by-case basis the Food and Drug 
Administration (FDA) requires risk evaluation and mitigation strategies (REMS) as part of the marketing 
authorisation in the US.9 REMS can consist a Medication Guide, a Communication Plan, Elements To 
Assure Safe Use (ETASU), an Implementation System and a Timetable for Submission of Assessments.10 
Risk management plan
In the EU the risk management approach, as part of proactive pharmacovigilance, started with the 
introduction of the risk management plan (RMP) in 2005. A RMP is an instrument for the planning of 
pharmacovigilance activities and risk minimisation measures.11 It allows regulators to specify conditions 
and restrictions necessary for safe and effective use of the drug in clinical practice, i.e., aRMMs, a 
possibility that did not exist earlier. For all new active substances approved after 2005 a RMP is in place 
and the need for aRMMs has been assessed. This has been done on a case-by-case basis, meaning 
that every single drug is assessed individually and aRMMs can be adapted to drug specific risks and 
to the context of drug use. Since aRMMs can be required during the entire life cycle of a drug, these 
additional measures can also be required for drugs that are already on the market. 
The risk management approach has become more prominently embedded in the EU Pharmacovigilance 
legislation operational since July 2012.6, 12 New regulatory guidelines on the RMP and risk minimisation 
measures were developed.5, 13 Once a drug requires aRMMs, the MAH and regulatory authorities agree 
on the general key elements of the aRMMs. These often are ‘Conditions and restrictions with regard 
to the safe and effective use of the medicinal product’ to be implemented by the MAH and valid in 
all EU member states. Since there can be variation across countries in national legislation, healthcare 
systems, daily routine care, language and patients’ attitudes, the actual implementation of aRMMs 
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usually occurs at national level with some flexibility to adapt the aRMMs to the local situation. The 
most important stakeholders in the development and use of aRMMs in clinical practice are described 
in Table 2. 
aRMMs=additional risk minimisation measures; HCPs=healthcare professionals; MAH=marketing authorisation holder
Table 2: Stakeholders of additional risk minimisation measures
Pharmaceutical industry 
Regulators
Healthcare professionals
Patients
The MAH of a drug is responsible for the development of the final aRMMs. The aRMMs 
need to be developed based on pre-defined key elements of aRMMs and agreed 
with regulatory authorities. The MAH is also responsible for the implementation and 
monitoring of the aRMMs in clinical practice following the agreed schedule.
As part of the continuous evaluation of the benefit-risk balance of a drug, regulatory 
authorities assess the need for aRMMs. If needed, key elements of the aRMMs are 
drafted which need to be translated to final aRMMs by the MAHs.
These can include physicians, pharmacists and other healthcare providers such as 
nurses. These stakeholders need to work with the aRMMs in daily practice. HCPs can be 
consulted within the assessment of aRMMs.
The patients should benefit from the implemented aRMMs by safe and effective use of 
the drug in clinical practice. 
Pregnancy prevention programme
For highly teratogenic drugs such as isotretinoin and thalidomide a pregnancy prevention programme 
(PPP) can be required.14, 15 Teratogenicity is a serious risk because use of teratogenic drugs shortly before 
or during pregnancy can lead to spontaneous abortion or birth defects.16 Women of reproductive age 
who start using these drugs should therefore not be and not become pregnant during their treatment. 
Teratogenic drugs should only be prescribed, dispensed and used according to the conditions of the 
PPP. Among others, these conditions can include educational tools for HCPs and patients about the 
teratogenic risks and recommendations for safe drug use, concomitant use of contraceptive measures 
and exclusion of pregnancy with pregnancy tests before and during treatment on a monthly basis. 
Limited compliance to the PPP may result in spontaneous and elective abortions and more importantly 
children with major congenital anomalies. Previous studies showed that in the Netherlands just between 
52% and 59% of the female isotretinoin users with reproductive age used hormonal contraceptives.17, 
18 Furthermore, isotretinoin-exposed pregnancies do still occur in several Western countries.19, 20 This 
emphasizes the ongoing need to evaluate the implementation and compliance to the conditions of 
the PPP, to identify deficiencies and adapt these measures when considered necessary.
Need to measure effectiveness of risk minimisation measures
Monitoring the outcome of RMMs has become mandatory with the EU Pharmacovigilance legislation 
effective since July 2012.6, 12 Besides the planning and implementation of RMMs, the assessment of 
their effectiveness is a key element of proactive pharmacovigilance and risk management during the 
life cycle of a drug. Knowledge on how the drug is used in clinical practice and the effects of possible 
changes in drug use is necessary to evaluate the effectiveness of aRMMs. Several issues limiting the 
implementation and effectiveness of aRMMs in clinical practice can be identified, requiring adjustment 
of the implementation or the type of aRMM itself. Furthermore, ineffective measures should not 
unnecessary burden the health system and should be avoided. The effectiveness of aRMMs might 
differ across types of aRMM and countries and may also vary among different patient populations. 
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Additionally, knowledge about successes and failures of aRMMs in specific situations can be helpful for 
regulators and MAHs to improve effective risk minimisation measures. In the future it might be possible 
to use these ‘best practices’ as a reference. Little is known about the implementation and effectiveness 
of aRMMs nor about the data sources that can be used to measure the effectiveness of aRMMs. Both 
in the US and the EU some regulatory guidance has become available but this is restricted to very high 
level recommendations.5, 10 This points to a substantial need to explore possibilities and challenges of 
methods that can be used to measure the effectiveness of risk minimisation measures. 
Pharmacoepidemiology has been defined as the study of the use and the effects of drugs in 
large numbers of people which uses the methods of epidemiology to study the content area of 
clinical pharmacology.21 Often this is done post-licensing in observational settings. While drug 
utilisation research can provide information on the pattern of drug use over time, across countries, 
subpopulations and under which conditions the drug is prescribed or dispensed, formal pharmacoepi-
demiology studies have to be conducted to evaluate the actual minimisation of the risk (e.g. using 
incidence rates, relative risks, odds ratios). It is known that electronic healthcare databases present 
opportunities to investigate associations between drugs and adverse events as well as to evaluate drug 
utilisation patterns.22, 23 These data sources can contain routinely collected longitudinal data of large 
patient populations representing actual care including data on clinical diagnosis, test results, drug 
prescriptions or dispensing and referral data.24 Examples of databases that can be used to evaluate 
the use and effects of drugs in clinical practice include primary care medical records, administrative 
(claim) databases or disease and drug registries. Considering the possible high utility of data available 
and the efficiency of conducting studies using these data sources, it is relevant to explore whether and 
how electronic healthcare databases can be used in the evaluation of effectiveness of risk minimisation 
measures.
Objectives of this thesis
The objective of this thesis is to get insight in the additional risk minimisation measures that are 
required in the EU and how the effectiveness of these measures can be evaluated. There is a specific 
focus on the risk minimisation measures of teratogenic drugs (i.e. pregnancy prevention programmes) 
and exposure to potentially teratogenic drugs in pregnant women. 
Outline of this thesis
The first part of the thesis focuses on the description of aRMMs and methods to evaluate the 
effectiveness of these measures. It starts with an overview of drugs approved for use by the EMA, 
the so called centrally authorised products. The aRMMs and the corresponding safety concerns of 
these drugs are presented in Chapter 2. After this inventory Chapter 3 describes which type of 
aRMMs can be assessed in electronic healthcare databases. With this, the actionable elements of the 
approved aRMMs as well as the feasibility of electronic healthcare databases in the evaluation of the 
effectiveness of aRMMs are explored. Chapter 4 describes the challenges of measuring effectiveness 
of aRMMs in a post-marketing setting. The possible methodologies involved and difficulties 
with the interpretation of results are also discussed. In addition, knowledge about evaluating the 
effectiveness of risk minimisation measures is acquired with a case study. In Chapter 5 the impact of 
the recommended dose restrictions for citalopram implemented in October 2011 to minimise the risk 
on prolonged QT interval during citalopram use is evaluated in two European countries. Two primary 
care databases are used; The Health Improvement Network (THIN) from the United Kingdom and the 
Dutch Interdisciplinary Processing of Clinical Information (IPCI). 
Chapter 1
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The second part of the thesis focuses on aRMMs regarding drug exposure during pregnancy. Pregnancy 
prevention programmes can be required for drugs with high teratogenic risks such as isotretinoin and 
thalidomide. In Chapter 6 the different pregnancy prevention programmes that are implemented in 
the EU are reviewed and compared. The implementation and success of the isotretinoin pregnancy 
prevention programme in the Netherlands are evaluated in Chapter 7. In this population-based study 
a linkage between the Netherlands Perinatal Registry (PRN) (Dutch birth registry) and the PHARMO 
Database Network of which the pharmacy dispensing data are used. Using the same cohort of Dutch 
pregnancies, Chapter 8 describes the dispensing of potentially teratogenic drugs in the 12-month 
period before conception or during pregnancy in the Netherlands between 1999 and 2007. 
Finally, a discussion on the main findings of this thesis, the lessons learned so far and future perspectives 
in the area of evaluation the effectiveness of aRMMs is presented in Chapter 9. 
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aBsTraCT
Background Since the new legislation on Risk Management, which came into force 
in November 2005, an EU Risk Management Plan (EU-RMP) is a required part of the 
authorisation dossier of innovative drugs licensed in the EU. The EU-RMP can include 
additional risk minimisation activities (RMAs) to strengthen the benefit-risk balance of a 
drug. This study describes the additional RMAs of centrally authorised medicinal products 
authorised between 1 January 1995 and 1 January 2010.
Methods The European Public Assessment Reports (EPARs) of all centrally authorised 
products were analysed to identify characteristics of the product (active substance, the 
authorisation date, Anatomical Therapeutic Chemical classification), the additional RMAs 
and the corresponding safety concerns (classified at Medical Dictionary for Regulatory 
Activities (MedDRA®) System Organ Class level). 
Results Additional RMAs were identified for 58 of the 391 active substances that were 
authorised as of 1 January 2010. The proportion of active substances with additional RMAs 
was 5% among those authorised before, and 29% among those approved after the new 
risk management legislation. Since the new legislation, blood products and anti-neoplastic 
and immunomodulating agents most often had additional RMAs. All active substances with 
additional RMAs required the provision of educational material, most frequently involving 
healthcare professionals (n=57) and the patient (n=31). Thirty-three active substances 
required additional RMAs on top of the provision of educational material, most frequently 
including patient monitoring and screening (n=19). 
Conclusions The proactive pharmacovigilance approach is evolving and the number 
of products with additional RMAs is growing since the introduction of the EU-RMP. The 
provision of educational material is the primary additional risk minimisation strategy in the 
EU. The effect of additional RMA implementation has to be explored.
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The knowledge of the full benefit-risk balance of a medicinal product is limited at the time of licensing 
and can change after approval. For this reason, this balance requires continuous reevaluation 
during the postmarketing phase when the product is used in clinical practice within a broader and 
more heterogeneous population compared with premarketing clinical trials.1 The dynamics of the 
benefit-risk balance necessitates a life cycle approach with continuous assessment and evaluation 
of the benefit-risk balance during the whole lifecycle.2 Proactive pharmacovigilance is part of the life 
cycle approach aimed at early detection and minimisation of risks, as stated in the strategic plans of 
European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA).3, 4 
According to the current EU legislation, in force since November 2005, Marketing Authorisation 
Applicants (MAAs) have to submit a detailed description of the risk management system as part of the 
application for drug licensing for innovative products.5, 6 For new chemical entities, biosimilar medicinal 
products and generics of substances for which a risk has been identified for the reference product, 
it is mandatory to submit an EU Risk Management Plan (EU-RMP).7 Furthermore, an EU-RMP can be 
requested by regulatory authorities. An EU-RMP consists of a set of pharmacovigilance activities and 
interventions that are designed to identify, characterise, prevent or minimise the risks during the life 
cycle of a drug.6 The EU-RMP aims to ensure that the benefits of a medicinal product exceed its risks 
to the largest possible extent, both at individual and population level.7 
For all medicinal products, an EU-RMP includes routine risk minimisation activities (RMA) aiming 
to reduce the probability or severity of adverse drug reactions (e.g. precautions in the Summary of 
Product Characteristics [SmPC]). Some medicinal products, however, may carry risks that require an 
extra level of risk minimisation, i.e. the additional RMAs. Examples of additional RMAs include the 
provision of educational material, implementation of a pregnancy prevention programme, or intensive 
monitoring of markers of potential harm, such as liver enzymes for the assessment of hepatic function.7 
Since 2007 the Food and Drug Administration Amendments Act authorised the FDA to require risk 
evaluation and mitigation strategies (REMS) as part of the authorisation documents in the US.3 An 
REMS can include the following elements: a Medication Guide, a Communication Plan, Elements To 
Assure Safe Use (ETASU), an Implementation System and a Timetable for Submission of Assessments.8 
A notable difference between the EU and the US is that it is mandatory for the EU-RMPs to be included 
in the marketing authorisation application for all new active substances and other required situations, 
while the FDA does not require REMS unless requested on a case-by-case basis. One of the specific 
challenges for the EU is the variation across countries and the national legislation that is often the main 
determinant of how additional RMAs are implemented. Since the implementation of the REMS, several 
studies have described the impact on patients, healthcare providers and health systems in the US.9-11 
Only a few publications have reviewed EU-RMPs and data on specifically additional RMAs specifically 
are even more limited.12-15 To explore the implementation and effectiveness of additional RMAs in the 
EU, it is necessary to have an overview of the currently approved additional RMAs. The objective of the 
present study is to describe additional RMAs of medicinal products, which have been licensed through 
the central authorisation procedure in the EU.
2
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MeThOds
Drugs of interest
Centrally authorised products (CAPs) were the medicinal products of interest in this study since 
information about these products is publicly available. Products authorised through the centralised 
procedure have a single application, evaluation and authorisation, which is valid throughout the 
EU market. The centralised procedure was introduced when the EMA was established in January 
1995.16 Although the scope of centralised procedure has been modified over time, the procedure 
included mainly products derived from biotechnology, officially designated orphan medicines, and 
those in therapeutic areas of HIV, cancer, neurodegenerative diseases and diabetes mellitus and other 
innovative products may apply for this procedure.5, 7 Other terms frequently used within the regulatory 
field are described in Appendix I. 
This cross-sectional study included all active substances authorised through the centralised procedure 
between 1 January 1995 and 1 January 2010, and which were still authorised as of 1 January 2010. 
Active substances withdrawn or suspended before 1 January 2010 (n=31) could not be included in 
our study since limited data regarding these substances was available. Active substance was the basis 
for the analysis, i.e. substances that were the subject of multiple and/or generic applications and 
biosimilar medicinal products were only counted once. 
Data sources
For each CAP, the European Public Assessment Report (EPAR) is published on the website of the 
EMA (www.ema.europa.eu) once the medicinal product has a positive decision from the European 
Commission. The information in the EPAR is updated throughout the lifecycle of the drug and changes 
to the original terms and conditions of the authorisation (i.e. variations, safety specifications, specific 
obligations) are included.17 Since November 2005, the EU-RMP is a mandatory part of the application 
dossier for drug licensing. The EU-RMP aims to strengthen the benefit-risk balance of a medicinal 
product by requiring the implementation of routine and additional pharmacovigilance and RMAs 
(Table 1). Summary information of the EU-RMP is reflected in the EPAR. For each active substance 
the following characteristics were extracted from the EPAR available as of 1 January 2010: product 
name(s), Anatomical Therapeutic Chemical (ATC) classification and marketing authorisation date.
Identification of additional risk minimisation activities (RMAs)
A marketing authorisation consists of several parts. If additional RMAs are required, these conditions are 
laid down in Annexes II and IV of the marketing authorisation. Annex IIB describes specific conditions 
and restrictions imposed on the Marketing Authorisation Holder (MAH) and Annex IV is addressed to 
the national authorities of the member states and requires them to ensure that the MAH complies with 
the conditions or restrictions in their territory. The EMA publishes Annex IIB and IV within the EPAR 
if special conditions or restrictions have been required. Additional RMAs were considered to be the 
conditions and restrictions with respect to the safe and effective use of a medicinal product described 
in these Annexes. Annex IIC of the marketing authorisation, which is also published in the EPAR, 
describes the specific obligations to be fulfilled by the MAH. To identify the active substances with 
additional RMAs, Annexes IIB and Annex IV within the EPAR of each active substance available as of 
1 January 2010 were analysed. In addition, the Annex IICs of all active substances has been reviewed 
for additional RMAs to account for the possibility that information might (erroneously) be included 
in Annex IIC. For active substances with additional RMAs as identified from Annexes IIB, IIC and IV, 
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Evaluation of the need for RMAs
Risk minimisation plan
 Routine RMAs
 Additional RMAs
Part II
Assessment of each safety concern whether any RMAs are needed beyond 
the pharmacovigilance plan, and whether routine RMAs will adequately 
address the safety concern
Warnings and information within the SmPCs and package leaflet, and the 
careful use of labelling and packaging, to reduce the probability of an adverse 
reaction occurring or its severity. The legal status of the product and the pack 
size are also considered to be routine RMAs
Activities that reduce the probability or severity of an adverse drug reaction 
which go beyond those activities considered as routine. These include 
educational information for HCPs  or patients or through conditions or 
restrictions that control the use of the medicine or activities for monitoring 
the patient status
EU-RMP=EU Risk Management Plan; HCPs=Healthcare professional; PASS=Post-Authorisation Safety Study; 
PSUR=Periodic Safety Update Report; RMAs=Risk Minimisation Activities; SmPC=Summary of Product Characteristics.
Table 1: Structure of the EU-RMP 6, 7, 12, 13
Safety Specification
Pharmacovigilance plan
 Routine pharmacovigilance  
 activities
 
 
 Additional 
 pharmacovigilance activities
Part I
Summaries the safety profile of a medicinal product at a particular point in 
time of its lifecycle, including important identified risks, important potential 
risks and important missing information that could affect the benefit-risk 
balance of the medicinal product or have implications for public health. It 
helps to identify the needs for specific data collection and facilitates building 
of a pharmacovigilance plan and risk minimisation plan
Pharmacovigilance activities that should be conducted for each medicinal 
product to detect safety signals including the reporting of suspected adverse 
drug reactions to regulatory authorities, submission of PSURs and other 
activities as required under EU legislation
Activities designed for medicinal product with significant important or 
potential risks, or significant missing information, in order to detect safety 
information, e.g. PASSs, clinical trials, monitoring ongoing studies, and 
registries
the summary information of the EU-RMP was reviewed to obtain detailed information regarding the 
corresponding safety concerns. 
The identified additional RMAs were categorised into six groups, based on the aim and target group 
of the activity. The additional RMAs are described in Table 2. To explore the effect of the introduction 
of the EU-RMP on the additional RMAs, the periods before and after the introduction of the new Risk 
Management legislation (1 November 2005) were analysed separately.
Safety concerns
The safety concerns that required additional RMAs were analysed. The safety concerns addressed by 
additional RMAs were identified from either the summary information of the EU-RMP or Annexes IIB 
and IV. These safety concerns were classified based on System Organ Class (SOC) level according to 
the Medical Dictionary for Regulatory Activities (MedDRA®), version 13.0.18 Safety concerns including 
specific patient groups e.g. paediatrics or HIV patients, were not included in the MedDRA dictionary 
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DHPC=Direct Healthcare Professional Communication; HCPs=Healthcare professional; PPP=Pregnancy Prevention 
Programme; RMAs=Risk Minimisation Activities; SmPC=Summary of Product Characteristics.
Table 2: Description of the additional risk minimisation activities  
Controlled distribution
Informed consent / treatment initiation 
forms
Patient monitoring / screening
PPP
Provision of educational material 
Registry
Special packages / labels 
Conditions and restrictions at drug distribution level. Distribution is controlled 
to ensure that certain conditions are met, e.g. medicine is only available in a 
qualified centre or after a special training programme
Document that ensures that the patient is fully informed of and understands 
the risk of the medicinal product
The need for monitoring of the patient’s health status prior or during treatment, 
e.g. liver function tests, regular blood tests. The need for patient monitoring is 
highly recommended in Annex IIB of the marketing authorisation, educational 
material and SmPC, however, it cannot be legally enforced
A programme, which can contain various elements, that is designed to 
eliminate the risk of pregnancy during drug exposure 
The provision of educational material in addition to the SmPC and package 
leaflet about specific safety concerns (risks) of a drug and measures to reduce 
these concerns. Educational material could be designed for various target 
groups (HCPs, patients, laboratories, patient associations etc). Examples of 
educational material types are DHPC, information brochures and specific 
training programmes. Various media types (written, audio, video) are possible
Patient registries to record results of tests, to ensure that the recommended 
conditions of use are being adhered to, and control access to a medicine. 
Regularly, registries are considered additional pharmacovigilance activities. 
However, patient registries acting as additional RMA when it is required for 
all users of that drug
Special packages (i.e. coolboxes) or additional labels (i.e. stickers for 
traceability of the product), which are required according Annex IIB of the 
Commission decision, to ensure safe and effective drug use
Chapter 2
and could not be classified. Therefore, an additional class ‘Special patients’ was created to review this 
group separately. Other safety concerns that could not be classified according to MedDRA dictionary 
(e.g. the term ‘long-term safety data’) were classified as ‘Not Elsewhere Classified’ (NEC). If a MedDRA 
preferred term was related to multiple SOCs, only the primary SOC was considered. A medically 
trained researcher (IZ) conducted categorisation. In case of doubt, two additional researchers (GT and 
FST) performed an independent assessment. In case of discrepancy, a fourth expert (SS) arbitrated.
resulTs
As of 1 January 2010, 391 independent active substances were authorised in the EU through the 
centralised procedure (Figure 1). For 58 active substances (15%), additional RMAs were identified 
either in Annex IIB (56 active substances) or Annex IIC (2 active substances) and 43 of these 58 
substances (74%) a Commission Decision concerning the additional RMAs addressed to the Member 
States in Annex IV was identified (see Appendix II). 
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At the time of the analysis, 5% (11 out of 227) of the active substances, authorised before the new 
legislation, had additional RMAs, while additional RMAs were identified for 29% (47 out of 164) of the 
active substances approved after the new legislation. Additional RMAs were most frequently agreed for 
active substances concerning ‘anti-neoplastic and immunomodulating’ agents (Figure 2a and b).This 
was not different for the two periods. In the period after the introduction of the new legislation 50% of 
the authorised blood products obtained additional RMAs, and 47% of the authorised anti-neoplastic 
and immunomodulating agents had additional RMAs. 
Characteristics of additional RMAs
All active substances with additional RMAs (n=58) required, as a minimum, the provision of educational 
material (Table 3). Educational material was always directed to healthcare professionals (e.g. Direct 
Healthcare Professional Communication (DHPC), training programme, brochure), except for one 
substance (requiring only a patient card). Furthermore, for 53% of the active substances, provision 
of additional risk information to the patient, such as a leaflet or guide (n=12), a Patient Alert Card 
(n=13) or both (n=6), was part of the additional RMAs. Of the active substances with additional RMAs, 
educational material to the patient was required for all substances for the sensory organs (n=2), for 4 
out of 5 active substances aimed at treatment of the cardiovascular system, and for the majority of the 
anti-neoplastic and immunomodulating agents (16 out of 20). In contrast, none of the anti-infective 
products required the provision of educational material to the patient. 
In addition to the provision of educational material, other types of additional RMAs were requested for 
57% (33 out of 58) substances (Figure 2a and b). As shown in Table 3, there were 19 active substances 
with a need for patient monitoring as an additional RMA. This patient monitoring was considered an 
additional RMA since it was identified from Annex IIB or IIC and not only described in the SmPC, in which 
case it would have been considered only routine risk minimisation. The need for patient monitoring 
identified as additional RMA included tuberculosis screening (n=4), regular blood tests (n=7) [e.g. 
International Normalised Ratio (INR), haemoglobin or haematocrit], liver function monitoring (n=6), and 
various others (n=9). Active substances with additional need for patient monitoring were in particular 
interleukin inhibitors (n=3), tumour necrosis factor alpha (TNF- ) inhibitors (n=3), anti-hypertensives 
indicated for pulmonary arterial hypertension (PAH) (n=3) and products acting on the nervous system 
risk Minimisation activities of Centrally authorised Products in the eu: a descriptive study
Figure 1: Active substances with and without additional RMAs per year of marketing authorisation
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(n=4). Four of the seven anti-infective products with additional RMAs (all vaccines), required a special 
package or labelling to enable traceability of the batches. The five active substances that required a 
pregnancy prevention programme also required a controlled distribution system. 
Safety concerns
We identified 268 safety concerns addressed by additional RMAs. The provision of educational 
material addressed 261 of the 268 identified safety concerns (97%) (Table 3). Products with additional 
RMAs most frequently contained safety concerns, for which additional RMAs were required, classified 
in SOCs ‘general disorders and administration site conditions’, ‘investigations’, ‘infections and 
infestations’, and ‘injury, poisoning and procedural complications’ (Table 4).
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Figure 2a: Distribution of active substances authorised before the new legislation on risk managment according to 
ATC classification system (n=227).
Figure 2b: Distribution of active substances authorised after the new legislation on risk managment according to 
ATC classification system (n=164).
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Provision of educational 
material – total
       to HCPs†
       to the patient
Patient monitoring / 
screening
Controlled distribution 
Pregnancy prevention 
programme
Special packages /labels 
(e.g. stickers, cool boxes)
Others‡
11 (100)
11(100)
8 (73)
2 (18)
3(27)
1 (9)
1 (9)
NA
HCP=Healthcare professional; RMAs=Risk Minimisation Activities.
*authorised before new legislation in italic
†Prescribers, pharmacists, nurses
‡Informed consent for the patient (n=1), registry (n=1), retesting of the antibody status in a reference laboratory (n=1), 
single-source distribution (n=1), systematic return of used and unused nasal spray solutions (n=1), treatment initiation 
form (n=1)
Table 3: Overview of additional risk minimisation activities classified by risk minimisation type
Additional
risk minimisation activity
Active 
substance 
authorised 
before new 
legislation 
[n=11] (%)
Active 
substance 
authorised 
after new 
legislation 
[n=47] (%)
Safety 
concerns 
addressed 
by additional 
RMAs 
[n=268]
Active substance* 
47 (100)
46 (98)
23 (49)
17 (36)
7 (15)
4 (9)
6 (13)
6 (13)
All active substances with additional 
RMAs (Appendix II)
Agomelatine, Ambrisentan, Bosentan, 
Caffeine, Canakinumab, Capsaicin, 
Certolizumab pegol, ChondroCelect®, 
Deferasirox, Golimumab, 
Hydroxycarbamide, Infliximab, 
Mecasermin, Methoxy polyethylene 
glycol-epoetin beta, Micafungin, 
Olanzapine, Rilonacept,  Sitaxentan, 
Ustekinumab 
5-aminolevulinic acid hydrochloride, 
Ambrisentan, Bosentan, Caffeine, 
ChondroCelect®, Eculizumab, 
Lenalidomide, Miglustat, Sildenafil, 
Sitaxentan  
Ambrisentan,  Bosentan, 
Lenalidomide, Thalidomide,  
Sitaxentan 
Fentanyl citrate, Moroctocog 
alfa, Pandemic influenza vaccines 
(Celvapan, Focetria and Pandemrix), 
Pneumococcal polysaccharide 
conjugate vaccine, Epoetin alpha 
ChondroCelect®, Clofarabine, 
Fentanyl citrate, Methoxy 
polyethylene glycol-epoetin beta, 
Rinolacept, Thalidomide
261
251
94
43
52
5
8
17
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Additional RMAs in addition to educational material were most often required for products with safety 
issues classified as hepatobiliary disorders (6 out of 7 active substances with hepatobiliary safety issues 
[86%]), for 83% of the active substances with congenital, familial and genetic safety concerns, for 60% 
of the active substances with renal and urinary safety concerns and for 50% of the active substances 
with safety concerns classified as metabolism and nutrition disorders. All safety concerns classified as 
‘congenital, familial and genetic disorders’ were addressed by a pregnancy prevention programme. In 
addition, 67% of the safety concerns classified as ‘infections and infestations’ were addressed by the 
provision of educational material to the patient.
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General disorders and administration site conditions
Injury, poisoning and procedural complications
Investigations
Infections and infestations
Blood and lymphatic system disorders
Immune system disorders
Special patient group
Nervous system disorders
Neoplasms benign, malignant and unspecified
Vascular disorders
Cardiac disorders
Metabolism and nutrition disorders
Surgical and medical procedures
Hepatobiliary disorders
Congenital, familial and genetic disorders
Musculoskeletal and connective tissue disorders
Renal and urinary disorders
Skin and subcutaneous tissue disorders
Pregnancy, puerperium and perinatal conditions
Other SOCs†
RMAs=Risk Minimisation Activities; SOC=System Organ Class 
*Percentage of all active substances with additional RMAs.
†Include SOCs Not elsewhere classified and SOCs with n < 5 safety concerns (Ear and labyrinth disorders; Eye disorders; 
Gastrointestinal disorders; Psychiatric disorders; Reproductive system and breast disorders; Respiratory, thoracic and 
mediastinal disorders).
Table 4: Safety concerns of the active substances with additional RMAs classified by System Organ Class
System Organ Class Active substances with 
additional RMAs [n=58]
21
19
18
14
11
10
10
10
9
9
8
8
8
7
6
5
5
5
5
21
7 (33)
6 (32)
8 (44)
5 (36)
5 (45)
1 (10)
2 (20)
5 (50)
3 (33)
2 (22)
2 (25)
4 (50)
2 (25)
6 (86)
5 (83)
2 (40)
3 (60)
0 (0)
1 (20)
7 (33)
Active substances with additional 
RMAs on top of educational 
material [n=33] (57%)*
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disCussiOn
To our knowledge, this is the first descriptive study aimed at exploring additional RMAs among CAPs 
in the EU. With the new legislation on Risk Management of 2005, the pharmacovigilance of medicines 
shifted from a largely reactive approach based on the spontaneous reports of suspected adverse drug 
reactions, to a continuous proactive life cycle management. The EU-RMP is a roadmap that evolves 
as the benefit-risk profile becomes further defined and additional RMAs facilitate proactive measures 
to improve the benefit-risk balance.15 It allows regulatory authorities to specify the conditions and 
restrictions necessary for the safe and effective use of the medicinal product as part of the marketing 
authorisation. Before the new legislation this possibility did not exist. 
We identified 58 (centrally authorised) active substances with additional RMAs. The proportion of 
active substances with additional RMAs authorised after the new legislation on risk management 
is substantially higher as compared to those authorised before the new legislation, 29% and 5% 
respectively. Comparing the period before and after the new legislation of 2005, the proportion of 
active substances with additional RMAs varied the most among anti-neoplastic and immunodulating 
agents. As of 1 January 2010, 9% of these products authorised before the new legislation included 
additional RMAs, compared to 47% of those that were approved afterwards. This increase is mainly 
due to the immunosupressants (including selective immunosuppressants, tumor necrosis factor alpha 
(TNF- ) inhibitors and interleukin inhibitors). Of the immunosupressants authorised before and after 
the new legislation, 2 out of 11 and 11 out of 12 had additional RMAs respectively. 
Although it was not specifically the subject of our analyses, it might be possible that the safety profile 
of newer products differ from older products, and additional RMAs might be more relevant for these 
newer products. We observed, however, no substantial changes over the years regarding the most 
commonly involved product classes of products with additional RMAs. In addition, the proposed 
additional RMAs of these products were not different, although the number of products with additional 
RMAs authorised before the new legislation was quite limited.
Since the adoption of legislation, the new proactive approach of pharmacovigilance has gained 
momentum, and there is increasing awareness of the available options to minimise risks, although 
we are still at the beginning of realising the full potential of proactive pharmacovigilance.15 The 
development towards a more proactive pharmacovigilance with a risk management approach has 
created additional possibilities for active substances to obtain additional RMAs. In addition, according 
to the current Guideline on risk management systems, the MAH should justify that there is no need 
for additional RMAs, suggesting that additional RMAs are needed by default.7 This might lead, on 
the one hand to more proposals and, on the other hand, to fewer rejections of proposed additional 
RMAs by the regulators, causing excessive use. Another concern expressed is the use of inappropriate 
educational material for commercial interests instead of the intended use. Strict monitoring of the 
additional RMAs should prevent this. Provisions in the new pharmacovigilance legislation that are to 
be implemented in July 2012 require monitoring the outcome of additional RMAs, which might limit 
this risk in the near future.
Educational material
Provision of educational material is the predominant strategy in the EU to reduce the probability or 
severity of an adverse drug reaction. All active substances with additional RMAs required the provision 
of educational material, which was used to address 97% of the safety concerns. This might be explained 
by the fact that provision of educational material is a relatively easy risk minimisation strategy, i.e. not 
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complicated to produce and simple to implement. In the EU, because different healthcare systems 
are in place, a certain level of flexibility seems important to facilitate national implementation. For this 
reason, often only key elements to be included in a certain type of educational material are agreed on 
EU level. However, at the same time the lack of a standardised approach complicates implementation 
for member states and MAHs, might hamper evaluation of the effectiveness and cause confusion for 
patients. In addition, educational material may be interpreted by healthcare professionals, due to, for 
example, glossy appearance, as promotional and may not have been appreciated as risk minimisation. 
An overload of educational material may result in a less effective risk minimisation or have a deterrent 
effect.19, 20
 
Although different legal bases to minimise risks are in force in the US, educational material is also the 
strategy of choice in the approved REMS. This is in line with our findings regarding the EU. As of June 
2010, nearly all (119 of the 123) products with approved REMS listed on the FDA website included 
at least a medication guide for the patient, and 25% of the REMS included a communication plan for 
the healthcare professional.20, 21 In the EU, a patient leaflet is provided routinely, whilst, in the US, a 
medication guide for patients is only required if requested according to the REMS.22 In the EU, the 
provision of educational material as additional RMA was always aimed at healthcare professionals and 
at patients in 54% of instances, in addition to the standard patient information leaflet.
In our study, 33 active substances in the EU obtained measures in addition to the provision of educational 
material, and the need for patient monitoring was the second most frequently identified additional 
RMA. Little consistency of additional RMAs across similar safety concerns was identified in this study, 
except for ‘teratogenicity’, that in all cases was addressed with a pregnancy prevention programme, 
and ‘hepatobiliary disorders’ which in four of the seven active substances, was addressed with 
patient monitoring or screening. This lack of consistency can partly be explained by the case-by-case 
consideration of each safety concern.7 This emphasizes that the need for additional RMAs can be very 
drug specific.
Strengths and limitations of the study
Only CAPs were included in this study, which limits the generalisability of our findings. Active substances 
authorised through other procedures could have additional RMAs as well since the Guideline on risk 
management systems applies to all medicinal products.7 However, additional RMAs are most likely 
for innovative, complex and technically advanced products, which are generally authorised through 
the centralised procedure. In view of the type of products authorised through other procedures, e.g. 
generic medicinal products, very few others would have additional RMAs. One well known example is 
the pregnancy prevention programme of isotretinoin, which aims to reduce the risk of teratogenicity.23
 
From our cross-sectional analysis it cannot be concluded if an active substance had additional RMAs at 
time of initial marketing authorisation, or whether these were obtained during post-authorisation. The 
EU-RMP is not designed as ‘on-off’, but rather as a continuous process amended as the experience 
growths and the benefit-risk profile of the drug further evolves.15 The EPAR can be appropriately 
adapted during the life-cycle of the drug, with only the most recent version published. The exact 
timing of additional RMAs coming into force is therefore difficult to assess from publicly available 
data. This information might be specifically relevant for the active substances authorised before the 
new legislation on risk management came into force, and which required additional RMAs during the 
lifecycle. 
The EPAR of some products contained discrepancies regarding information on additional RMAs. 
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Differences between Annex IIB and the summary information of the EU-RMP were observed, in 
which either of these two documents contained extra additional RMAs. Furthermore, difficulties with 
the difference between pharmacovigilance activities and additional RMAs were observed in these 
documents. In some instances, pharmacovigilance activities such as close monitoring of the safety 
issue in the Period Safety Update Report or long-term safety and effectiveness studies, were presented 
as additional RMAs. The aim of pharmacovigilance activities essentially differs from additional 
RMAs; while the former aims to study post marketing safety concerns, the latter aims to reduce the 
probability of an adverse drug reaction. The discrepancies can easily be explained by a change in 
the characteristics of EU-RMPs, and the quality of the corresponding summary information of the 
EU-RMPs and Annexes IIB over time (improvements from learning and interventions), which will reduce 
the chance of such misclassification in future. The quality of the first EPARs can explain the two active 
substances with additional RMAs described in Annex IIC instead of Annex IIB. We might have missed 
active substances with additional RMAs, of which details regarding additional RMAs were lacking in 
the EPAR. We agree, in line with previous studies, that the quality of the publicly available information 
regarding additional RMAs should be improved.12, 13 A possible solution might be to provide a periodic 
overview of the required additional RMAs, including changes over time and updates of the EU-RMP 
regarding both additional pharmacovigilance and additional RMAs. 
Giezen et al.13 evaluated post-authorisation safety studies (PASS) as part of the EU-RMP. The authors 
observed limited availability of full/partial study protocols of the PASS, precluding a scientific 
assessment of these studies at time of regulatory approval. In line with previous findings, also in our 
study, limited availability of comprehensive information concerning additional RMAs precluded an 
in-depth description of the additional RMAs and the corresponding risks. Although all stakeholders, 
including healthcare professionals, have theoretically full access to product information (including 
annex IIB) and public assessment reports of the CAPs via the EMA website, it is a challenge to find 
information and instructions regarding the additional RMAs, e.g. which medicinal products require 
special obligations or restrictions and the type of measures involved. More transparency and easier 
access to information concerning additional RMAs, the corresponding risks and the evaluation 
of the need for additional RMAs may enhance awareness of the role that these activities have in 
clinical practice and might facilitate implementation at the national level. Equal critical points were 
identified by Frau et al.12 The authors identified limited transparency as one of the main issues that 
influences adequate implementation of EU-RMPs. We agree with the authors that better access to 
pharmacovigilance activities and doctor and patient programmes is needed to improve the effect of 
the additional RMAs.
Implications
Since 2005, the growing experience on the EU-RMP and the additional RMAs has led to a better 
understanding of the possibilities and challenges of this proactive approach. The EU-RMP offers 
knowledge gain regarding the drug’s benefit-risk profile and possibilities to ensure safe drug use during 
the product lifecycle. The new pharmacovigilance legislation that will come into force mid-2012 will 
further broaden the opportunities. There will be major changes to existing processes in the member 
states, the EMA and MAHs with regard to evaluation of risks associated with medicinal products. In 
addition, the framework on how the EU takes harmonised regulatory action on drug safety needs to 
implemented in July 2012.24 
The full opportunities offered by the EU-RMP are only beginning to be appreciated and challenges 
concerning the implementation and the assessment of effectiveness of additional RMAs will need to 
be further addressed. Actual implementation of the additional RMAs takes place at national level and 
risk Minimisation activities of Centrally authorised Products in the eu: a descriptive study
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has to take into account national requirements e.g. health systems, language and health believes. 
This national phase allows the realisation of better fitting programmes and better compliance of the 
healthcare professionals and patients, which in turn might positively influence the effects of additional 
RMAs. Additional RMAs put an extra burden on the system and should therefore not only be carefully 
drafted and monitored, but also only requested if added value of the benefit-risk balance is to be 
expected. It is in the interest of patients, healthcare professionals, industry and regulators that the least 
harm and the maximum benefit results from using a medicine, and to avoid unnecessary, inefficient 
measures.
Recommendations in the new pharmacovigilance legislation offer opportunities to better address the 
limitations of the current guidance since it requires the EMA, the member states and the MAHs to 
monitor the outcome of additional RMAs.25, 26 Knowledge regarding the effectiveness of additional 
RMAs will impact the drafting and implementation of additional RMAs and will, in future, lead to 
improved benefit-risk balance and increased patient safety. Currently there is limited knowledge 
available regarding the effectiveness of additional RMAs.27-32 In view of the new pharmacovigilance 
legislation, methods to evaluate the implementation and effectiveness of additional RMAs need to 
be developed. In addition, it will be relevant to study the implementation of the additional RMAs 
and have a closer look at the differences across countries and the influences on the individual patient 
safety.
Conclusions
This study describes the additional RMAs of CAPs that are required to be implemented when the 
drug has been, or will be, marketed in an EU member state. The risk management approach is 
developing and the number of products with additional RMAs is growing after the introduction of 
the EU-RMP. Almost one third of the recent CAPs required additional RMAs, which emphasised the 
need for evaluation of these measures. Future research should explore the effects of additional RMA 
implementation in the minimisation of risks associated with drug therapies in EU at both patient and 
population level
Chapter 2
35risk Minimisation activities of Centrally authorised Products in the eu: a descriptive study
Appendix I: Short description of terms frequently used within the regulatory field of medicines evaluation
ATC classification system
Annex IIB
Annex IIC
Annex IV
Biological medicinal 
product
Biosimilar medicinal 
product
Centralised authorisation 
procedure
CMDh
CHMP
European Commission 
decision
EMA
Term
This drug classification system divides the active substances into different groups 
according to the organ or system on which they act and their therapeutic, pharmaco-
logical and chemical properties. The classification system is controlled by the WHO 
Collaborating Centre for Drug Statistics Methodology18
The EMA publishes Annex IIB of the European Commission Decision in the publicly 
available EPAR to present the conditions imposed on the MAH. Annex IIB includes the 
conditions or restrictions imposed on the MAH, with regard to the safe and effective use 
of the medicinal product which reflect the additional RMAs approved for the product
The EMA publishes Annex IIC of the European Commission Decision in the publicly 
available EPAR to present the specific obligations to be fulfilled by the MAH. Specific 
obligations data to be submitted in the post-authorisation phase are specific to 
marketing authorisations granted under exceptional circumstances due to limited 
efficacy and/or safety data available at the time of the CHMP opinion  
In addition to Annex IIB, the EMA may publish Annex IV of the European Commission 
decision. This is a decision addressed by the Commission to the national authorities 
of the EU member states and contains conditions or restrictions with regard to the 
safe and effective use of the medicinal product. Annex IV of the Commission Decision 
requires the national authorities to ensure that the MAH implements the additional risk 
minimisation activities in their territory
Biological medicines are made by a living organism, such as a bacterium or yeast, and 
can consist of relatively small molecules such as human insulin or erythropoietin or 
complex molecules such as monoclonal antibodies33
A ‘biosimilar’ medicine is a biological medicine that is similar to another biological 
medicine (the ‘biological reference medicine’) that has already been authorised for 
use33
The EMA is responsible for the centralised authorisation procedure. It is a registration 
procedure for which a single application and evaluation, if positive, results in a single 
marketing authorisation applicable to the whole EU. The centralised procedure includes 
mainly medicinal products derived from biotechnology, for officially designated 
‘orphan medicines’, for those in certain therapeutic areas (HIV, cancer, neurodegenera-
tive diseases, diabetes mellitus, immunosuppressive diseases and viral diseases) and is 
available for other innovative products5 
The CMDh is the co-ordination group of the EMA and examines questions relating 
to the marketing authorisation of a medicinal product for human use in two or 
more Member States in accordance with the mutual recognition procedure or the 
decentralised procedure5
The CHMP is the scientific Committee of the EMA and is responsible for providing the 
European Commission with a scientific opinion on the quality, safety and efficacy of the 
medicinal product, especially with regard to centralised authorisation procedures. The 
members and alternates of the CHMP are nominated by the EU Member States, based 
on their individual expertise5
In case of marketing application, the CHMP’s opinion is transmitted to the European 
Commission which gives a decision. If the Decision is positive, the MAA can grant a 
marketing authorisation5 
The EMA is a decentralised body of the EU located in London and was established 
under Regulation 2309/93 EC to harmonise the work of national medicine regulatory 
bodies. It came into being in January 1995. Its main responsibility is the protection 
and promotion of public and animal health, through the evaluation and supervision of 
medicines for human and veterinary use16
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Appendix I: Short description of terms frequently used within the regulatory field of medicines evaluation
EPAR
Generic medicinal products
Life cycle approach
Multiple applications
Pharmacovigilance
PhVWP
REMS
EU-RMP
US FDA
Term
The scientific grounds for the CHMP opinion concerning the approval of a medicinal 
product are reflected in the EPAR, which includes the product information (SmPC, 
labelling and package leaflet) for the medicine, details of the procedural steps taken 
during the assessment process and the CHMP Assessment Report with confidential 
parts removed. The EPAR of all centrally authorised products are published on the 
EMA website17
Once the 10-year data protection of a medicinal product expires, another MAA can 
apply for a marketing authorisation for a generic medicine. A generic medicinal 
product is equivalent to the original medicinal product, since the generic medicinal 
product contains the same active substances at the same concentration and has similar 
therapeutic efficacy and safety as the original medicinal product5
The continuous evaluation and integration of drug safety and efficacy during the entire 
lifecycle of a drug. After approval, when the drug is used within a broader population, 
benefit-risk assessment with post-authorisation data is an ongoing activity1, 2
A term used when MAAs wish to obtain, either simultaneously or successively, more 
than one marketing authorisation for a specific medicinal product, under different 
invented names5
Pharmacovigilance is defined by the WHO as the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any other 
drug-related problem34
PhVWP is a working party of the CHMP, which provides recommendations to the CHMP 
on the safety of medicinal products and on the investigation of adverse reactions 
associated with medicinal products authorised in the EU and other issues relating to 
pharmacovigilance35
The FDA Amendments Act of 2007 has given the FDA the authority to require a REMS 
from MAAs to ensure that the benefits of a drug or biological product outweigh its risks. 
REMS contain an analysis of possible risks and measures to mange known or expected 
safety issues3
The EU-RMP describes the risk management system of a medicinal product, which is 
a required part of certain applications for drug licensing. This requirement was part of 
the new legislation which came into force in November 2005. It is mandatory to submit 
an EU-RMP for new chemical entities, biosimilar medicinal products and generics of 
substances for which a risk has been identified for the reference product. Furthermore, 
it can be requested by regulatory authorities.5, 7 See Table 1 for a further description 
of the EU-RMP 
The FDA is responsible for protecting public health by assuring the safety, efficacy 
and security of human and veterinary drugs, biological products, medical devices, the 
nation’s food supply, cosmetics, products that emit radiation, and tobacco products. In 
addition, the FDA is responsible for advancing the public health by helping to speed 
innovations that make medicines and foods more effective, safer, and more affordable; 
and helping the public get the accurate, science-based information they need to use 
medicines and foods to improve their health36
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ATC=Anatomical Therapeutic Chemical; CHMP=Committee for Medicinal Products for Human Use; CMDh=Co-
ordination Group for Mutual Recognition and Decentralised Procedures – human; EMA=European Medicines Agency; 
EPAR=European Public Assessment Report; EU-RMP=EU Risk Management Plan; FDA=Food and Drug Administration; 
MAAs=Marketing Authorisation Applicants; MAH=Marketing Authorisation Holder; PhVWP=Pharmacovigilance Working 
Party. REMS=Risk Evaluation and Mitigation Strategy; RMAs=Risk Minimisation Activities; SmPC=Summary of Product 
Characteristics.
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5-aminolevulinic acid hydrochloride
Abatacept
Adalimumab
Agomelatine
Alemtuzumab
Ambrisentan
Anidulatungin 
Bosentan 
Caffeine citrate
Canakinumab
Capsaicin
Certolizumab
Characterised viable autologous cartilage 
cells expanded ex vivo expressing specific 
marker proteins
Clofarabine
Deferasirox
Degarelix
Dronedarone
Eculizumab
Efavirenz/emtricitabine/tenofovir disoproxil 
Epoetin alfa
Epoetin zeta
Eptacog alfa (activated)
Eptotermin alfa
Fentanyl citrate
Gadoversetamide
Golimumab
Hydroxycarbamide
Indacaterol
Infliximab
Lasofoxifene
Lenalidomide
Mecasermin
Methoxy polyethylene glycol-epoetin beta
Micafungin (as sodium salt)
Miglustat
Moroctocog alfa
Natalizumab
Nilotinib
Nonacog alfa
Gliolan®
Orencia®
Humira®
Thymanax®,
Valdoxan®
MabCampath®
Volibris®
Ecalta®
Tracleer®
Nymusa®
Ilaris®
Qutenza® (Transacin)
Cimzia®
ChondroCelect®
Evoltra®
Exjade®
Firmagon®
Multaq®
Soliris®
Atripla®
Abseamed®,
Binocrit®,
Epoetin alfa Hexal®
Retacrit®,
Silapo®
NovoSeven®
Opgenra®
Instanyl®
OptiMARK®
Simponi®
Siklos®
Hirobriz Breezhaler®, 
Onbrez Breezhaler®, 
Oslif Breezhaler®
Remicade®
Fablyn®
Revlimid®
Increlex®
Mircera®
Mycamine®
Zavesca®
ReFacto AF®
Tysabri®
Tasigna®
BeneFIX®
Appendix II: Centrally authorised active substances with additional RMAs in the EPAR at 1 January 2010 
Active substance Product name ATC code Date of issue 
of marketing 
authorisation
L01XD04
L04AA24
L04AB04
N06AX22
L01XC04
C02KX02
J02AX06
C02KX01
N06BC01
L04AC08
N01BX04
L04AB05
M09AX02
L01BB06
V03AC03
L02BX02
C01BD07
L04AA25
J05AR06
B03XA01
B03XA01
B02BD08
M05BC02
N02AB03
V08CA06
L04AB06
L01XX05
R03AC18
L04AB02
G03XC03
L04AX04
H01AC03
B03XA03
J02AX05
A16AX06
B02BD02
L04AA23
L01XE08
B02BD09
Annex
IIB + IV
IIB
IIB
IIB + IV
IIB + IV
IIB + IV
IIB
IIB + IV
IIB + IV
IIB + IV
IIB
IIB + IV
IIB + IV
IIC
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIB
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIB
IIB + IV
IIB + IV
IIB
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIC
IIB + IV
IIB + IV
IIB + IV
IIB
07-Sep-07
21-May-07
08-Sep-03
19-Feb-09
06-Jul-01
21-Apr-08
20-Aep-07
15-May-02
02-Jul-09
23-Oct-09
15-May-09
01-Oct-09
05-Oct-09
29-May-06
28-Aug-06
17-Feb-09
26-Nov-09
20-Jun-07
13-Dec-07
28-Aug-07
18-Dec-07
23-Feb-96
19-Feb-09
20-Jul-09
23-Jul-07
01-Oct-09
29-Jun-07
30-Nov-09
13-Aug-99
24-Feb-09
14-Jun-07
03-Aug-07
20-Jul-07
25-Apr-08
20-Nov-02
13-Apr-99
27-Jun-06
19-Nov-07
27-Aug-97
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Olanzapine (as pamoate monohydrate)
Pandemic influenza vaccine
Pandemic influenza vaccine
Pandemic influenza vaccine
Pegaptanib sodium
Pneumococcal polysaccharide conjugate 
vaccine (13-valent, adsorbed)  
Porfimer sodium
Prasugrel
Ranibizumab
Ranolazine
Rilonacept
Romiplostim
Sevelamer carbonate
Sildenafil
Sitaxentan 
Thalidomide
Tocilizumab
Ustekinumab
Zoledronic acid
Zypadhera®
Celvapan®
Focetria®
Pandemrix®
Macugen®
Prevenar 13®
PhotoBarr®
Efient®
Lucentis®
Ranexa® (Latixa)
Arcalyst®
Nplate®
Renvela®
Revatio®
Thelin®
Thalidomide 
Celgene®
RoActemra®
Stelara®
Aclasta®
ATC=Anatomical Therapeutic Chemical; EPAR=European Public Assessment Report; RMAs=Risk Minimisation Activities
Active substance Product name ATC code Date of issue 
of marketing 
authorisation
N05AH03
J07BB01
J07BB02
J07BB02
S01LA03
J07AL02
L01XD01
B01AC22
S01LA04
C01EB18
L04AC08
B02BX04
V03AE02
G04BE03
C02KX03
L04AX02
L04AC07
L04AC05
M05BA08
Annex
IIB + IV
IIB
IIB
IIB
IIB + IV
IIB
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIB + IV
IIB
IIB + IV
IIB + IV
IIB + IV
IIB + IV
19-Nov-08
04-Mar-09
02-May-07
20-May-08
31-Jan-06
09-Dec-09
25-Mar-04
25-Feb-09
22-Jan-07
09-Jul-08
23-Oct-09
04-Feb-09
10-Jun-09
28-Oct-05
10-Aug-06
16-Apr-08
16-Jan-09
16-Jan-09
15-Apr-05
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aBsTraCT
Background Additional risk minimisation measures (aRMMs) can be necessary to 
optimize the benefit-risk balance of a drug. Evaluation of effectiveness of these measures 
has become mandatory with the new European Union (EU) pharmacovigilance legislation 
in force since July 2012. The aim of this study was to classify the aRMMs in the EU with a 
special emphasis on the possibilities to analyse the effectiveness of these aRMMs in existing 
electronic healthcare databases (EHDs).
Methods European Public Assessment Reports were reviewed to identify key elements 
of the aRMMs. Researchers categorised the key elements based on the objectives, i.e. 
knowledge change or behavioural change and sub-categorised the behavioural changes. 
They assessed for each key element if it would be eligible for analysis in existing EHDs. 
Results 68 drugs with aRMMs contained 801 key elements of which 57% aimed at 
behavioural changes. 22% of all key elements, all aimed behavioural changes, were assessed 
eligible for analysis in existing EHDs. These mainly concerned recommendations targeted 
at healthcare professionals regarding drug prescription, e.g. dose recommendations, 
contraindications or the need to perform laboratory tests for patient monitoring. 
Conclusions Only a limited proportion of key elements of the aRMMs could potentially 
be monitored in existing EHDs as these data sources cannot capture all the required data. 
Due to difference between existing EHDs, not necessarily all available EHDs are appropriate 
for every drug or aRMM. To facilitate rapid evaluation of aRMM implementation and timely 
adjustments, industry and regulatory authorities should agree well-defined key elements of 
aRMMs leading to unambiguous actions of the target group.
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Key POinTs
•	 Measuring the effectiveness of additional risk minimisation measures (aRMMs) is essential in the 
continuous evaluation of the benefit-risk balance of a drug and recently has become a legal 
requirement in the EU. 
•	 Rapid aRMMs assessment is necessary to modify aRMMs and improve implementation in an early 
stage to further optimise the benefit-risk balance of a drug. 
•	 Electronic healthcare databases have been extensively used in pharmacoepidemiology, and may 
present opportunities to investigate the implementation and performance of aRMMs rapidly.
•	 Currently, the majority of the aRMMs is however not considered suitable for evaluation in 
electronic healthcare databases, and it remains a challenge to analyse these aRMMs in an efficient 
and proper way. 
•	 To facilitate the rapid evaluation of aRMMs and timely aRMM adjustment, it is essential that 
industry and regulatory authorities agree on well-defined aRMM key elements leading to 
unambiguous actions of the target group.
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inTrOduCTiOn
Risk minimisation measures (RMMs) are an essential part of life cycle management of a drug. These 
measures intend to reduce the occurrence of an adverse drug reaction (ADR) or to reduce its severity 
should it occur.1 Routine RMMs required for all drugs include the summary of product characteristics, 
the labelling, the package leaflet, the pack size and the legal status of the drug.1 Sometimes additional 
risk minimisation measures (aRMMs) are necessary to optimize the benefit-risk balance of a drug. 
aRMMs are those measures that go beyond the routine requirements and should only be required to 
address specific critical safety issues not sufficiently addressed by routine RMMs only.2 In the European 
Union (EU) aRMMs are described in the Risk Management Plan (EU-RMP), a mandatory part of a 
marketing application since the end of 2005.1, 3 Examples of aRMMs are extra education for healthcare 
professionals (HCPs) and patients, pregnancy prevention programme and patient screening. aRMMs 
pose an extra burden on the health system and should therefore be carefully justified, drafted and 
monitored, and only requested if added value is expected. It is in the interest of patients, HCPs, 
industry and regulators that the least harm and maximum benefit results from using a medicine, and 
to avoid unnecessary, ineffective measures. 
Proactive and proportionate pharmacovigilance during the life cycle of a medicinal product is 
firmly embedded in the new European pharmacovigilance legislation effective since July 2012, and 
monitoring the outcome of RMMs became mandatory for regulators and marketing authorisation 
holders (MAHs).4-6 Since these outcomes can impact the benefit-risk balance of drug, evaluation 
of aRMMs is an essential part of the continuous evaluation of the benefit-risk balance of a drug. 
Assessment of actual implementation of aRMM in clinical practice is necessary to evaluate whether 
aRMMs can successfully improve the drug’s benefit-risk profile in routine daily care. The evaluation of 
actual implementation of aRMMs can comprise different elements (Figure 1), including assessment 
of the effect of aRMM on the clinical knowledge of patients and HCPs as well assessment of desired 
behavioural changes of HCPs or patients.
Figure 1: Evaluation of risk minimisation measures
aRMM=additional risk minimisation measure; RM=risk minimisation
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There is a need for rapid evaluation and timely feedback on the implementation and the effectiveness 
of the aRMMs to allow adjustment in an early stage. Prospective data collection (e.g. by means 
of a survey) can be lengthy and unnecessarily delay such an assessment. Since existing electronic 
healthcare databases (EHDs) present opportunities to investigate rapidly the associations between a 
drugs and adverse events,7, 8 it is relevant to explore whether these resources can be used to explore 
the implementation and performance of aRMMs. However, currently only limited knowledge on how 
aRMM evaluation can be conducted and on the data sources that can be used for the measurement of 
the aRMM effectiveness is available.9, 10
The aim of this study was therefore to classify the aRMMs of the medicinal products authorised in the 
EU with a special emphasis on the possibilities to analyse the effectiveness of these aRMMs in existing 
EHDs.
MeThOds
Medicinal products included in this study were the centrally authorised products with aRMMs, 
authorised as of 1 April 2011. Products authorised before the EU-RMP became a mandatory part of the 
application in 2005 were included since also for these products aRMMs can be in place. The method 
for identification of drugs with aRMMs have been previously described.2 For each drug included in 
our study the European Public Assessment Report, which is published on the website of the EMA 
(www.ema.europa.eu), was reviewed to identify key elements. Key elements are those components 
of aRMMs that are agreed by regulatory authorities at European level and provide guidance for 
implementation of aRMMs at member state level. For each drug multiple key elements can be agreed, 
e.g. instructions regarding drug administration; recommendation to monitor creatinine clearance or 
perform an electrocardiogram. For this study, the key elements of the aRMMs were the unit of analysis.
Categorisation of the key elements
The aRMM key elements were classified by the researchers into ten categories according the objective 
of the key element. The different categories are described in Table 1. For each key element, the 
objective was classified as ‘knowledge change’ or ‘behavioural change’. In addition, the target group 
was identified as ‘HCPs’ or ‘patients’. Key element aiming at behavioural changes in patients were 
subcategorised in ‘recommended actions to be followed during treatment use’ (e.g. patient should 
avoid sunlight exposure) and ‘recommended actions to early detect or treat/resolve ADRs’ (e.g. patient 
should contact your doctor when you experience symptoms). Key elements aimed at behavioural 
changes in HCPs were subcategorised in ‘recommended actions regarding drug prescription’ (e.g. 
contraindication or dose recommendations), ‘recommended actions regarding the drug administration 
process’ (e.g. patient should lay down during infusion), ‘recommended actions to perform clinical 
examinations or laboratory tests’ (e.g. monthly blood tests) and ‘recommended actions to treat/
resolve ADRs’ (e.g. HCPs should stop treatment if bleeding occurs). The key elements that could not 
be categorised in any of the groups were included in a separate category ‘others’ (e.g. instructions to 
immediately report adverse events). 
The classification of the key elements in the different categories was performed by two medically 
trained researchers (IZ and FST) independently. In case of disagreement consensus was sought via 
discussion, and in case of remaining disagreement, a third researcher arbitrated (SMS). The same 
approach was applied for the assessment of ‘eligibility’ of the key element for analysis in existing 
EHDs.
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ADR=adverse drug reaction; HCP=healthcare professional
Table 1: Description of the key element categories based on objective and target group 
Knowledge change
Targeted at patients 
Targeted at HCPs
Behavioural change
Targeted at patients
Recommended actions 
to be followed during 
treatment use 
Recommended actions 
to early detect or treat/
resolve ADRs
Targeted at HCPs 
Recommended actions 
regarding drug 
prescription
Recommended actions 
regarding the drug 
administration process
Recommended actions 
to perform clinical 
examinations and 
laboratory tests
Recommended actions 
to treat/resolve ADRs
Other
Pharmacovigilance 
instructions
Not elsewhere classified
Information provision to increase the patients’ or HCPs understanding and awareness 
of the risk associated with the drug, e.g. mechanism of action, risk factors of the safety 
concern, signs and symptoms of ADRs, risk frequency. 
Recommended actions or behaviour to be followed or avoided by the patient 
concerning treatment use, e.g. self-injection instructions, avoidance of grapefruit juice 
due to interaction risk, not giving the drug to another person.
Recommended actions to be taken by the patient when an ADR or symptoms of an ADR 
occurs, e.g. contact your doctor.
Guidance on contra-indications, use of co-medication, dosage and duration of use, 
eligibility of the patients to receive the treatment.
Recommendations regarding drug reconstitution, administration and dispensing, e.g. 
prescription for qualified HCP or centres only, HCP should monitor the patient (or 
specific patient groups) directly after receiving the medication for a pre-specified period.
The HCP should
•	 perform pre-prescription assessments to exclude inappropriate use, i.e. pregnancy 
test, tuberculosis test.
•	 examine the patient on a frequent basis to early detect ADRs. 
Recommended actions to be taken on the management of the risks when an ADR occurs, 
e.g. discontinue treatment, lower the dosage, change medication, contact prescriber or 
specialist.
Instructions regarding spontaneous reporting or other requirements to facilitate the 
collection of post-marketing safety data.
Recommendations regarding the facilities for identification and traceability of a 
medicinal product; the need for post-marketing and compliance assessment; differences 
in packing.
Category Description
Key elements eligible for analysis in existing EHDs
In this study, EHDs refer to already existing computerised data sources containing routinely collected 
medical information from actual care and which are commonly used for pharmacoepidemiology and 
pharmacovigilance research.8 There is wide variation between EHDs. To obtain characteristics of 
these type of databases, we explored the database registry of the European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP), a collaborative scientific network in the 
fields of pharmacoepidemiology and pharmacovigilance.7 EHDs included in this registry mainly are 
administrative (claims) databases, routine primary care databases, pharmacy dispensing databases 
and some contain also hospital data e.g. Danish Medical Registries, GPRD, THIN, HealthSearch, IMS 
Lifelink Health Plan US, IMS Lifelink EMR FR, IPCI.11 In addition to the ENCePP database registry 
(www.encepp.eu/encepp/resourcesDatabase.jsp),11 we explored a relevant overview of databases 
from the book Pharmacoepidemiolgy12 to identify the type of information that can be retrieved from 
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existing EHDs. The information considered retrievable from existing EHDs in our study include: patient 
demographics, information regarding drug prescription/dispensing, medical events which can include 
adverse events, symptoms/signs, diagnosis in primary care, specialist diagnosis, hospital discharge 
diagnosis, laboratory values, death, clinical procedures, overdoses and teratogenic events. This 
information was the basis for the assessment whether the key element was eligible for analysis in 
EHDs. The researchers classified independently each key element as ‘possibly eligible for analysis in 
EHDs’, ‘not eligible for analysis in EHDs unless more clearly defined’, ‘not eligible for analysis in EHDs’ 
or ‘not eligible for analysis at all’ (Table 2).
Data that reflects the 
desired effect of the key 
element (recommended 
actions resulting from the 
key element) is considered 
retrievable from EHDs. †
Table 2: Description of the classes of ‘eligibility for analysis in EHDs’  
Possibly eligible for 
analysis in EHDs*
Not eligible for analysis in 
EHDs unless more clearly 
defined *
Not eligible for analysis 
in EHDs *
Not eligible for analysis 
at all
The key element was 
considered vague or 
ambiguously formulated 
and therefore the objective 
was not clear. If the key 
element would have been 
more clearly formulated, 
the data that reflects the 
desired effect of the key 
element (recommended 
actions resulting from the 
key element) is expected 
to be retrievable from 
EHDs. †
Data that reflects the 
desired effect of the key 
elements could not be 
retrieved from EHDs. 
Prospective data collection 
via survey (questionnaire 
or interview), patient 
chart review or any 
other method to collect 
information is needed for 
analysis.
The objective to minimise 
drug related risks is 
unclear or not applicable. 
Sine no effect with regard 
to a minimised risk could 
be achieved, these key 
elements were considered 
not eligible for analysis 
at all.
*EHDs=electronic healthcare databases. These include databases of routinely collected medical information that are 
commonly used in pharmacoepidemiolic and pharmacovigilance research and contain data on drug prescription, 
diagnosis and events. 
†The key elements are also eligible for analysis with newly collected data.
Data analysis
Descriptive statistics were used to describe the key elements and the possibility to analyse the key 
elements in existing EHDs.
resulTs
By 1st April 2011, for 11 of the 227 active substances authorised before 2005 and 57 of the 199 
authorised after the requirement on EU-RMP came into force in 2005 had aRMMs. The 68 active 
substances with aRMMs included in our study are presented in Appendix I. In total, 801 key elements 
were identified for these active substances. Table 3 shows that the median of the number of key 
elements per active substance was 9.5 (ranging from 1 to 68).
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Total
Categorised key elements
Knowledge change
Behavioural change
Others
Eligible for analysis
Possibly eligible for analysis in 
EHDs
Not eligible for analysis in EHDs 
unless more clearly defined
Not eligible for analysis in EHDs
Not eligible for analysis at all
Table 3: Number of key elements per active substance
Total (%) Median number of key 
elements (range)
Active substances with at 
least one key element of 
that category
801 (100)
287 (36)
459 (57)
55 (7)
175(22)
87 (11)
521 (65)
18(2)
9.5 (1-68)
3 (0-23)
4 (0-42)
0 (0-5)
2 (0-13)
1 (0-5)
5 (0-59)
0 (0-3)
68
59
61
25
49
40
63
13
EHD=electronic healthcare database
The identified key elements are described in Tables 3 and 4. Overall, 36% of the key elements aimed 
knowledge changes and 57% aimed behavioural changes. 66% of the key elements were targeted to 
HCPs of which the majority (64%; 337 of the 529) aimed behavioural changes of this target group. These 
key elements were most frequently classified as ‘recommended actions regarding drug prescription’ 
(n=136) followed by ‘recommended actions regarding the drug administration process’ (n=94). 56% 
of the key elements targeted at patients (122 of the 217) aimed a behavioural change, which mainly 
concerned ‘recommended actions to be followed during treatment use’ (n=112). Per active substance 
the median number of key elements that aimed a knowledge change and behavioural change was 3 
(range 0 - 23) and 4 (range 0 - 42), respectively. 
The researchers assessed 22% of all key elements possibly eligible for analysis in EHDs based on 
the data that was considered retrievable from existing EHDs. None of these key element aimed a 
knowledge change. 37% of key elements that aimed a behavioural change (172 of the 459) was 
classified possibly eligible for analysis in EHDs of which the majority was targeted to HCPs (98%; 168 of 
the 172). These key element were most frequently classified as ‘recommended actions regarding drug 
prescription’ (n=88) or ‘recommended actions to perform clinical examinations and laboratory tests’ 
(n=58). Only 3% of the key elements classified as ‘recommended actions regarding drug administration 
process’ (3 of the 94) was assessed possibly eligible for analysis in EHDs.
16% of the key elements aimed at behavioural changes (72 of the 459) were assessed not eligible 
for analysis in EHDs unless more clearly defined. These key elements were distributed over 40 active 
substances and all targeted at HCPs. The majority was categorised as ‘recommended actions regarding 
drug prescription’ (67%; 48 of the 72), which correspond to 35% of the key elements in this category 
(48 of the 136). The majority of the key elements assessed not eligible for analysis at all (15 of the 18) 
concerned pharmacovigilance instructions, i.e. regarding the need to report adverse events.
 
Overall, 49 active substances (72%) had at least one key element (median of 3 key elements, ranging 
between 1 to 13) that was assessed possibly eligible for analysis in EHDs. Most frequently, this 
concerned a key element categorised as ‘recommended action regarding drug prescription’ (38 
active substances) and for 28 active substances a key element categorised as ‘recommended action to 
perform clinical examinations and laboratory tests’. 
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Total
Knowledge change
Targeted to patients
Targeted to HCPs
Behavioural change
Targeted to patients
Recommended actions 
to be followed during 
treatment use
Recommended actions 
to early detect or treat/
resolve ADRs
Targeted to HCPs
Recommended actions 
regarding drug 
prescription
Recommended actions 
regarding the drug 
administration process
Recommended actions 
to perform clinical 
examinations and 
laboratory tests
Recommended actions 
to treat/resolve ADRs
Other
PhV instructions
Not elsewhere classified
Table 4: Categorised key elements of the active substances with aRMMs licensed at 1 April 2011
Category Total 
(%) *
Possibly 
eligible 
for 
analysis 
in EHDs 
(%)†
Not eligible 
for analysis in 
EHDs unless 
more clearly 
defined (%)†
801 
(100)
95
(12)
192
(24)
112
(14)
10 (1)
136
(17)
94
(12)
73
(9)
34
(4)
44 (5)
11 (1)
ADR=adverse drug reaction; EHD=electronic healthcare database; HCP=healthcare professional; PhV=pharmacovigilance 
*Colum percentage
†Row percentage of the total number of key elements of that category
§ One active substance can have multiple key elements concerning different categories 
Not eligible 
for analysis 
in EHDs 
(%)†
Not eligible 
for analysis 
at all (%)†
Total 
(%) *
With key 
elements 
eligible for 
analysis in 
EHDs §
175 (22)
0 (0)
0 (0)
4 (4)
0 (0)
88 (65)
3 (3)
58 (80)
19 (56)
3 (7)
0 (0)
87 (11)
0 (0)
15 (8)
0 (0)
0 (0)
48 (35)
6 (6)
8 (11)
10 (29)
0 (0)
0 (0)
521 (65)
95 (100)
177 (92)
108 (96)
10 (100)
0 (0)
85 (90)
7 (10)
5 (15)
26 (59)
8 (73)
18 (2)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
15 (34)
3 (27)
68
31
56
23
8
46
38
34
19
22
9
49
0
0
3
0
 
38
3
28
 
11
3
0
Number of key elements
Number of active 
substances
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disCussiOn
This study provides a first review on the eligibility of aRMMs for analysis in existing EHDs. Currently, 22% 
of the aRMM key elements are considered suitable for assessment in EHDs, based on the information 
we considered retrievable from these data sources. These mainly concerned key elements aimed at 
behavioural changes of HCPs, e.g. recommendations regarding the dose, concomitant medications or 
to perform a laboratory test. 
Overall, only 50% of the key elements aimed at behavioural change of HCPs were assessed eligible 
for analysis in EHDs. For those key elements that were not considered eligible for analysis in EHDs, 
either the data necessary to measure the desired effects were not recorded routinely in these systems 
or the key elements per se were not clear and do therefore not allow monitoring. Still 21% of the 
key elements aimed at behavioural changes of HCPs were assessed not eligible for analysis in EHDs 
due to ambiguous formulated key elements, e.g. use the drug with caution; carefully select patients. 
These key elements should be reformulated into clear recommended actions. This could improve the 
adherence to the aRMMs and facilitate rapid assessment of aRMM effectiveness. It is in the interest 
of individual patients and public health that industry and regulatory authorities work with carefully 
formulated aRMMs resulting in clear objectives that optimise the benefit-risk balance of a drug.
Key elements that aimed behavioural changes in patients (e.g. recommendations for patients on 
how to take their medication or a warnings to avoid exposure to sunlight) are difficult to monitor in 
existing EHDs, since it is unlikely this information is routinely collected and captured by EHDs. The 
same holds for key elements aimed at knowledge change which covered a large proportion of all 
key elements, e.g. information on the most serious adverse reactions of the drug; information on 
the medical implications of a drug-drug interaction. If these recommendations and knowledge are 
deemed essential for maintaining a positive benefit-risk balance, the challenge is how to analyse its 
effectiveness in a swift and proper way using prospective data collection. aRMMs aiming a knowledge 
change may contribute considerably to the aRMM effectiveness and can therefore not be disregarded. 
Risk awareness is an essential aspect to obtain behavioural changes.13 In addition, education on early 
recognition of signs and symptoms of ADRs can improve the patient’s outcome, relevant for individual 
patients as well as for public health.14 
Data collection
As shown in this study, approaches that go beyond the use of EHDs are needed to allow assessment of 
knowledge and behavioural changes. It remains however a challenge to perform these aRMM analyses 
timely and in an appropriate way. Alternative strategies to prospectively collect new information can 
include surveys (questionnaire or interviews) or review of case reports or patient’s charts.15-17 Prospective 
data collection via surveys can be time consuming and delay the assessment whereas insufficient 
aRMMs need to be identified in an early stage to enable prompt improvement. Furthermore, surveys 
can yield non-response bias and sampling error that may prevent drawing valid conclusions from 
the assessment of aRMM’s effectiveness.18, 19 However, also the number of subjects using drugs 
with aRMMs available in EHDs can be limited, particularly in outpatient setting (i.e. general practice 
databases) since drugs with aRMMs are often used for treating serious disease in hospital. The type of 
data used for the evaluation of aRMMs and the possible impact on the methodology, validity of the 
data, time planning, possible outcome measures or other potential biases should be well considered 
by researchers, regulators and MAHs.
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Strengths and limitations of the study
A formal categorisation for aRMM key elements does not (yet) exist. Because of the heterogeneity 
of the data, we classified the key elements based on objective (knowledge and behavioural change) 
and target group in ten categories. This categorisation was necessary to adequately describe the key 
elements in our study, but may need further improvement. However, using smaller categories result 
in many key elements that can be classified in several categories which would be complicated and 
inaccurate. It will also increase the chance of misclassified key elements.
Existing EHDs can vary substantially and we did not formally review particular EHDs. Instead, we used 
the knowledge available regarding such data sources and obtained characteristics of EHDs commonly 
used within pharmacoepidemiology and pharmacovigilance research from ENCePP. Our aim was not 
to draw conclusions regarding specific databases, while providing information about the eligibility 
to analyse the effectiveness of aRMM in these resources. We assessed whether in general an aRMM 
might be suitable for analysis in existing EHDs. The feasibility of particular databases need to be 
verified separately. 
To our knowledge, this is the first study that reviewed whether the approved aRMMs in the EU are 
eligible for analysis specially in existing EHDs. The results of this study can be used to improve aRMMs, 
and facilitate monitoring of effectiveness which is mandatory since the new EU pharmacovigilance 
legislation. To facilitate assessment of aRMM’s effectiveness, besides the need for well-defined 
aRMMs with clear objectives, there is a need for pre-defined indicators of success to be agreed in 
a study protocol. Without pre-defined objectives the assessment of the aRMMs and its effect on 
clinical practice and consequently the benefit-risk balance of a drug may still be open for discussion. 
Although some guidance is available,1, 10, 20 there is a clear need for further development of evaluation 
methodologies and interpretation of the outcomes with regard to the benefit-risk balance of the drug. 
Conclusions 
Using readily available data from existing EHDs provide an efficient way to allow rapid and timely 
assessment, which is necessary to modify aRMMs and improve implementation in early stages if 
warranted. However, the results of the study show that only a limited proportion of the key elements 
of aRMMs is considered eligible for analysis in existing EHDs as these data sources cannot capture all 
the required data. Due to difference between existing EHDs, not necessarily all available EHDs will 
be appropriate to monitor effectiveness for every drug or aRMM. Based on these findings, industry 
and regulatory authorities should agree on well-defined aRMM key elements leading to unambiguous 
actions of the target group. This could improve adherence to aRMMs and facilitate the assessment of 
effectiveness of aRMMs which is a new legal obligation for MAHs and regulatory authorities.
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5-aminolevulinic acid hydrochloride
abatacept
adalimumab
agomelatine
alemtuzumab
ambrisentan
anidulafungin
besilesomab
bosentan
caffeine
canakinumab
capsaicin
certolizumab pegol
characterised viable autologous 
cartilage cells expanded ex vivo 
expressing specific marker proteins. 
(ChondroCelect©)
collagenase clostridium histolyticum
conestat alfa
deferasirox
degarelix
dexamethasone
dronedarone
eculizumab
efavirenz/emtricitabine/tenofovir 
disoproxil
eltrombopag
epoetin alpha
eptacog alfa (activated)
eptotermin alfa
fentanyl (buccal tablets)
fentanyl (nasal spray)
fingolimod
gadoversetamide
golimumab
hydroxycarbamide
indacaterol
infliximab
Appendix I: Active substances with aRMMs included in the study and their key elements
Active substance Number of key 
elements
Active substance
15
1
5
7
7
47
7
1
23
12
10
6
5
11
7
21
18
4
10
12
4
1
27
5
9
10
17
19
17
3
5
14
3
6
lasofoxifene
leflunomide
lenalidomide
mecasermin
methoxy polyethylene glycol-epoetin beta
micafungin
moroctocog alfa
natalizumab
nilotinib
nonacog alfa
olanzapine
pandemic influenza vaccine (Focetria©)
pandemic influenza vaccine (H1N1) 
(Humenza©)
pandemic influenza vaccine (H5N1) 
(Celvapan©)
pandemic influenza vaccine (H5N1) 
(Pandemrix©)
pegaptanib
pirfenidone
pneumococcal polysaccharide conjugate 
vaccine (13-valent, adsorbed)
porfimer
prasugrel
ranibizumab
ranolazine
retigabine
rilonacept
roflumilast
romiplostim
sevelamer
sildenafil
silodosin
thalidomide
tocilizumab
ustekinumab
vernakalant
zoledronic acid
7
6
52
16
6
9
16
13
11
10
15
5
5
5
5
13
8
2
27
5
10
14
4
11
17
12
3
3
5
68
13
9
15
12
Number of key 
elements
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aBsTraCT
Evaluation of the effectiveness of drug risk minimisation measures is mandatory for both 
risk evaluation and mitigation strategies (REMS) in the United States and risk management 
plans in the European Union (EU-RMPs). Such evaluations aim to assess the impact of 
risk minimisation measures on the knowledge, attitudes or behaviours of healthcare 
professionals or patients, the incidence of safety concerns, and their impact on the overall 
benefit-risk balance. Although many effectiveness evaluation models and methods are 
available, regulatory guidance and policy are still evolving. This paper considers evaluation 
strategies, challenges in evaluating risk minimisation post-authorisation, possible outcome 
measures and their interpretation, and potential emerging regulatory policy issues. Particular 
challenges include appropriate data collection, perceived and real burdens of performing 
evaluation on clinical practice, lack of comparators and benchmarking, and uncertainty 
about the best outcome measures.
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inTrOduCTiOn
For some drugs with serious risks it may be necessary to improve the benefit-risk balance with measures 
extending beyond the routinely required summary of product characteristics (SmPC), package leaflet, 
packaging labelling, pack size and design, and legal status of a drug.1 In the European Union (EU), 
such extra activities are referred to as additional risk minimisation measures (aRMMs). 
Examples of aRMMs include educational programmes for healthcare professionals (HCPs) and patients, 
and required interventions such as pre-prescription screening of patients to ensure the appropriate 
patient population.2 The measures are often implemented through use of appropriately selected tools, 
such as a prescriber brochure and patient card. In the EU, when an aRMM is necessary, this is set 
out in the risk minimisation section of the risk management plan (RMP), a mandatory part of all new 
marketing applications.3 The RMP considers the important identified and potential safety concerns 
of the drug and missing information within the safety specification, the planned pharmacovigilance 
activities to monitor and further characterise these safety concerns during the post-marketing period 
(including post-authorisation safety studies), and risk minimisation measures (RMMs), both routine and 
additional, that aim to prevent and mitigate the safety concerns in clinical practice.1 In the United States 
(US), the Food and Drug Administration (FDA) can require a risk evaluation and mitigation strategy 
(REMS) for a medicinal product, which can be a compulsory element of usage of the drug.4 Although 
the specific legislation differs between EU and the US, in both jurisdictions these additional measures 
are interventions that aim to minimise the occurrence and/or impact of adverse drug reactions (ADRs).
The risk management approach, including the use of RMMs, is evolving,5 and new standards are 
required under the EU pharmacovigilance legislation that came into effect in 2012.1, 6, 7 The need for 
aRMMs or a REMS is evaluated during the registration process of a drug and also on a continuous 
basis during the lifecycle of the drug (Figure 1). The number of products with aRMMs has grown. 
The proportion of centrally approved active substances with aRMMs in the EU was 5% among 
products authorised before the RMP became mandatory in 2005; and 29% among products approved 
afterwards.2 As a result, the need for adequate evaluation has also increased. 
Measuring effectiveness of the RMMs and REMS post-marketing is an important part of the continuous 
re-evaluation of the benefit-risk balance of a drug. This also includes an assessment of whether the 
existing RMMs are sufficient and enables modification of the initial measures to improve the risk 
minimisation strategy if warranted. A feedback loop to detect potential issues with the adopted RMMs, 
so that corrective actions can be implemented promptly, is a key component of the overall approach. 
With the recent EU pharmacovigilance legislation, monitoring the effectiveness of the aRMMs has 
become mandatory for both marketing authorisation holders (MAHs) and regulatory authorities.6 
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Figure 1: Evaluation of risk minimisation at different lifecycle stages
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In the US, a REMS assessment plan needs to be approved in advance of REMS implementation. The 
REMS effectiveness analysis is normally needed at 18 months, 3 years and 7 years after REMS approval.4 
The REMS assessments should include an evaluation of the extent to which each of the REMS elements 
is meeting the goals and objectives of the REMS, and whether or not the goals, objectives, or REMS 
elements should be modified. Other regions are developing their own RMP requirements. Many are 
based closely on the EU-RMP template (such as Brazil), some have a country-specific addendum (such 
as Australia), whilst others, including Japan, have implemented their own template. However, it is likely 
that all will require some form of post-launch evaluation of any aRMMs, so the principles discussed in 
this paper are relevant for their potential impact on global regulatory policies. 
Currently, there is limited knowledge on the approaches for evaluating tools, and the determinants 
of success of RMMs. In this paper, the evaluation strategies and the challenges involved in evaluating 
RMMs during the post-marketing phase are discussed. Potential outcome measures and their 
interpretation are also considered. 
MOdels OF evaluaTiOn OF eFFeCTiveness
Prieto et al.8 described a model assessing RMMs and their implementation (process indicators), 
including measurement of tool delivery and acquired clinical knowledge, as well as the resulting clinical 
behaviours. Effectiveness of the risk minimisation strategy as a whole can be evaluated by demonstrating 
a reduction in the occurrence or severity of ADRs (Figure 2). A key goal for some programmes may 
be appropriate patient selection to ensure maximal benefit-risk balance. Proper patient selection may 
exclude high-risk patients from treatment or could optimise outcomes by maximising benefit even 
though the frequency and severity of ADRs may not change. Prieto’s model usefully differentiates 
between process indicators and final outcome indicators, providing a basic hierarchy of evidence for 
RMM evaluation. However, both this model and the good pharmacovigilance practices (GVP) Module 
XVI on the evaluation of risk minimisation measures remain relatively non-specific regarding detailed 
methodology for evaluating the risk minimisation plan as a whole; other than suggesting the use of 
epidemiological outcomes studies.1, 7
61Post-approval evaluation of effectiveness of risk Minimisation: Methods, Challenges and interpretation
Figure 2: Evaluation of the effectiveness of risk minimisation plans by a dual evidence approach – the 
implementation process and the outcomes (adapted from Prieto et al.8
ADR=adverse drug reaction; RMM=risk minimisatoin measures; RMP=risk management plan
A 5-level model9 (Figure 3) with different evaluation levels, resulting in increasing utility of information, 
may be used to determine RMM effectiveness. The evaluation levels range from: level 1 (risk 
minimisation tool coverage) addressing the distribution of the risk minimisation tools, to level 5 (safety 
outcomes), covering linkage of risk minimisation tool usage to safety outcomes, i.e., occurrence of 
ADRs. Behavioural (level 4) and safety outcomes (level 5) data may be harder to obtain but generally 
have higher value than information on tool coverage (level 1), awareness and usage (level 2) and 
knowledge (level 3) metrics. The effectiveness of individual tools can be measured at all levels, 
whereas the success of the overall programme in meeting goals and objectives can be evaluated at 
levels 3 to 5. This 5-level model adds a detailed hierarchy of evidence into the evaluation of tools, 
and attempts to link the evaluation of individual tools and the risk minimisation plan as a whole into a 
single continuum.
A complementary model10 (Figure 4) evaluates effectiveness at various intervals. In this model, the 
complete RMM strategy and risk minimisation tool content and face validity can be assessed in level 
1 (pre-approval phase). Assessment of the implementation of the risk minimisation tools includes use 
of the tools and the acquired clinical knowledge and behaviour (level 2). The overall effectiveness of 
the RMM and the impact on the occurrence or severity of the safety concern is assessed in level 3. 
The second and third levels provide complementary information relevant for the assessment of the 
RMM’s impact on the benefit-risk balance of the drug. This latter model makes the iterative elements 
of evaluation, correction and re-audit integral to the overall chronological process. These three models 
should prove useful for communicating the concept of assessing both implementation and outcomes, 
and aiding more detailed planning of components in the evaluation of effectiveness post-marketing.
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Figure 3: A 5-level framework covers both individual risk minimisation tools and programme evaluation, and 
focuses on the quality of evidence
Chapter 4
PASS=post authorisation safety study; RM=risk minimisation
Figure 4: Evaluation steps increase in utility of information with time after implementation10
aRMM=additional risk minimisation measure; RM=risk minimisation
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shOrTCOMings OF CurrenT risK MiniMisaTiOn evaluaTiOn aPPrOaChes
Regardless of the model, a number of challenges emerge when considering effectiveness evaluation 
systems in general.
Appropriate data collection
Appropriate data collection is important to adequately assess the RMMs and many data sources can 
be used. Some examples of potential suitable metrics and their interpretation are shown in Table 1 
for each level of the 5-step model. Information on patients’ or HCPs’ knowledge, behaviour and drug 
use can be prospectively collected via surveys. With this type of data collection, specific and detailed 
information from the target group can be collected. However, issues with recruiting participants; and 
small or unrepresentative sample sizes may occur which make it difficult to draw robust conclusions.11 
Level 1:
Risk minimisation tool 
coverage
Level 2:
Risk minimisation tool 
awareness and usage
Level 3:
Risk knowledge and 
comprehension
Level 4:
Behavioural 
modification
Level 5:
(Correlation with) 
Safety outcomes
ADR=Adverse drug reaction; HCP=Healthcare professional
Table 1: Possible risk minimisation tool evaluation metrics and suggested interpretations based on the          
5-level model (see Figure 3)
Evaluation level Example metrics and data to be collected
Tool distribution over time (in total and by 
category, such as country or type of HCP)
Download frequency of electronic tools 
Rate of tool use over time (including by 
country, region, or type of HCP)
Which fields within a tool are completed and 
the time taken
How frequently specific information about 
drug-related risks is accessed for an electronic 
tool
Results from knowledge surveys for both tool 
users and non-users
Extent of deviations from ideal behaviour (e.g. 
off-label prescribing)
Frequency of linked risk minimisation actions 
(e.g. HCP providing patient with educational 
information)
Relevant ADR frequencies and severities
Increase or decline in tool use and 
geographic coverage over time
Gaps or bottlenecks in access and active 
tool use
Whether the level of knowledge about 
key risks and their mitigation is sufficient, 
or suggests modifications to tools are 
required
Whether knowledge is due to the tools or 
gained from other sources
Appropriateness of actions by HCPs and 
patients, consistent with the product 
information and best practice guidance 
where available (e.g. for patient selection 
and providing the appropriate information 
to the right patient)
Comparing ADR rates and/or severities 
from suitable sources against appropriate 
reference values
Interpretation
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An independent study of REMS assessments submitted by MAHs and reviewed by the FDA in 
the period 2008 to 2011, highlighted issues with submission on time, completeness and meeting 
their stated goals. The issues identified included difficulties with data collection (predominantly 
survey-based methods were used) and sample sizes that were too small for enabling conclusions to be 
drawn. Almost half of the REMS assessments reviewed did not include all the information requested in 
FDA assessment plans. Based on these results, the FDA was recommended to identify and implement 
reliable methods for assessing the effectiveness of REMS, decrease its reliance on survey data in REMS 
assessments and work with MAHs and HCPs to develop more accurate evaluation methods.12 
Other known limitations for surveys include sample populations that do not reflect the demographics 
of the target population, bias caused by convenience samples (‘lower-risk’ patients and HCPs are often 
more likely to take part in such surveys13, 14) and a lack of objective standards to measure knowledge of 
risks. Furthermore, knowledge and behaviour surveys are usually based on a subject’s recall of events 
or expectations, rather than direct measurement of how risk education affects behaviour, meaning 
surveys may fail to reflect real tool use and utility for all intended users. Response rates to surveys are 
often low, indicating that they may represent a burden on clinical practice.15
 
Evaluations of aRMMs or REMS effectiveness that allow assessment of safety outcomes often rely on 
integration with data sourced from electronic healthcare records, or from disease or drug registries,16, 
17 as electronic healthcare databases include information on drug prescription (which reflects the 
HCP’s behaviour) and patient safety outcomes. These data sources are often used within pharma-
coepidemiology and pharmacovigilance research and provide opportunities to study effectiveness 
of RMMs. Using routinely collected data reflecting actual care is efficient, and timely feedback on the 
RMMs may be provided. However, electronic healthcare databases may not capture sufficient and 
relevant data10 and only cover some drugs.18 Examples of electronic healthcare databases are the 
administrative (claims) databases, routine primary care databases, pharmacy dispensing databases, 
hospital databases and disease/drug registries.19, 20 Several claims databases (e.g., Premier in the US) 
and prescription databases, such as the Nordic prescriber databases and Clinical Practice Research 
Datalink (CPRD), can give valuable information on drug utilisation. Studies can examine the extent of 
off-label use, indication, dosage and prescriber characteristics, offering useful indirect information on 
safety outcomes that can be correlated with behaviours. However, although HCP behaviour on drug 
prescribing and patient follow-up information in the form of coded events is available, knowledge 
cannot be measured from these data sources.
Spontaneous reporting systems are also possible data sources as these include case reports of patients 
that developed adverse events. These systems, however, suffer from biases such as under-reporting 
and lack of a suitable overall denominator (i.e., total exposure to the drug, number of patients exposed 
or number of drug doses administered), which inevitably hampers interpretation of results. The use of 
spontaneous reports may therefore not be suitable or sufficient.
Another issue is the timing of effectiveness evaluation. The interval between tool deployment, data 
collection, interpretation and actioning changes can often be a number of years, whereas ideally, 
efficient and timely evaluation is needed to allow early closure of the audit loop and timely aRMM 
amendment if necessary. It takes time for a newly-launched drug to sufficiently penetrate the 
market and often certain sample sizes are necessary to be able to observe desired effects and draw 
conclusions on the study outcomes. Therefore, the timing of assessment should be appropriate for the 
intervention, and the expectations of all stakeholders, including regulators, should be realistic. REMS 
have a mandated timeline for assessments which may not be an appropriate fit for every REMS.
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Overall, strengths and limitations of the type of data collection should be carefully considered on a 
case-by-case basis depending on the RMMs, the safety concerns and drug involved. 
Lack of comparators 
Drugs with RMMs that are required at the time of initial marketing authorisation do not have defined, 
unbiased comparator groups of tool non-users for post-launch RMM evaluation. Post-hoc analysis 
may be used, where risk minimisation tool users are compared with non-users, although in practice it 
may be difficult to distinguish them. Furthermore, there may be other confounding factors, such as a 
propensity to riskier clinical practice by ‘non-users’ that contributes to an increased risk of occurrence 
of a particular safety concern. This makes any observed difference difficult to attribute to any positive 
effects of the tools themselves. 
It would also not be ethical in the post-approval setting to have a control group where RMMs, that 
contribute to the favourable benefit-risk balance of the drug, were not available. However, when the 
value of the risk minimisation is unclear, a potential approach could be a phased implementation of 
aRMMs that initially includes a comparator population that does not use the aRMMs. Such an approach 
has been utilised for modifying the risk minimisation of an already-launched antifungal product, with 
the management of unresolved hepatotoxicity safety issues involving a modified aRMM approach 
piloted in two EU countries, prior to interim evaluation and subsequent rollout in the rest of the EU.21
An alternative solution would be to test the proposed risk minimisation measure in a proportion of the 
phase III study population. This allows some valuable comparative information to be gained, albeit not 
in a real-world setting. It may also be possible to compare different drugs, with and without aRMMs, or 
compare the safety outcomes for the drug with a reference value for the target or general population.22 
Nevertheless, all comparisons will have their limitations and the most appropriate solution should be 
selected on a case-by-case basis, and will be dependent on the data available.
Lack of meaningful outcomes
RMMs aim to minimise the inherent risks of drug treatments, thus optimising the benefit-risk balance 
of the drug. Ideally, successful implementation should lead to a reduced ADR rate and/or severity, by 
increasing the patients’ and HCPs’ knowledge and adapting their behaviour (e.g., appropriate patient 
selection), as shown in Figure 2. Since the aRMMs are developed for each drug product independently, 
a ‘gold standard’ set of standard outcome measures cannot currently be defined and only the broad 
outcomes can be outlined. 
For example, in drugs with the risk of teratogenicity, a meaningful outcome is prevention of pregnancy 
or no fetal exposure to the drug in question. The aim is to guide desired behaviours (e.g., use of 
contraceptives and HCPs providing appropriate advice to patients) to meet this goal.23 However, even 
with drugs such as isotretinoin, where strict RMMs have been implemented in the form of a pregnancy 
prevention programme, pregnancies still occur. The real outcome of interest might be minimisation 
of infants with congenital malformations by preventing pregnancies.24, 25 In the case of pregnancies 
occurring, the issue of determining an acceptable threshold based on the benefit-risk profile of the 
drug still arises; that is, evidence of successful effectiveness of an RMM relies on a stated goal for 
defining success.26 
Most evaluations have so far concentrated on measures of process, such as tool distribution and 
utilisation results, rather than clinical outcomes, such as reducing or eliminating ADRs, or fewer 
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patients with absolute or relative contraindications.26 The three models discussed earlier highlight the 
need to also evaluate the latter.
Linking risk management activities to meaningful changes in safety outcomes remains a challenge, as 
demonstrated by the FDA’s recent exercise to address prescription opioid abuse and over-prescribing,27 
which mirrors the experience in other markets. Although evaluation of effectiveness was being 
performed, the data collected failed to either support the goal of improving RMMs, or providing 
evidence to enable future ‘de-commissioning’ of RMMs that have outlived their original purpose. 
Uncertainty about interpretation of evaluation metrics
It is rare to be able to directly associate a reduction in ADRs with specific RMMs. Often, only 
cross-sectional data on safety outcomes are available that are not directly linked to data on the 
patients’ usage/non-usage of tools. Baseline data on knowledge and behaviour are also frequently 
not available. 
Spontaneous reporting rates of ADRs have too many biases, such as under-reporting, to enable a 
change in the frequency of ADR reports to be directly attributed to a risk minimisation intervention. 
This is particularly the case in the period shortly after the aRMM has been introduced or when there 
has been public communication about a serious event. The outcome may be an apparent rise in 
spontaneously reported ADRs, due to better prescriber and patient awareness of a risk increasing the 
reporting rate rather than an increase in the actual ADR rate.
The impact of RMMs on drug use is difficult to predict. Reber et al.28 examined changes in use for 
58 new drugs following direct healthcare professional communications (DHPCs) – colloquially known 
as ‘Dear Doctor letters’. The results showed that DHPCs have a complex effect in changing clinical 
prescription behaviour. In about half the evaluated cases, DHPCs lowered overall drug use in the short 
term, and for around a third of the drugs long-term use was reduced. 
Examination of prescribing outcomes linked to the patient’s condition can identify patients in risk 
groups who may be receiving the drug inappropriately (i.e., not in line with the risk minimisation 
recommendations). HCPs may decide to prescribe a drug not in accordance with the recommended 
RMMs based on valid clinical reasons for individual patients; whereas the aRMMs and REMS aim to 
improve the benefit-risk of a drug at a patient population level. Whilst this is acceptable, it means 
that 100 percent adherence to risk minimisation recommendations is not feasible in clinical practice. 
However, if the frequency or severity of reported ADRs remains high and the benefit-risk balance of 
the drug therefore remains uncertain, appropriate regulatory action should be taken. This may include 
modification of the risk minimisation strategies.
Lack of benchmarking
It is difficult to predict what acceptable levels of distribution, tool uptake and impact on knowledge, 
behaviours and attitudes, constitute success. A first round of evaluation, following market authorisation, 
provides a benchmark, against which future evaluations may be compared. As the number of drugs 
with aRMMs grows, and experience with evaluating these measures evolves, acceptable outcome 
measures will be developed. Such benchmarking will allow newly-introduced aRMMs to be compared 
against these first-round evaluation measures. However, in order to be meaningful, benchmarking 
will need to cover different patient groups, specialist versus generalist prescribers, geography and 
therapeutic area, as these and similar factors may alter risk minimisation tool uptake. Further research 
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is needed to understand the impact of these multiple factors on influencing the implementation of 
individual RMMs. Continued collaboration between industry and regulatory agencies will be necessary, 
to facilitate and agree suitable benchmarking metrics, and will also require an overt regulatory policy 
on greater transparency on publication of the results of effectiveness evaluation. 
innOvaTive WeB-Based TOOls FaCiliTaTe daTa COlleCTiOn
Many of the shortcomings of current evaluation methods could be addressed by implementation 
approaches that allow consistent, timely collection of evaluation data, relevant to the objectives of the 
specific RMMs deployed. 
Web-based risk minimisation tools can facilitate data collection for the evaluation of the aRMMs. 
They can be combined with simultaneous collection of data reflecting actual behaviour of tool 
users, providing timely and ongoing evaluation (Figure 5).29, 30 Internet facilities in healthcare centres 
are widely available globally. For example, in the EU an estimated 80 percent of hospitals have 
implemented electronic patient record systems, suggesting a potential to become paperless in 
future.31 This supports an increase in both web-based risk minimisation tools and web-centric risk 
minimisation evaluation programmes. 
Web-based tools can enhance HCP-to-patient communications (Pope Woodhead. User testing for 
new drug product X. 2013), for example, enabling HCPs to send automated reminder messages to 
patients. Furthermore, web-based tools can be used to confirm whether patient counselling was 
provided when the drug was prescribed, encourage ADR reporting and link tools to other post-launch 
data-gathering initiatives, including spontaneous reporting systems and registries. Routine collection 
of anonymised data from risk minimisation tool users, processed continuously in real time, permits 
rapid assessment of the effectiveness of the implementation and tools themselves, and provides a 
straightforward approach to periodic evaluation.32 In the future, patient-reported outcomes of adverse 
events (PRO-AEs) may offer a useful and relevant approach for assessing the success of RMMs.33, 34 
However, a number of factors need to be considered when deploying web-based RMMs (for both HCPs 
and patients), for example, tool penetration and usability, how to achieve coverage where the internet 
is not available, and data protection issues (which may vary between countries). Hence, a web-based 
risk minimisation approach that incorporates evaluation requires careful design and supporting IT 
infrastructure, though over the lifetime of a product. Complexity can also arise in integrating data 
from multiple sources such as PROs, patient drug lists, health outcomes, provider education and 
assessment results. The numerous health records systems within the US and differences between EU 
member states provide further complexity.
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Figure 5: Web-based behavioural risk minimisation tools can combine education, communication and real-time 
evaluation
RM=risk minimisation
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POTenTial iMPaCT On regulaTOry POliCies
From a regulatory policy perspective, aspects to consider include corrective actions, establishment 
of an agreed baseline, and potentially more combined/single RMPs for a product class to allow more 
impactful comparisons. 
For effectiveness evaluation to be useful, an audit loop should be closed; i.e., corrective actions should 
be taken based on the collected results if necessary. Whilst appropriate actions may include modifying 
the aRMMs or individual risk minimisation tools, sometimes the MAH in conjunction with regulatory 
authorities might consider making the programme less onerous (particularly if it is clear that adequate 
risk minimisation is successfully occurring without the need for tool intervention; e.g., despite low tool 
usage).
Effective processes in risk management are essential, so steps should be incorporated to allow 
elimination of ineffective tools or programmes. Measures impose a considerable burden on clinicians, 
support staff and patients, and are often expensive to implement. Effectiveness depends on the quality 
of the tools and overall programme and both should be scrutinised, by establishing clear success 
criteria for each. Table 2 outlines proposed actions to improve effectiveness of both risk minimisation 
tools and the aRMMs overall for a product. The suggested action depends on the success of the 
deployment versus the effectiveness of risk minimisation as a whole. In this framework, deployment is 
defined by tool coverage and usage, measured by distribution/utilisation and tracking metrics (levels 
1 and 2 of the 5-level model shown in Figure 3); and effectiveness of the risk minimisation is measured 
by knowledge, attitudes and behaviours and the safety outcomes themselves (levels 3, 4 and 5 of the 
5-step model in Figure 3).
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Low
High
HCP=Healthcare professional
a If utilisation of the distributed tools is low,35 raise awareness or provide training as a first step36, 37
b Monitoring of tool effectiveness over time may indicate appropriate use of the drug, leading to the opportunity to reduce 
or remove aRMMs38
c Many programmes have experienced fewer than 20 percent of prescribers and patients using the tool(s)39
d Collaboration with stakeholders is important in the design of aRMMs.
e Over time, wider experience of aRMM evaluation may allow therapy- and user- specific acceptable ranges for tool usage 
to be established22
Table 2: Possible actions following risk minimisation effectiveness evaluation
Deployment of risk 
minimisation measures
Effectiveness of risk minimisation
1. Increase tool awareness via enhanced   
    education and communication with HCPs
2. Targeted training to increase correct tool 
    usea
3. Adapt tools to encourage greater 
    utilisationc
4. Introduce stricter controls to drive tool use 
    (e.g. compulsory rather than voluntary)c 
5. Re-evaluate to ensure effectiveness
1. Redesign risk minimisation strategy and     
    reconsider choice of risk minimisation 
    toolsd
2. Modify the content and format of tools, as 
    appropriate
3. Re-evaluate to ensure effectiveness
1. Consider whether risk minimisation 
    measures can be scaled backb
2. If measures are modified, re-evaluate 
    to ensure adequate risk minimisation is 
    maintained
1. Continue risk minimisation in current 
    form
2. Further evaluation to ensure standards 
    are maintainede 
Low 
 
Other issues that potentially impact regulatory policy will be a move towards transparency of the 
results of effectiveness evaluation and corrective actions taken. This will eventually allow prospective 
benchmarking and, potentially, the setting of target standards of deployment expected from MAHs 
at the time of approval if possible. Greater harmonisation between the aRMMs, perhaps with 
class-specific risk minimisation, would allow greater efficiency and less confusion for prescribers and 
patients, promoting greater engagement of the end-user with voluntary aRMMs.40 
Regulators should ensure that the requirements for effectiveness evaluation of aRMMs with accepted 
methodologies are transparent. 
High
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COnClusiOns
Measuring the effectiveness of aRMMs and REMS is an important aspect of the benefit-risk evaluation 
of a drug. Limited detailed guidance is currently available on the evaluation of effectiveness of aRMMs, 
leading to a lack of consistency which is only partly addressed by the recent GVP guidance and the 
REMS guidance. Available models include assessment of effectiveness at different levels, with varying 
utility of information. 
Specific challenges in evaluation include appropriate data collection, lack of comparators, uncertainty 
on the best outcome measures and lack of benchmarking or pre-defined aRMM objectives, which may 
be indicative of a weak underlying risk minimisation strategy. The difficulty of collecting adequate and 
timely data may be impeding evaluation of effectiveness of aRMMs. The result is that the reaction 
time to safety issues is slow, and revisions to implemented RMPs to address potential safety issues are 
protracted. 
Optimal risk minimisation evaluation involves assessment of aRMM deployment and use, as well as the 
knowledge and behaviour of patients and HCPs, and the safety outcomes. Evaluation methods need 
to be tailored to specific safety concerns, the actual aRMMs deployed and the drug involved. Global 
regulatory policy must also embrace industry, patients and prescribers to pre-define comprehensive, 
but feasible, objectives and evaluation plans and iteratively close the audit loop in a timely way on 
any aRMMs.
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aBsTraCT
Background In October 2011 risk minimisation measures in the form of dose restrictions 
were recommended to minimise the dose dependent risk of QT interval prolongation 
associated with citalopram. The maximum daily doses were reduced from 60 mg to 40 mg 
and in patients aged ≥ 65 from 40 mg to 20 mg. The objective of this study was to assess 
the impact of these recommendations on the use of citalopram in the Netherlands (NL) and 
the United Kingdom (UK).
Methods A retrospective population-based study was conducted within primary care 
databases in NL (IPCI: 1998 – 2012) and UK (THIN: 1996 – 2013). Monthly prevalence 
and incidence rates of citalopram were calculated (users/1,000 person years (PY)) and 
stratified by country, age group (<65; ≥ 65) and daily dose category ≤ 20 mg (low); >20 
to ≤ 40 mg (moderate); > 40 mg (high). Interrupted time-series analysis using an ARIMA 
(autoregressive integrated moving average) model was performed to assess the effect of 
the dose restrictions on the use of citalopram.
Results Over the entire study period the monthly prevalence rate of citalopram use was 
higher in UK compared with NL and independent of country and age group, monthly 
prevalence rates were highest for citalopram low dose and very low for high dose citalopram. 
After the dose restrictions, in the population ≥ 65 years the use of citalopram with moderate 
dosage significantly decreased both in UK and NL. In UK this was also observed for the high 
dose in this older population, since use was low in NL a further significant decrease was not 
observed. Among the British and Dutch population below 65 years of age the use of high 
dose significantly reduced, low and moderate dosages did not decrease significantly in this 
age group. Monthly rates of new citalopram users were higher among the population ≥ 65 
years compared to those < 65 years and reduced after the dose restrictions independent 
of country and age categories. Although the trends were the same, the change was only 
significant in the British population of ≥ 65 years (p=0.003).
Conclusions Following the dose restrictions in October 2011 the use of citalopram 
high and moderate dosages decreased in UK and NL. The effects seemed to be stronger 
in UK compared to NL. An additional effect was the decrease in elderly patients starting 
citalopram after the dose restrictions.
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inTrOduCTiOn
Citalopram is a selective serotonin reuptake inhibitor (SSRI) indicated to treat depressive episodes and 
panic disorders and authorised in the European Union (EU) since 1989.1 The product is available in 10 
mg, 20 mg, 40 mg tablets and in a 40 mg per ml solution (oral drops). The recommended starting dose 
of citalopram is 20 mg daily which can be increased depending on the individual patient response, 
before stopping it should be gradually reduced to avoid withdrawal effects.1 In 2011 new safety 
information for citalopram became available and the United States (US) Food and Drug Authority 
(FDA) as well as the European Medicines Agency (EMA) issued a warning for dose dependent QT 
interval prolongation following the use of citalopram.2, 3 The QT interval represents the duration of 
ventricular depolarisation and subsequent repolarisation, and is measured from the beginning of the 
QRS complex to the end of the T wave.4 A delay in cardiac repolarisation creates an electrophysiologi-
cal environment that favours the development of cardiac arrhythmias, most clearly torsade de pointes, 
but possibly other (fatal) ventricular arrhythmias as well.4, 5 Prolongation of the QT interval associated 
with a drug has led to regulatory action in the past including drug withdrawals or risk minimisation 
measures such as precautionary statements or prescribing restrictions.6-8 Risk minimisation measures 
are defined as interventions intended to prevent or reduce the occurrence of adverse drug reactions, 
or to reduce their severity or impact on the patient should the adverse drug reaction occur.9
To minimise the risk of QT interval prolongation, the European regulatory authorities recommended 
reducing the maximum daily dose of citalopram from 60 mg to 40 mg and from 40 mg to 20 mg in 
elderly (≥ 65 years) and those with reduced liver function as they achieve higher systemic exposure 
to the drug than younger patients and those with normal hepatic function.2 Furthermore, citalopram 
has been contraindicated for concomitant use with other medicines known to prolong the QT interval 
and in patients with established QT prolongation or congenital QT syndromes. A direct healthcare 
professional communication (DHPC) was sent to inform healthcare professionals (HCPs) at the end of 
October 2011.10, 11 The product information of citalopram was updated with new safety information, 
dose restrictions and contraindications of citalopram.12 The impact of these risk minimisation measures 
on the use of citalopram in the EU has not yet been evaluated. Therefore, the objective of this study 
was to assess the impact of the risk minimisation measures issued at the end of October 2011 on the 
use of citalopram in two European countries.
MeThOds
Data sources
In this study primary care databases from two European countries were used. 
The Health Improvement Network (THIN) database 
THIN is a longitudinal database of primary care medical records from the United Kingdom (UK). 
Electronic medical records date back to 1985. The database contains anonymised medical records 
including data on patient demographics, medical diagnoses and prescriptions written by general 
practitioners (GPs), diagnoses from specialists, referrals and hospital admissions, laboratory test results, 
and some lifestyle characteristics as smoking and alcohol consumption. Diagnoses and symptoms 
are recorded using READ codes. Information on drug prescriptions is coded with MULTILEX product 
dictionary and British National Formulary (BNF) codes.13 Currently, the cumulative database contains 
information on about 8 million patients registered with 580 practices in the UK.
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Interdisciplinary Processing of Clinical Information (IPCI) database
The IPCI database is a longitudinal observational database that contains data from computer-based 
patient records of a selected group of GPs throughout the Netherlands (NL). The database contains 
information on patient demographics, drug prescriptions, clinical diagnosis, physician-linked 
indications for therapy, physical findings, and laboratory values (e.g. potassium, creatinine). Diagnoses 
and complaints are recorded using the International Classification of Primary Care (ICPC) coding 
system, free text and hospital discharge letters.14 Information on drug prescription is coded according 
to the Anatomical Therapeutical Chemical (ATC) classification, and also the product name, quantity 
dispensed, dosage regimens and strength are available. In the beginning of 2013, the cumulative 
database contained information on about 1.6 million patients.
Study population 
The study population comprised all patients registered in the THIN database between 1st January 
1996 until 31 August 2013 and all patients registered in IPCI between 1st May 1998 and 31 December 
2012. To be able to identify new users of citalopram, only subjects with a registration in the database 
of at least 365 days were included in the study. A patient was considered a new user if citalopram was 
prescribed after at least a previous 365 days period of non-citalopram use. Patients included in the 
cohort were followed from start of study period or from registration with GP plus 365 days (whichever 
latest) until the end of the study period, transferring out the database or death, whichever date came 
first. 
Exposure of interest
Prescriptions of citalopram tablets (ATC code N06AB04) were identified from the THIN and IPCI 
database. Prescriptions of citalopram oral drops were not considered in the study since the prescribed 
daily dose could not be adequately calculated from the prescriptions. For each prescription the daily 
dose was calculated using the prescribed regimen. The daily dose was categorised in three classes 
i.e. ≤ 20 mg (low dose), > 20 mg to ≤ 40 mg (moderate dose), > 40 mg (high dose). Citalopram 
prescriptions with exactly similar prescription dates and different strengths were assumed to be used 
simultaneously and therefore these prescriptions were pooled and considered as one prescription 
(e.g. the prescriptions of a 10 mg and 20 mg tablets to reach a daily dosage of 30 mg). For each 
prescription the duration of citalopram exposure in person time (in days) was calculated by dividing 
the total number units prescribed by the number of units prescribed daily. 
Outcomes of interest
To get a general picture of citalopram use we measured monthly prevalence and incidence rates of 
citalopram use in the total cohort. Furthermore, characteristics of patients that started citalopram 
before and after the recommended dose restrictions were compared to investigate whether there 
were differences in age at treatment initiation, sex and mean length of prescription. Compliance to the 
dose recommendations was reviewed by assessing changes in the distribution of the prescribed daily 
dose categories among all citalopram users per month. In addition, it was assessed whether patients 
using citalopram at time of the new dose restrictions were issued (i.e. 31 October 2011) changed 
the daily dose of their subsequent prescription. Those without a prescription within 30 days after the 
previous prescription ended were considered to have discontinued citalopram treatment.
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Analysis
Monthly prevalence rates and monthly incidence rates for citalopram were calculated by dividing 
the number of subjects receiving at least one prescription with the total person time of the cohort 
and expressed per 1,000 person years (PY). Rates, including the 95% confidence interval (95% CI), 
were calculated and stratified by country, age categories (< 65; ≥ 65) and daily dose categories (low, 
moderate, high). Patients receiving prescriptions for different daily dose categories in one time period 
contributed to both dose categories. The proportion of citalopram users that received a citalopram 
prescription with a particular daily dose was calculated by dividing the number of patients using 
citalopram daily dose category low, moderate or high by the total number of prevalent users per 
month, per country and for patients aged < 65 and ≥ 65 separately. To assess the effect of the risk 
minimisation measures issued in October 2011 on the prevalence and incidence rates of citalopram, 
interrupted time series analyses were performed using an autoregressive, integrated, moving average 
(ARIMA [p, d ,q]) model. In this model, p represents the lingering effects of preceding scores, d is 
the integrated element which represents the trends in the data, and the moving average element q 
represents the lingering effects of preceding random shocks. The risk minimisation measures issued 
in October 2011 were considered the intervention and a variable was created with a value of 0 prior 
to the date of intervention and with a value of 1 after the date of intervention. ARIMA models were 
estimated prior to the intervention using the expert modeller function within SPSS, which accounted 
for possible seasonality within the data. This estimated model was applied on the entire set using the 
prevalence and incidence rate of the study drug as outcome and the intervention as independent 
variable. We stratified for daily dosage (low, moderate, high) and age groups (< 65 and ≥ 65). The 
output was the change in prevalence due to the intervention (ß) with a corresponding p-value. 
Statistical significance was assumed for two-sided p-values < 0.05. Interrupted time series analyses 
were also performed to assess the impact of the risk minimisation measures on the distribution of the 
daily dose among the citalopram users. The t-test or chi-square test was used to derive p-values when 
comparing continuous or categorical variables between incident citalopram users before and after the 
risk minimisation measures were issued. Statistical significance was assumed for two-sided p-values < 
0.05. The interrupted time series analyses were performed using SPSS software version 15.0 (SPSS Inc, 
Chicago, IL, US). All other analyses were carried out using SAS version 9.2 (Cary, North Carolina, US).
resulTs
From the UK a total number of 7,193,431 subjects were included in the cohort contributing 44,397,740 
PY of follow-up between 1 January 1996 and 31 August 2013. The Dutch cohort included a total of 
1,676,802 subjects contributing 4,672,494 PY of follow-up between 1 May 1998 and 31 December 
2012. The study populations are described in Table 1.
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Prevalence rates
Both in the UK and NL an increase in the monthly prevalence rates of citalopram for all three daily dose 
categories among patients aged < 65 and ≥ 65 was observed during the study period (Figure 1a and 
1b). As shown in these figures, over the entire study period the monthly prevalence rate of citalopram 
use was higher in UK compared with NL and in both countries the prevalence rate of citalopram was 
higher in elderly (≥ 65 years) compared to the population younger than 65 years of age. Independent 
of country and age group, the monthly prevalence rates were highest for low dose citalopram use 
and very low for high dose citalopram use over the complete study period. After the dose restrictions 
were issued in October 2011, the monthly prevalence rates of citalopram in UK did not increase 
any further while in NL the prevalence rate remained more or less stable (Figure 1a and 1b). Among 
the British elderly population, the monthly prevalence rates of moderate and high citalopram dose 
reduced significantly (p<0.000), whereas the lowest daily dose category (≤ 20 mg) among this patient 
population was not significantly affected (p=0.283). Among the Dutch elderly population a significant 
decrease in citalopram use was observed only for the moderate daily dose category (p=0.012). The 
use of high dose citalopram was minimal already before the warning came. Among the British and 
Dutch population younger than 65 years of age the use of high dose significantly reduced (p=0.011 
and p=0.004), low and moderate dosages did not decrease significantly in this age group.
New citalopram users 
In UK and NL the monthly incidence (new user) rates of citalopram use were generally higher among 
the elderly population (≥ 65 years) compared to those younger than 65 years and reduced after the 
dose restrictions of citalopram both in UK and NL and in both age categories (Figure 2a and 2b). 
Comparing characteristics of new citalopram users before and after the dose restrictions showed that 
the proportion of new users aged 65 or older at treatment initiation significantly reduced 27.1% to 
25.0% in NL (p=0.026) and from 19.1% to 17.7% in UK (p<0.000) (Table 2). Furthermore, among the 
British new citalopram users the proportion of males was significantly higher and the mean age at 
treatment initiation significantly lower in the period after the dose restrictions compared with the 
period before. No significant changes in these characteristics were observed in NL.
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Study period
Total subjects
Total person-time in PY
Sex, Male, N (%)
Mean age in years (95% CI)
Citalopram users, N (%)
Citalopram exposure in PY (%)
CI=confidence interval; IPCI=Interdisciplinary Processing of Clinical Information; PY=person year; THIN=The Health 
Improvement Network; 
Table 1: Description of the study populations
United Kingdom
THIN
1 January 1996 to 31 August 2013
7,193,431
44,397,740 PY
3,531,972 (49.1)
40.7 (40.7 – 40.7)
492,522 (6.8)
508,227 PY (1.1)
IPCI
1 May 1998 to 31 December 2012
1,676,802
4,672,494 PY
819,240 (48.9)
39.8 (39.8 – 39.8)
17,465 (1.0)
17,113 PY (0.4)
the Netherlands
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Figure 1a: Monthly prevalence rates of citalopram use in the Netherlands
Figure 1b: Monthly prevalence rates of citalopram use in the Netherlands
The date the dose restrictions were communicated is indicated with the vertical dotted line. The p-values of the 
interrupted time-series analyses reflect whether subsequent observations per month after the dose restrictions were 
significantly affected
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Patient characteristics at treatment initiation
Incident users
1.Jan.1996 to 
31.Oct.2011
[N=422,198]
32.46 
(32.31 – 32.60)
47.54 
(47.49-47.60)
N=80,521;
19.07 
(18.95 – 19.19)
3,839,235
32.29 
(32.28 – 32.31)
CI=Confidence Interval; UK=United Kingdom.
*Incident users are patients starting citalopram after a citalopram free period of 365 days. A patient can be included as an 
incident user more than once and in both study periods.
†Including prescriptions of the incident users prescribed during the corresponding period. 
Table 2: Characteristics of incident citalopram users and their prescriptions in UK and the Netherlands*
United Kingdom The Netherlands
Incident users
1.Nov.2011 to 
31.Aug.2013
[N=87,664]
34.07 
(33.76 – 34.39)
46.60 
(46.48-48)
N=15,537;
17.72 
(17.47 – 17.98)
425,536
32.21 
(32.17 – 32.26)
p-value
<0.000
<0.000
<0.000
<0.000
Incident users
1.Jan.1996 to 
31.Oct.2011
[N=422,198]
36.25
(35.17 – 37.32)
52.23
(51.79 – 52.67)
N=2082;
27.10 
(26.10 – 28.09)
49,135
36.96 
(36.71 – 37.22)
Incident users
1.Nov.2011 to 
31.Aug.2013
[N=87,664]
36.57
(34.86 –38.28)
51.70
(51.02 -52.38)
N=765;
25.00 
(23.46 – 26.54)
12,464
33.71 
(33.23 – 34.18)
p-value
0.756
0.202
0.026
<0.000
Sex, Male % (95% CI)
Mean Age (95% CI)
65 year or older, N; % 
(95% CI)
Number of 
prescriptions
Mean length per 
prescription, in days 
(95% CI)
Prescriptions of incident users†
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Figure 2a: Incidence rates of citalopram use in the Netherlands for patients aged < 65 and ≥ 65
Figure 2b: Incidence rates of citalopram use in the United Kingdom for patients aged < 65 and ≥ 65
The date the dose restrictions were communicated is indicated with the vertical dotted line. The p-values of the 
interrupted time-series analyses reflect whether subsequent observations per month after the dose restrictions were 
significantly affected
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Figure 3a: Distribution of daily dosages in Dutch 
prevalent citalopram users aged < 65 years
Figure 3b: Distribution of daily dosages in Dutch 
prevalent citalopram users aged  ≥ 65 years
Figure 3c: Distribution of daily dosages in British 
prevalent citalopram users aged < 65 years
Figure 3d: Distribution of daily dosages in British 
prevalent citalopram users aged  ≥ 65 years
The date the dose restrictions were communicated is indicated with the vertical dotted line. The p-values of the 
interrupted time-series analyses reflect whether subsequent observations per month after the dose restrictions were 
significantly affected
Table 3a and 3b show that independent of the daily dose category, the majority of citalopram users 
at 31 October 2011 continued the dosage that was used at 31 October 2011. Among the British, 
the first prescriptions (N=58,311) that followed after this date were prescribed in November 2011 
(76%), December 2011 (22%), January 2012 (2%) or ≥ February 2012 (0.1%). In NL (N=3,515), these 
proportions were 56%, 28%, 13% and 2%, respectively. Although the largest effects were observed 
among patients using citalopram at high dose, still a large majority continued using this daily dose, 
73.8% of the elderly and 70.4% of the users younger than 65 years in UK which was 72.7% and 73.9% 
in NL, respectively. The proportion of patients aged ≥ 65 that continued with citalopram in moderate 
daily dose was 87.3% in UK and 79.2% in NL.
Compliance to dose restrictions
No significant changes in the distribution of the three daily dose categories after the dose restrictions 
were recommended were observed in Dutch citalopram users (Figure 3a and 3b). In contrast, in the 
UK, the proportion of citalopram users that used citalopram at high daily dose significantly decreased 
in users aged < 65 (p<0.000) as well as among those ≥ 65 years (p=0.002) (Figure 3c and 3d). While 
in the older British prevalent citalopram users the proportion using moderate dosages decreased 
significantly after the new dose recommendations (p=0.013), this proportion significantly increased 
among the younger British prevalent citalopram users (p=0.048).
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Discontinued* 
Low dose
Moderate dose
High dose
Table 3a: Change in daily doses of citalopram users at 31 October 2011 in NL (N=4,034) by age category
Daily dose of 
prescription followed 
after 31 October 
2011
< 65
N=2,015 (%)
≥ 65 
N=86 (%)
< 65 
N=853 (%)
269 (13.3)
1,691 (83.9)
52 (2.6)
3 (0.1)
*When the last day of the prescription was followed with 30 days in which no new prescription, the patient was 
discontinued with citalopram
Low dose(≤ 20 mg daily), moderate dose (>20 mg to ≤ 40 mg daily), high dose (> 40 mg daily) 
NL=the Netherlands
≥ 65 
N=174 (%)
< 65 
N=115 (%)
≥ 65 
N=11 (%)
105 (12.1
752 (86.8)
9 (1.0)
0 (0.0)
111 (13.0)
25 (2.9)
711 (83.3)
6 (0.7)
19 (10.9)
8 (4.6)
147 (84.4)
0 (0.0)
13 (11.3)
1 (0.9)
16 (13.9)
85 (73.9)
2 (18.2)
-
1 (9.1)
8 (72.7)
Daily dose at 31 October 2011
Low Dose Moderate Dose High Dose
Discontinued* 
Low dose
Moderate dose
High dose
Table 3b: Change in daily doses of citalopram users at 31 October 2011 in UK (N=64,741) by age category 
Daily dose of 
prescription followed 
after 31 October 
2011
< 65
N=32,533 (%)
≥ 65 
N=14,689 (%)
< 65
N=12,669 
4,018 (12.4)
27,275 (83.8)
1,181 (3.6)
59 (0.2)
*When the last day of the prescription was followed with 30 days in which no new prescription, the patient was 
discontinued with citalopram
Low dose(≤ 20 mg daily), moderate dose (>20 mg to ≤ 40 mg daily), high dose (> 40 mg daily) 
UK=United Kingdom
≥ 65 
N=2,764 (%)
< 65 
N=1,929 (%)
≥ 65 
N=157 (%)
848 (5.8)
13,687 (93.2)
150 (1.0)
4 (0.0)
111 (13.0)
25 (2.9)
711 (83.3)
6 (0.7)
118 (4.3)
147 (5.3)
2,492 (90.2)
7 (0.3)
191 (9.9)
70 (3.6)
309 (16.0)
1,359 (70.4)
10 (6.4)
7 (4.4)
24 (15.3)
116 (73.8)
Daily dose at 31 October 2011
Low Dose Moderate Dose High Dose
disCussiOn
Following the dose restrictions recommended by regulatory authorities in October 2011 to minimise 
the risk of dose dependent QT interval prolongation in association with citalopram, in elderly the use of 
citalopram with moderate dosage decreased significantly both in the UK and NL and in British elderly 
also the use of high dose. In patients younger than 65 years, in both countries only the high dose of 
citalopram decreased significantly. Independent of country and age categories, a large majority of 
patients using citalopram at 31 October 2011 continued using the same daily dose, including high 
dosages. An additional effect of the risk minimisation measures was the decrease in new citalopram 
users of 65 year and older, which was not anticipated. 
The dose restrictions seemed to have larger effect in UK than in NL. The proportion of British 
citalopram users that used moderate and high doses significantly reduced after the recommended 
dose restriction which was not significant in NL. The modest changes among Dutch prevalent users 
after the dose restrictions may be explained by an overall lower prevalent use of citalopram as well as 
the stable monthly prevalence rates in the period before the dose restrictions were issued while during 
this period in the UK an increasing trend of prevalent use was observed for all daily dose categories. 
Furthermore, the effects of dose restrictions seem to be more prominent in new users than in patients 
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that were already using citalopram at time of the regulatory measures and continued using citalopram. 
Those on treatment were less likely to have the dose changed compared to new users. These different 
behaviours show that different recommendations may need to be given for those that actually start 
treatment and those patients on treatment with a drug that needs dose escalation to avoid withdrawal 
symptoms. 
Apart from the regulatory actions (the DHPC and updated product information) that were implemented 
in all EU member states, there might be other factors that potentially contributed to the changes 
in citalopram use or may (partly) explain differences between UK and NL. The recommended dose 
restrictions of citalopram were implemented in the Dutch drug prescribing and dispensing systems, 
the British National Formulary and NICE medicines and prescribing associates in UK shortly after they 
were issued.15 These systems may have contributed to the effects on citalopram use as observed in 
this study. On the contrary, considering clinical guidelines, no information on maximum daily dose of 
citalopram was included in the Dutch GP guideline, Dutch guideline for specialists and neither in the 
UK guideline (NICE) for the treatment of depression and this did not change after the new dosing 
recommendations.16-18 Regulatory warnings possibly lead to media attention which may affect drug 
prescription.19-22 However, apart from the DHPC published at the website of the Dutch Medicines 
Evaluation Board and an announcement of the Netherlands Pharmacovigilance Centre,23 there was no 
media attention with regard to the QT interval prolongation of citalopram neither escitalopram in NL. 
In the UK the Medicines and Healthcare products Regulatory Agency (MHRA) published information 
on the new dose recommendations for citalopram on their webpage in a Drug Safety Update and 
updated their learning module on SSRIs.24, 25 Information on the issue in the British newspapers was 
limited and only appeared a few months later, in July 2012 and January 2013.26-28 
Strengths and limitations
This study used two primary care databases which contain a large number of patients, reflect the 
underlying population and allowed the evaluation of a 14 to 16 year period. A major advantage of the 
study was also that we studied the impact in two European populations while using same definitions 
and analysis. This enabled us to directly compare the effects of the risk minimisation measures on 
citalopram use across two countries. Interrupted time series design is preferred to study the impact 
of policy changes where it difficult to employ a control group, and account for potential biases in 
the effect of the intervention including secular trend, seasonal effects, random fluctuations and 
autocorrelations.29
 
Since in our study primary care data was used there are several limitations. We could only assess the 
impact of the recommended dose restrictions on prescription of citalopram by GPs. Prescriptions from 
specialists were not included but previous research has shown that in NL and other western countries 
the majority of the SSRIs are prescribed by GPs.19, 30, 31 A further limitation of the study is that not 
all aspects of the risk minimisation measures communicated in October 2011 were evaluated. We 
did not assess compliance with the contraindication of concomitant use with other drugs known to 
prolong the QT interval. More importantly, the impact on the occurrence of QT interval prolongation 
in citalopram users has not been studied while minimising this risk was the primary aim of the risk 
minimisation measures. Future research should study the impact of the risk minimisation measures 
on the occurrence of prolonged QT interval or other relevant outcomes such as torsades de pointes, 
ventricular arrhythmia or sudden cardiac death. 
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Conclusions
After the risk minimisation measures were issued in October 2011, the use of high and moderate 
dose citalopram decreased in both UK and NL, although stronger in UK. While in both countries the 
decrease in elderly people starting citalopram after the dose restrictions was considered an additional 
effect, changes in prescriptions of patients that were using citalopram at time of the regulatory 
action were limited. It might be that the overall higher and up until than increasing prevalent use of 
citalopram in UK before October 2011 resulted in stronger visible effects compared to NL but it may 
also be possible that the British prescribers react more prompt to regulatory warnings compared to 
the Dutch prescribers.
impact of risk minimisation measures on citalopram use in two european countries
5
88 Chapter 5
College ter Beoordeling van Geneesmiddelen. Summary of Product Characteristics: Cipramil. Available from: http://
db.cbg-meb.nl/IB-teksten/h19593.pdf. Accessed 21 March, 2014.
European Medicine Agency (EMA). Pharmacovigilance working party (PhVWP) Monthly Report October Meeting. 2011; 
Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/10/WC500117061.pdf. Accessed 21 
March, 2014.
MedWatch The FDA Safety Information and Adverse Event Reporting Program. Celexa (citalopram hydrobromide): Drug Safety 
Communication - Abnormal Heart Rhythms Associated With High Doses. 2011; Available from: http://www.fda.gov/Safety/
MedWatch/SafetyInformation/SafetyAlertsforhumanmedicalproducts/ucm269481.htm. Accessed 21 March 2014.
van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010 
70(1):16-23.
Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004 350(10):1013-22.
Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals 
for prescription medications. JAMA 2002 287(17):2215-20.
De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or 
induce torsade de pointes: an overview. Drug Saf 2002 25(4):263-86.
European Medicine Agency (EMA). Restrictions on the use of domperidone-containing medicines. 2014; Available from: http://
www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Domperidone_31/European_Commission_final_
decision/WC500172573.pdf. Accessed 4 November, 2014.
European Medicine Agency (EMA). Guideline on good pharmacovigilance practices (GVP) Module XVI– Risk minimisation 
measures: selection of tools and effectiveness indicators. 2014; Available from: http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2014/02/WC500162051.pdf. Accessed 23 March, 2014.
Direct Healthcare Professional Communication: Cipramil (citalopram). 2011; Available from: http://www.cbg-meb.nl/NR/
rdonlyres/F90D8CE6-AD7A-492A-A471-E5862466571A/0/111031DHPCCitalopram.pdf. Accessed 21 October, 2014.
Direct Healthcare Professional Communication: Cipralmil (citalopram). 2011; Available from: http://www.mhra.gov.uk/home/
groups/pl-p/documents/websiteresources/con134754.pdf. Accessed 11 August, 2013.
Citalopram and the risk of QT prolongation - Final SmPC and PL wording agreed by the PhVWP in October 2011. 2011; Available 
from: http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Product_Information/PhVWP_Recommendations/
Citalopram/CMDh_PhVWP_033_2011_Rev0.pdf. Accessed 21 October, 2014.
Lewis J, Schinnar R, Bilker W, Wang X, Strom B. Validation studies of the health improvement network (THIN) database for 
pharmacoepidemiology research. Pharmacoepidemiol & Drug Safety 2007 16(393-401.
Lamberts H, Wood M. International Classification of Primary Care. Oxford: Oxford Univeristy Press, 1987.
Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (KNMP). G-update: January 2012. 2012.
Van Weel-Baumgarten E, Van Gelderen M, Grundmeijer H, Licht-Strunk E, Van Marwijk H, Van Rijswijk H, et al. NHG-Standaard 
Depressie (tweede herziening). Huisarts Wet 2012 55(6):252-9.
Spijker J, Bockting C, Meeuwissen J, Van Vliet I, Emmelkamp P, Hermens M, et al. Multidisciplinaire richtlijn Depressie (Derde 
revisie). Richtlijn voor de diagnostiek, behandeling en begeleiding van volwassen patiënten met een depressieve stoornis. 
2013; Available from: http://www.ggzrichtlijnen.nl/index.php?pagina=/richtlijn/item/pagina.php&richtlijn_id=88. Accessed 21 
October, 2014.
National Institute for Heath and Care Excellence (NICE). Depression in adults with a chronic physical health problem: Treatment 
and management. 2009; Available from: http://www.nice.org.uk/guidance/cg91/resources/guidance-depression-in-adults-
with-a-chronic-physical-health-problem-pdf. Accessed 21 October 2014.
Hernandez JF, Mantel-Teeuwisse AK, van Thiel GJ, Belitser SV, Warmerdam J, de Valk V, et al. A 10-year analysis of the effects 
of media coverage of regulatory warnings on antidepressant use in The Netherlands and UK. PLoS One 2012 7(9):e45515.
Murray ML, Thompson M, Santosh PJ, Wong IC. Effects of the Committee on Safety of Medicines advice on antidepressant 
prescribing to children and adolescents in the UK. Drug Saf 2005 28(12):1151-7.
Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, et al. Early evidence on the effects of regulators’ suicidality 
warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007 164(9):1356-63.
Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort 
study in The Health Improvement Network (THIN). PLoS One 2012 7(3):e33181.
Lareb. QT-interval verlenging bij citalopram (Cipramil®). 2011; Available from: http://www.lareb.nl/Nieuws/2011/QT-interval-
verlenging-bij-citalopram-(Cipramil%C2%AE). Accessed 24 October, 2014.
Medicines and Healthcare products Regulatory Agency (MHRA). Citalopram and escitalopram: QT interval prolongation—new 
maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. 2011; Available from: http://
www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137769. Accessed 4 November, 2014.
Medicines and Healthcare products Regulatory Agency (MHRA). Selective serotonin reuptake inhibitors (SSRIs) learning module 
- main section. Available from: http://www.mhra.gov.uk/ConferencesLearningCentre/LearningCentre/Medicineslearningmod-
ules/SSRIlearningmodule/CON146583?useSecondary=&showpage=20. Accessed 21 October, 2014.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
reFerenCes
89impact of risk minimisation measures on citalopram use in two european countries
Telegraph TD. Antidepressants: Safety warning over Britain’s most common drug. 2012; Available from: http://www.telegraph.
co.uk/health/9367001/Safety-warning-over-Britains-most-common-antidepressant.html. Accessed 11 October, 2014.
NHS. Antidepressant citalopram heart safety warning. 2012; Available from: http://www.nhs.uk/news/2012/07July/Pages/
antidepressant-citalopram-qt-heart-rhythm-safety-warning.aspx. Accessed 10 October, 2014.
BBC. Heart risk link to SSRI antidepressants confirmed. 2013; Available from: http://www.bbc.com/news/health-21247330. 
Accessed 24 October, 2014.
Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series designs in health technology assessment: 
lessons from two systematic reviews of behavior change strategies. Int J Technol Assess Health Care 2003 19(4):613-23.
Gardarsdottir H, Heerdink ER, Egberts AC. Potential bias in pharmacoepidemiological studies due to the length of the drug 
free period: a study on antidepressant drug use in adults in the Netherlands. Pharmacoepidemiol Drug Saf 2006 15(5):338-43.
Trifiro G, Patadia V, Schuemie MJ, Coloma PM, Gini R, Herings R, et al. EU-ADR healthcare database network vs. spontaneous 
reporting system database: preliminary comparison of signal detection. Stud Health Technol Inform 2011 166(25-30.
26.
27.
28.
29.
30.
31.
5

a coMPaRison of PREGnancy PREvEntion 
PRoGRaMMEs in EuRoPE
6
Ineke H.J.M.J. Crijns*, 
Ingeborg M. Zomerdijk*, 
Miriam C.J.M. Sturkenboom, 
Lolkje T.W. de Jong-van den Berg  
and Sabine M.J.M. Straus 
*the first two authors contributed 
equally to this work.
Expert Opinion on Drug Safety. 
2014; 13(4): 411-20.
92 Chapter 6
aBsTraCT
Background Pregnancy Prevention Programmes (PPP) can be imposed by regulatory 
authorities to minimise the risk of exposure to teratogenic drugs during pregnancy, thus 
preventing congenital anomalies. The objective of this study was to explore the reasons to 
request PPPs in the EU and the elements that these programmes included. 
Methods For the seven drugs with a PPP, the Summary of Product Characteristics (SmPC) 
and publicly available assessment reports at the EMA website were used to obtain data.
Results Five of the seven drugs obtained a PPP based on an established or expected 
high teratogenic risk in humans. Similarities in the PPPs were: pregnancy tests both before 
and monthly during drug use; contraceptive use and pregnancy prevention counselling. 
Differences regarded educational materials, restricted drug supply, continuation of 
contraceptive use and pregnancy tests after treatment discontinuation. The last two 
differences could be explained by pharmacological characteristics of the drug. 
Conclusions The reason for requesting a PPP is not always clearly defined and variation 
in risk minimisation measures for teratogenic drugs exists. There is a need for regulatory 
guidance on proper judgment to request for a PPP and its development. Knowledge on the 
benefits and burden of PPPs in clinical practice is necessary to optimise PPPs.
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inTrOduCTiOn
Teratogenicity of a drug is a risk that can significantly impact its benefit-risk balance due to the 
occurrence of congenital anomalies when used shortly before or during pregnancy. Teratogens can 
irreversibly modify growth, structure, or function of the developing embryo or fetus.1 A well-known 
teratogenic drug is thalidomide. Thalidomide was introduced at the European market in the late 
1950s as sedative and morning-sickness treatment. In 1961, it was discovered that thalidomide 
caused congenital anomalies in new-borns of women who had taken thalidomide during pregnancy 
and subsequently the drug was withdrawn.2, 3 Since there is a very low tolerance for teratogenic drug 
exposure in pregnant women, it becomes important to minimise the risk with appropriate measures to 
improve the benefit-risk balance of teratogenic drugs. 
Risk minimisation measures are interventions that aim to minimise the occurrence or severity of safety 
concerns related to a drug.4 Routinely required risk minimisation measures are the Summary of Product 
Characteristics (SmPC), the package leaflet (PIL), pack size and legal (prescription) status, which are 
considered sufficient for most drugs. However, some drugs contain serious important risks requiring an 
extra form of risk minimisation, that is, additional risks minimisation measures (aRMMs).4 An example 
of an aRMM is a pregnancy prevention programme (PPP), which can be required to minimise the risk 
of exposure to teratogenic drugs during pregnancy to prevent congenital anomalies.
Currently there are seven drugs for which a PPP is required in the European Union (EU). In 2008 
thalidomide was reintroduced as treatment for multiple myeloma with strict risk minimisation measures 
including a PPP that should be implemented.5 In addition to thalidomide, another immunosuppressant, 
lenalidomide, also has a PPP as well as isotretinoin, acitretin and alitretinoin (vitamin A derivatives), 
bosentan and ambrisentan (endothelin receptor antagonists [ERAs]). Elements and tools that can 
be part of a PPP include educational programmes for prescribers and patients, concomitant use of 
contraception and the need for pregnancy tests before and during treatment on a monthly basis. In 
clinical practice different stakeholders can be involved with the PPP, for example, patients, physicians, 
pharmacists and wholesalers.6 Implementation of a PPP in clinical practice can impose additional 
burden on patients and the healthcare system. To avoid unnecessary and ineffective measures, the 
PPP should be carefully justified, drafted and monitored after implementation. 
Currently, clear guidance or criteria when and which aRMMs should be required remains limited 
and decisions are usually made on a case-by-case basis. PPPs should only be imposed to minimise 
clearly defined serious safety concerns but there might have been different rationales for the 
currently implemented PPPs. Furthermore, there is no standard PPP and the PPPs currently in place 
may, therefore, consist of different elements and recommendations which could potentially lead to 
confusion and diminished compliance by prescribers, patients or other stakeholders. The aim of this 
research was to review the regulatory rationale and criteria to require a PPP in the EU and to describe 
the different elements included in the existing PPPs in the EU.
MeThOds
Regulatory rationale to require PPPs
The rationale to require a PPP was assessed for the seven drugs with a PPP in the EU using publicly 
available information from the summary of product characteristics (SmPC) as available on 5 August 
2011. The SmPCs were obtained either from the European Public Assessment Reports (EPAR) via 
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the European Medicines Agency (EMA) website7 or from the Heads of Medicines Agencies (HMA) 
website.8 In addition, for the centrally authorised products the scientific discussion presented in the 
EPAR was reviewed. 
For each drug included in this study the following information was identified: the active substance, 
indication for use, date of authorisation and drug half-life. Information on teratogenicity was taken 
verbatim from SmPC Section 4.6 ‘fertility, pregnancy and lactation’, Section 5.3 ‘preclinical safety data’ 
and from the scientific discussion presented in the EPAR.
PPP elements 
The approved SmPC of each drug and, if available, Annex II ‘Conditions and restrictions of the 
marketing authorisation’ were reviewed to identify elements of the currently approved PPPs. An annex 
II includes conditions and restrictions regarding the safe and effective use of the medicinal product as 
agreed in the RMP and is available for centrally authorised products and drugs assessed in regulatory 
referral procedures (isotretinoin). 
Drug exposure
For each drug of interest the exposure was identified in the EU-ADR network and the InterActionDataBase 
(IADB). The EU-ADR network consists of anonymous drug prescription or dispensing information of 
approximately 30 million individuals from seven population-based electronic healthcare databases 
of four European countries (Denmark, Italy, the Netherlands and the United Kingdom).9 The IADB 
is a Dutch community pharmacy database and contains prescriptions of approximately 600,000 
individuals.10
The total drug exposure was identified for each drug of interest per calendar year and presented for 
both data sources separately. The drug exposure in EU-ADR network databases was calculated in 
person-years for the period 2000 - 2010. For each prescription, the exposure in person time (days) 
was calculated by dividing the total number of units prescribed by the number of units prescribed 
daily. Per calendar year, the sum of the exposed person time in days was divided by 365.25 to convert 
the exposure unit to person-year. Drug exposure in the IADB was identified by counting the number 
of patients who received the drugs under study during the period 2000 - 2009. Alitretinoin may not 
be marketed during 2000 - 2010 which resulted in no drug exposure for this drug in neither EU-ADR 
network nor the IADB.
Women of childbearing potential (WCBP), defined as female patients between 15 and 49 years of 
age, exposed to the drugs under study, were identified in both data sources. Besides the total drug 
exposure per calendar year, for each drug the percentage of drug exposure covered by WCBP was 
calculated by dividing the exposed WCBP by the total drug exposure of each drug. 
Descriptive statistics were used to calculate the drug exposure.
resulTs
Drug specific information for all drugs with a PPP in the EU is presented in Table 1. According to the 
SmPCs of the drugs, the vitamin A derivatives are authorised for dermatological indications, such as 
severe forms of acne, psoriasis and chronic hand eczema. The immunosuppressants thalidomide and 
lenalidomide are currently authorised to treat the orphan indication multiple myeloma. Both ERAs, 
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bosentan and ambrisentan, are indicated to treat pulmonary arterial hypertension (PAH). Bosentan is 
also licensed to treat systemic sclerosis.
Regulatory rationale to require PPPs
Teratogenicity in humans is established for thalidomide and based on structural and pharmacological 
similarities and pre-clinical evidence; teratogenicity in humans is expected for lenalidomide. An 
established high risk for congenital anomalies in humans is known for vitamin A derivatives and 
determined for isotretinoin. For all three retinoids (isotretinoin, acitretin and alitretinoin) teratogenic 
effects have been observed in animal studies. In contrast, for the ERAs (bosentan and ambrisentan), 
teratogenicity has only been observed in animal studies and implications for humans were unknown 
at the time of licensing and are still not fully known. The scientific information from the EPAR and 
the SmPC of bosentan described that PAH severely deteriorates during pregnancy, and that the 
disease itself and the teratogenicity in animals did lead to a contraindication for bosentan use during 
pregnancy. For ambrisentan, according to the EPAR, the availability of alternative therapeutics was 
also reason to contraindicate use during pregnancy.
Review of PPP elements
The elements of the seven PPPs are summarised in Table 2. Common elements in all PPPs included: a 
contraindication for use during pregnancy and for WCBP unless conditions of the PPP are met; required 
pregnancy tests before treatment initiation and monthly during treatment; need for contraceptive 
measures; patient counselling on pregnancy prevention. All seven drugs had educational material in 
addition to the SmPC and package leaflet for prescribers and patients
The continuation of contraceptive use and performance of pregnancy tests after treatment 
discontinuation varies per drug, that is, not at all, for a 4 weeks period or up to 1 year. These variations 
are due to pharmacological differences such as the drug half-life or the metabolite half-life. Other 
differences observed were additional educational material targeted to the pharmacist, which was 
only required for isotretinoin and alitretinoin. Furthermore, only three PPPs included a patient card. 
Dispensing restrictions were limited to three PPPs. Confirmation of the patient’s understanding of the 
teratogenic risk to be obtained by the prescriber was part of four PPPs. 
An interesting difference was identified for the generic formulations of acitretin, authorised through 
decentralised procedure (DCP), which have educational material in addition to the SmPC and package 
leaflet whereas for the reference product (nationally authorised) only the SmPC provide information on 
the PPP and no educational materials are involved.
Comparison of the SmPCs of the seven drugs, showed that references to the PPP were made in 
different SmPC sections, that is, Section 4.4 ‘Precautions and warnings’ or Section 4.6 ‘Pregnancy and 
lactation’ or both.
 
Drug exposure
Tables 3 and 4 present the total drug exposure and percentage covered by WCBP in the EU-ADR 
databases and the IADB, respectively. As expected, isotretinoin and acitretin both were more widely 
prescribed, in general, as well as among women of childbearing potential, compared to the orphan 
drugs, thalidomide, lenalidomide, bosentan and ambrisentan.
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disCussiOn
In the EU, the PPPs of thalidomide, lenalidomide and the vitamin A derivatives have been imposed 
based on an established or expected high teratogenic risk in humans. For bosentan and ambrisentan, 
the reasoning for the imposed PPP was less clear. The PPPs contained common elements in all PPPs 
such as a contraindication during pregnancy, the need for contraception and regular pregnancy tests. 
Differences between PPPs were observed with respect to the additional educational material and 
restricted drug supply. Both the total drug exposure and exposure among WCBP were the highest for 
isotretinoin. 
The indication of a drug might explain the different percentages of use among WCBP. For instance, 
isotretinoin is indicated to treat severe forms of acne which frequently concerns WCBP while 
thalidomide is indicated for the treatment of multiple myeloma, a disease which occurs at an older 
age. The fact that teratogenic effects of vitamin A derivatives are established and that patients treated 
with these drugs relatively frequent concerned WCBP, stresses the importance for adequate measures 
to prevent exposure during pregnancy in this patient population. 
For the ERAs, teratogenicity has only been shown in animals, but the indication of the drug, PAH, is 
known to severely deteriorate during pregnancy.11 The need for a PPP may be open for discussion since 
risk minimisation measures are intended to minimise drug-related risks while for the ERAs the disease 
related risk, together with evidence from animal studies, might have led to a PPP.4 A comparable 
disease-related risk is present for other drugs indicated for PAH, for example, sildenafil and tadalafil. 
However, in contrast with the ERAs, animal studies do not indicate direct or indirect harmful effects 
on embryonal or foetal development for sildenafil and tadalafil,12, 13 which might explain why these 
drugs neither have a PPP nor a contraindication for use during pregnancy. The non-clinical evidence 
for embyonal or foetal toxicity for the ERAs and the availability of alternative PAH therapies besides 
the ERAs, seems to have led to a PPP and may explain the stricter risk minimisation measures for the 
ERAs compared to other PAH therapies.
For some drugs with known teratogenicity in animals or humans a PPP has not been requested 
but risk minimisation measures are restricted to a contraindication for use during pregnancy and 
warnings in the SmPC, for example, for methotrexate.14 Although these drugs do not have a formal 
PPP, some restrictions are imposed on these drugs by the SmPC, such as a negative pregnancy test 
before treatment initiation in WCBP and a recommendation to use effective contraception during 
treatment.14-17 For fingolimod and leflunomide these recommendations are also addressed with 
aRMMs, however, a formal PPP has not been requested. 
There are also several drugs with a known teratogenic risk in humans which neither have a PPP nor a 
contraindication for use during pregnancy such as antiepileptic drugs valproic acid or carbamazepine.18, 
19 Once women with these medical conditions are planning to become pregnant antiepileptic treatment 
options should be carefully reviewed and potential treatment benefits should be weighed against the 
possible harms for the developing fetus. Although a PPP seems standard for high teratogenic drugs 
as thalidomide and the vitamin A derivatives, variation in the rationale to request PPPs, aRMMs or 
contraindication pregnancy for teratogenic drugs was observed. 
The EU ‘Guideline on risk assessment of medicinal products on human reproduction and lactation: from 
data to labelling’ describes factors to be considered in the assessment of SmPC wordings regarding 
drug use during pregnancy, that is, contraindication, warnings and recommendations.20 Factors to 
be considered include human experience, relevant non-clinical studies, possible alternative safer 
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treatment options and the possibility to delay treatment until the pregnancy has ended. It is difficult 
to assess whether these factors can explain the variation in the risk minimisation measures taken for 
teratogenic drugs observed in this study or whether inconsistent regulatory decisions were made. 
The current EU guideline does not address reasons for requesting a PPP or possible elements to be 
included in a PPP. Further regulatory guidance on these topics would be relevant for the assessment 
and development of PPPs, especially for new drug classes. Recently, a PPP has been requested for 
the first drug of the new drug class of Hedgehog pathway inhibitors, that is, vismodegib, indicated for 
basal cell carcinoma.21
PPP elements 
The first PPP in the EU was established for isotretinoin in 1988 and in 2003 the European Commission 
released a harmonised EU PPP for this drug.22 This PPP seems to be used as a starting point in the 
development of the PPPs of the other drugs, which resulted in similarities between the PPPs, especially 
for comparable drugs as the other retinoids. Variety in the period to continue contraceptive use and 
regular pregnancy tests after drug discontinuation, can be explained by drug-specific characteristics 
as the drug half-life or its metabolites. However, differences in drug dispensing restrictions (i.e., drug 
dispensing within 7 days after prescription; prescription restricted to 30 days) and variation in the type 
of educational materials used (initiation forms, patient cards) which were aimed at different target 
groups (the pharmacist was not always involved) are difficult to explain. The absence of regulatory 
guidance on PPPs and the fact that PPPs can be designed on a case-by-case level, possibly explain the 
variation in regulatory decisions. 
Benefits and burden of the PPP
A consequence of implementing a PPP in clinical practice is the increased burden on the patient 
and healthcare system with extra administrative tasks, use of risk minimisation tools and monthly 
consultations with patients. Whether this burden can be accepted depends on the benefits and the 
existing alternatives of a PPP. Knowledge on the actual benefits and burden of the different PPPs is 
however limited. Different outcome measures can be used to indicate PPP effectiveness in clinical 
practice. Preferably, both the occurrence of drug exposure during pregnancy (known as the ‘final 
outcome measure’) as well as the compliance to PPP elements (the so called ‘process indicators’) 
should be used.23 The latter includes evaluation of prescriber’s and patients’ behavior with regard to 
the PPP requirements, for example, length of isotretinoin prescription or concomitant prescription of 
contraceptives and conclusions on occurrence of drug exposure during pregnancy could not be drawn. 
Studies on the effectiveness of PPPs in the US and EU concluded that compliance to PPPs (e.g., rate of 
contraceptive use) could be improved, but conclusions on the pregnancy rates were less clear.24, 25 The 
effectiveness of the monthly pregnancy tests during isotretinoin use has been studied and seems not 
to reduce the pregnancy exposure rate, whereas the regular pregnancy tests considerably contributes 
to the burden of the PPP.26 Different versions of the isotretinoin PPP in the US have been evaluated. 
In 2002, SMART (System to Manage Accutane Related Teratogenicity) was implemented but due to 
dissatisfied results an even stricter PPP, iPLEDGE, has been implemented since 2006. Both SMART and 
iPLEDGE did not result in reduced number of isotretinoin exposed pregnancies in the US as compared 
to the PPP implemented before 2002, even though compliance to the stricter requirements had 
increased.27-29 Thus, a more stringent PPP does not guarantee better results with regard to pregnancy 
exposure rates, while it may place an unnecessary additional burden on the stakeholders. 
There might be a maximum threshold for the effectiveness of PPPs and more strict programmes may 
not have additional effect. Although it may not be possible to completely eliminate drug exposure 
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shortly before and during pregnancy, this should be reduced to a minimum. Considering the expected 
burden of the PPP and the fact that drugs as thalidomide, lenalidomide and the ERAs are rarely 
prescribed to WCBP due to the indication,30-32 the need for a PPP for these drugs may be open for 
discussion. Especially for the ERAs since the reason for the PPP seems less clear as compared to high 
teratogenic drugs. It can be questioned whether a PPP is the most efficient tool to prevent pregnancies 
for these rarely prescribed drugs and there might be solutions that limit the burden of the PPP. 
Strengths and limitations 
Only the PPPs implemented in the EU have been reviewed in this study which limits the generalisability 
of this study. Since legal bases and regulatory systems differ across countries and continents, this study 
focused on the PPPs in the EU to be able to provide recommendations targeted at the EU regulatory 
system. Comparisons of the PPPs and the effectiveness of these programmes between the different 
continents might be quite interesting.
This study provides a comparison of the PPPs currently implemented in the EU. It would be relevant 
to study the benefits and burdens of single PPP elements to be able to implement the most efficient 
PPPs. This might even differ between countries. 
Recommendations
PPPs are developed on a case by case basis, however, knowledge and guidance on when requesting 
a PPP and the content of a PPP is limited. During the assessment of the need for a PPP and the 
development of such a programme, drug-specific characteristics, previous experiences as well as the 
feasibility in clinical practice should be considered by involving stakeholders, for example, prescribers, 
pharmacists and patients. It may be helpful to provide guidance on standard requirements and optional 
elements of PPPs in the European guideline on human reproduction and lactation. Furthermore, to 
facilitate compliance in clinical practice, PPPs should be easy to be adhered to and understandable 
for stakeholders. Due to differences in healthcare systems, the roles and responsibilities of prescribers 
and pharmacists may vary between EU member states and national adjustments might be necessary. 
Possibilities for harmonisation at national level are both the type of educational tools and the content 
of these materials, which currently vary a lot among the different drugs. 
Conclusions
Risk minimisation measures for teratogenic drugs can vary. The reasons for requiring a PPP seems not 
consistent for drugs that currently have a PPP in the EU. Differences between the existing PPPs in the 
EU are identified which not all could be explained. There is a need for more and better regulatory 
guidance on requesting a PPP and knowledge on the benefits and burden of PPP elements in order 
to develop optimal PPPs.
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aBsTraCT
Objective To estimate isotretinoin exposure in Dutch pregnant women despite the 
implemented pregnancy prevention programme (PPP) and second, to analyse the 
occurrence of adverse fetal or neonatal outcomes in these isotretinoin exposed pregnancies
Design Population-based study
Setting The Netherlands 
Participants A cohort of 203,962 pregnancies with onset between 1 January 1999 and 1 
September 2007 consisting of 208,161 fetuses or neonates.
Main outcome measures Isotretinoin exposure in the 30 days before or during 
pregnancy. Proportions of adverse fetal or neonatal outcomes, defined as intrauterine 
deaths ≥ 16 week of gestation and neonates with major congenital anomalies. Odds ratios 
(ORs) with 95% confidence intervals (CI) adjusted for maternal age were calculated to 
estimate the risk of adverse fetal or neonatal outcome after maternal isotretinoin exposure.
Results 51 pregnancies, 2.5 (95% CI 1.9 to 3.3) per 10,000 pregnancies, were exposed to 
isotretinoin despite the pregnancy prevention programme. Forty-five of these pregnancies, 
2.2 (95% CI 1.6 to 2.9) per 10,000 pregnancies, were exposed to isotretinoin during 
pregnancy and six additional women became pregnant within 30 days after isotretinoin 
discontinuation. In 60% of isotretinoin exposed pregnancies, women started isotretinoin 
while already pregnant. In five out of the 51 isotretinoin exposed pregnancies (53 fetuses), 
9.4% (95% CI 1.3% to 17.6%), had an adverse fetal or neonatal outcome. The OR for 
adverse fetal or neonatal outcomes after isotretinoin exposure in 30 days before or during 
pregnancy was 2.3 (95% CI 0.9 to 5.7) after adjustment for maternal age.
Conclusions Although a PPP was already implemented in 1988, we showed that 
isotretinoin exposed pregnancies and adverse fetal and neonatal events potentially related 
to the exposure still occur. These findings from the Netherlands add to the evidence that 
there is no full compliance to the isotretinoin PPP in many Western countries. Given the 
limited success of iPLEDGE, the question is which further measures are able to improve 
compliance.
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arTiCle suMMary
Strengths and limitations of this study
•	 This is the first population-based study in the European Union (EU) on isotretinoin exposure 
during pregnancy in a large cohort of more than 200,000 pregnancies which enabled estimating 
isotretinoin exposure rates among pregnant women and its consequences on a nationwide scale. 
•	 From the virtually complete and detailed drug dispensing data, isotretinoin exposure could only 
be estimated since drug dispensing data does not ascertain actual drug use and precise exposure 
intervals. However, patients coming for refills are usually taking their drug.
•	 Spontaneous abortions before gestational age of 16 weeks and elective abortions were not 
included in our cohort and therefore our results probably underestimate the number of isotretinoin 
exposed pregnancies and its consequences.
•	 Specific teratogenic risks could not be estimated with data lacking information on pregnancies 
until 16 weeks of gestation and lacking detailed descriptions of adverse fetal and neonatal 
outcomes. 
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inTrOduCTiOn
Isotretinoin, a vitamin A derivative, is licensed in the European Union (EU) since 1983 and is indicated 
for systemic treatment of severe acne (such as nodular or conglobate acne or acne at risk of permanent 
scarring) in patients resistant to adequate courses of standard therapy with systemic antibacterials 
and topical therapy.1 The teratogenic potential is an important characteristic of isotretinoin. Animal 
studies already suggested teratogenic effects in humans and isotretinoin has been contraindicated 
for use during pregnancy since the very beginning of the marketing authorisation. Despite this 
contraindication, the first cases of congenital anomalies after isotretinoin use during pregnancy were 
documented already in 1983.2 As described by Lammer et al. in 1985, isotretinoin embryopathy consists 
of craniofacial, cardiac, thymic and central nervous system defects.3 They found a relative risk of 26 for 
this group of major congenital malformations after systemic isotretinoin exposure during some parts 
of the first 10 weeks after conception.3 Elective termination of pregnancy (ETOP) was decided in more 
than 50% of exposed pregnancies and 20% of the remaining pregnancies ended in a first trimester 
spontaneous abortion.3 Reports of congenital anomalies after isotretinoin use accumulated and 
consequently, in 1988 the marketing authorisation holder of isotretinoin implemented a world-wide 
Pregnancy Prevention Programme (PPP) to better prevent pregnancies among systemic isotretinoin 
users.4 The PPP included an educational programme for prescribers and patients including material 
to be used in counselling women about the need to prevent pregnancy while taking isotretinoin. 
Conditions for prescribing included a negative pregnancy test, the use of reliable contraception and 
a signed patient consent form.4 In 2003, a review of isotretinoin by the European Medicine Agency 
(EMA) resulted in a compulsory European harmonised PPP for all isotretinoin containing products.1 The 
elements of the European wide PPP are listed in box 1. 
Box 1: Elements of the European Union isotretinoin pregnancy prevention programme
Isotretinoin is contraindicated in pregnant women and should only be initiated in women of reproductive age who 
understand the teratogenic risk and the need for regular follow-up.
Use of effective contraceptive measures from 4 weeks before isotretinoin initiation until 4 weeks after treatment 
discontinuation. At least one and preferably two complementary forms of contraception including a barrier 
method should be used.
Pregnancy testing should be performed before, during and 5 weeks after discontinuation of isotretinoin.
Isotretinoin should only be prescribed by or under the supervision of a physician with experience in the use of 
systemic retinoids.
Prescription should be limited to 30 days of treatment and continuation of treatment requires a new prescription.
Dispensing of isotretinoin should occur within a maximum of 7 days after prescription. 
Educational programmes for healthcare professionals including prescribers and pharmacists, and patients are in 
place to inform them about the teratogenic risk and to create awareness of the pregnancy prevention programme. 
1.
2.
3.
4.
5.
6.
7.
The safe use of isotretinoin in women of reproductive age is in the interest of public health because of 
the potential risk of spontaneous and elective abortions, and, more importantly, children with major 
congenital anomalies require continuous healthcare throughout their life. Although a PPP has been 
implemented in the EU, pregnancies during isotretinoin therapy still occur.5, 6 The regulatory authorities 
of 16 EU member states responded in 2009 to a survey that isotretinoin exposed pregnancies have 
occurred in their country.7 A French study between 2003 and 2006 estimated a pregnancy rate from 0.4 
to 1.2 / 1000 female isotretinoin users within reproductive age.6 Studies in the Netherlands observed 
that only 52 – 59% of the female isotretinoin users of reproductive age used concomitant hormonal 
contraceptives, which was higher than the 39 – 46% observed in the general female population of 
similar age, but lower than anticipated.8, 9 Although these studies show limited compliance with the 
113isotretinoin exposure during pregnancy: a population-based study in the netherlands
isotretinoin PPP, it is not known whether isotretinoin exposure also occurs during pregnancy and 
what the outcome of these pregnancies is. Therefore, the objective of our study was to estimate 
isotretinoin exposure in Dutch pregnant women despite the implemented PPP and second, to analyse 
the occurrence of adverse fetal and neonatal outcomes in these isotretinoin exposed pregnancies.
MeThOds
Data sources
For this population-based study a cohort of 203,962 pregnancies consisting of 208,161 fetuses was 
constructed using a linkage between the PHARMO Database Network and the Netherlands Perinatal 
Registry (PRN). The PHARMO Database Network is a dynamic population-based cohort including, 
among other information, drug-dispensing records from community pharmacies for more than 3 million 
individuals in the Netherlands (approximately 20% of the Dutch population) that are collected since 
1986.10 The drug dispensing data contain the following information per prescription: the Anatomical 
Therapeutic Chemical (ATC) classification of the drug, dispensing date, regimen, quantity dispensed 
and estimated length of duration of use.11 The PRN is a nationwide registry that contains linked and 
validated data from four databases: the national obstetric database for midwives (LVR-1), the national 
obstetric database for gynaecologists (LVR-2), the national obstetric database for general practitioners 
(LVR-h) and the national neonatal/paediatric database (LNR).12 The registry contains information about 
care before, during and after delivery as well as maternal and neonatal characteristics and outcome 
of 95% of 180,000 pregnancies annually in the Netherlands with a gestational age of at least 16 
weeks. The PRN includes information on pregnancy outcome including congenital anomalies detected 
during pregnancy, at birth or within the first year after birth. The probabilistic linking method between 
PHARMO and PRN has been described in detail elsewhere but was generally based on the birth date 
of the mother and child and their postal zip codes.13 To be included in the cohort the mother should be 
registered in the community pharmacy database of PHARMO during the whole pregnancy. The date of 
conception was estimated based on the last menstrual period or ultrasound, as recorded in the PRN, 
and was truncated to full weeks. 
Isotretinoin dispensings
All dispensings for systemic (oral) isotretinoin (ATC D10BA01) filled in community pharmacies 
by women included in our cohort within the 12 months period before or during pregnancy were 
extracted from the PHARMO Database Network. Considering a daily dosage of 0.5 – 1 mg / kg daily,1 
isotretinoin prescriptions dispensed on the same day were assumed to be used simultaneously and 
therefore these dispensings were pooled and considered as one dispensing (e.g., the prescriptions 
of 10 mg and 20 mg tablets dispensed at the same time to reach a daily dosage of 30 mg). For each 
isotretinoin dispensing, the length of the dispensing was calculated by dividing the total number of 
prescribed units by the number of units (doses) to be taken per day. In case isotretinoin dispensings 
that were pooled together had different lengths, the length of the single dispensing with the longest 
duration was used. To assess compliance with the PPP, we calculated the proportion of dispensings 
that exceeded 30 days, which is the maximum length according to the EU PPP.
Drug exposure interval
For all pregnancies (N=203,962) with gestational age of at least 16 weeks included in the cohort, 
isotretinoin exposure was estimated based on isotretinoin dispensing data (ATC D10BA01) filled by 
the mother during the 12 months period before and during pregnancy. Exposure in person time (days) 
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was calculated by dividing the total number of prescribed units by the number of prescribed units 
per day. Isotretinoin exposure periods were defined considering a possible overlap of isotretinoin 
dispensings. Gaps, isotretinoin free periods between two isotretinoin dispensings, were not permitted 
meaning that an isotretinoin exposure period ends once an isotretinoin free period was identified. 
Using the start and end date of the isotretinoin exposure period, the number of days exposed was 
estimated for the following exposure intervals: 30 days before conception, first 90 days of gestation 
(first trimester), day 90 – 179 of gestation (second trimester) and day 180 – delivery (third trimester). In 
addition, the entire period 30 days before pregnancy until delivery as well as the period from 30 days 
before till the end of the first trimester were analysed separately.
 
Adverse fetal or neonatal outcomes
For each fetus (N=208,161), we determined whether adverse fetal or neonatal outcomes were 
reported. Adverse fetal or neonatal outcomes were defined as all intrauterine deaths ≥ 16 week of 
gestation and liveborn infants with major congenital anomalies. If possible, congenital anomalies were 
categorised into nine subgroups: abdominal wall and skin disorders; cardiovascular defects; defects 
in the digestive system; defects in the nervous system; musculoskeletal defects; respiratory defects; 
urogenital defects; multiple, syndrome or chromosomal anomalies; or other congenital malformations. 
As we were interested in adverse fetal outcomes potentially induced by maternal drug exposure, 
chromosomal anomalies were not considered as an adverse outcome in the analyses.
Analysis
Potential exposure to isotretinoin in the 30 days before or during pregnancy was calculated per 10,000 
pregnancies for the aforementioned exposure intervals including their 95% confidence intervals (95% 
CIs). The proportions of adverse fetal outcome among isotretinoin exposed and unexposed fetuses 
or neonates were calculated including their 95% CIs. We used multiple logistic regression models to 
calculate odds ratios (ORs) and 95% CIs to estimate associations between adverse fetal or neonatal 
outcome and maternal isotretinoin exposure. We adjusted for maternal age at conception (<20, 20-24, 
25-29, 30-34, ≥35), and if possible also for calendar time (year of conception) and gender of the infant. 
Analyses for specific congenital anomalies were performed when > 3 cases were observed. The t test 
or Fisher exact test was used to derive p-values when comparing continuous or categorical variables 
between study groups. Statistical significance was assumed for two-sided p-values <0.05. Statistical 
analyses were performed using SAS version 9.2 (SAS Institute, Cary, North Carolina, US).
resulTs
Between 1 January 1999 and 1 September 2007 in the Netherlands, a total of 203,962 pregnancies 
corresponding to 208,161 fetuses (including multiple births) were included in our study. The mean 
maternal age at conception was 30.3 years (SD 4.6) and mean duration of pregnancy was 39 weeks 
and 3 days (SD 19 days). 
Isotretinoin dispensings 
A total of 416 isotretinoin dispensings to 130 of the 203,962 women in the 12 months period before 
or during pregnancy were identified. In 139 of the 416 isotretinoin dispensings (33.4%), the dispensing 
consisted of > 30 days of isotretinoin use. Figure 1 shows that the percentage of isotretinoin dispensings 
in the year before or during pregnancy exceeding the maximum duration of 30 days decreased over 
calendar time from 50% in 2001 to 13% in 2007. 
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Figure 1: Percentage of isotretinoin dispensing exceeding the maximum duration of 30 days by calendar year
Isotretinoin exposed pregnancies
Demographics for isotretinoin exposed and unexposed pregnancies are presented in Table 1.
Pregnancies (N=203,962)
Mean (±SD) maternal age at 
conception in years (95% CI)
Mean (±SD) gestational age at 
delivery in weeks (95% CI)
Fetuses (N=208,161)
Gender (boy %)
< 20
≥ 20 - 25
≥ 25 - 30
≥ 30 - 35
≥ 35
< 27
27 - 30 
31 - 33 
34 - 36 
37 - 39 
> 39 
Adverse fetal outcome, N;
% (95% CI)
Table 1: Description of the study population
Isotretinoin exposed* Isotretinoin unexposed p-value
51
29.1 (4.9)
(27.8 – 30.5)
39 (25 days)
(38  – 40)
53
47.2%
(33.3 – 61.1)
2 (3.8%)
7 (13.2%)
21 (39.6%)
14 (26.4%)
9 (17.0%)
1 (1.9%)
1 (1.9%)
0 (0.0%)
3 (5.7%)
12 (22.6%)
36 (67.9%)
5;
9.4% (1.3 – 17.6)
203,911
30.3 (4.7)
(30.3 – 30.3)
39, 3 days (19 days)
(39, 3 days – 39, 3 days)
208,108
51.5%
(51.3 – 51.7)
4,063 (2.0%)
22,144 (10.6%)
68,366 (32.9%)
81,581 (39.2%)
31,951 (15.4%)
2,198 (1.1%)
1,167 (0.6%)
2,008 (1.0%)
7,126 (3.4%)
50,854 (24.4%)
144,755 (69.5%)
9,041;
4.3% (4.3 – 4.4)
0.56
0.33
0.53
0.37
0.64
0.08
CI=Confidence interval
*In the 30 days before conception or during pregnancy
Maternal age at conception in years, N, column %
Gestational age at delivery in weeks, N, column %.
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Overall, 51 pregnancies, 2.5 (95% CI 1.9 – 3.3) per 10,000 pregnancies, were potentially exposed 
to isotretinoin in the 30 days before conception or during pregnancy, despite the implemented PPP. 
Forty-five pregnant women, 2.2 (95% CI 1.6 – 2.9) per 10,000 pregnancies, were estimated to be 
exposed to isotretinoin during pregnancy of whom 27 (60%) started isotretinoin treatment while already 
being pregnant. In 18 pregnancies (40%), the conception occurred during isotretinoin treatment. Six 
pregnancies were identified within 1 month after isotretinoin discontinuation and were estimated to 
be exposed only before conception. In 40 out of 203,962 pregnancies, 2.0 (95% CI 1.4 – 2.6) per 
10,000 pregnancies, an isotretinoin prescription was filled during pregnancy and 32 pregnancies, 1.6 
(95% CI 1.1 – 2.2) per 10,000 pregnancies, received isotretinoin more than once during pregnancy. 
The number of isotretinoin dispensings per pregnancy ranged from 1 to 7, with a median of 2.5. The 
estimated isotretinoin exposure per exposure interval is presented in Table 2. 
30 days before conception
(30 days period)
1st trimester
(90 days period)
2nd trimester
(90 days period)
3rd trimester
(90-103 days period)
During pregnancy
(270 days period)
30 days before or during pregnancy
(300 days period)
30 days before or during 1st trimester
(120 days period)
Table 2: Potential isotretinoin exposed pregnancies per exposure interval
Exposed pregnancies 
(N=203,962)
Exposed pregnancies per 
10,000 pregnancies 
(95% CI)
23
28
25
26
45
51
35
1.1 (0.7 – 1.7)
1.4 (0.9 – 2.0)
1.2 (0.8 – 1.8)
1.3 (0.9 – 1.8)
2.2 (1.6 – 2.9)
2.5 (1.9 – 3.3)
1.7 (1.2 – 2.4)
CI=Confidence interval
*Categories are not mutually exclusive but indicate the number of pregnancies exposed to isotretinoin during that 
exposure interval
Isotretinoin exposure interval* Median number of days 
exposed per pregnancy 
(range)
24 (3 – 30)
31 (3 – 88)
57 (1 – 90)
62 (1 – 103)
63 (3 – 236)
63 (7 – 236)
32 (7 – 114)
Among the pregnancies estimated to be exposed to isotretinoin during pregnancy (N=45), the number 
of exposed days during pregnancy ranged from 3 to 236 days with a median of 63 days. Figure 2 
shows that the number of women estimated to be exposed to isotretinoin during pregnancy was the 
highest in 2006 with 3.5 pregnancies (95% CI 1.7 – 6.4) per 10,000 pregnancies.
Adverse fetal or neonatal outcomes
Independent of isotretinoin exposure, adverse fetal or neonatal outcomes were observed for 9,046 
of the 208,161 fetuses (4.4% (95% CI 4.3 % – 4.4%)). The 51 pregnancies potentially exposed to 
isotretinoin in 30 days before conception or during pregnancy corresponded to 53 fetuses or neonates 
including two multiple births. Five of these, all singletons, had an adverse fetal or neonatal outcome 
(9.4% (95% CI 3.5% – 19.7%)). These included three intrauterine deaths and two liveborn infants with 
major congenital anomalies (see Table 3). Among those potentially exposed during pregnancy only 
(N=47), 6.4% (95% CI 1.7% – 16.4%) had an adverse fetal or neonatal outcome. The OR for adverse fetal 
or neonatal outcome after potential isotretinoin exposure in the 30 days before or during pregnancy 
was 2.3 (95% CI 0.9 – 5.7) after adjustment for maternal age (see Table 3). Restricting the analysis to 
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Figure 2: Isotretinoin exposed pregnancies per 10,000 pregnancies by calendar year
the potential isotretinoin exposure during pregnancy, the adjusted OR of an adverse fetal outcome 
was 1.5 (95% CI 0.5 – 4.8). The number of cases was too low to allow for adjustments in addition to 
maternal age. The adjusted OR of any fetal or neonatal outcome was significantly increased at 3.6 
(95% CI 1.4 – 9.4) for isotretinoin exposure during the 30 days before or first trimester of pregnancy. 
30 days before conception
During pregnancy (N=47)
30 days before or during pregnancy (N=53)
30 days before or 1st trimester (N=35)
Table 3: Odds ratios for adverse fetal and neonatal outcomes and isotretinoin exposure in 30 days before or 
during pregnancy
Exposed fetuses with 
adverse outcomes
3†
5†‡
5†‡
CI=confidence interval
*maternal age in categories (<20, 20-24, 25-29, 30-34, ≥35)
† Includes three intrauterine deaths 
 1) in week 19, potentially exposed first 29 days following conception. 
 2) in week 35, potentially exposed 10 weeks following conception and from week 18 until week 32. 
 3) in week 38, also reported an unspecified septal defect; potentially exposed first 8 days following   
    conception, during week 12 until week 24 and during week 28 until week 38. 
‡ Includes two liveborn infants with major congenital anomalies.
 1) Neural tube defect, potentially exposed all 30 days before conception, not after conception.
 2) Major congenital anomaly not further specified, potentially exposed the first 15 days of the 30 days before 
     conception, not after conception.
Isotretinoin exposed fetuses OR
(95% CI)
1.5
(0.5 – 4.8)
2.3
(0.9 – 5.8)
3.7
(1.4 – 9.5)
Adjusted OR*
(95% CI)
1.5
(0.5 – 4.8)
2.3
(0.9 – 5.7)
3.6
(1.4 – 9.4)
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disCussiOn
This study shows that 2 per 10,000 pregnancies were exposed to isotretinoin despite the PPP which is 
implemented to prevent isotretinoin use during pregnancy. Although this study was not intended to 
estimate the teratogenic risks of isotretinoin, adverse fetal and neonatal outcomes potentially related 
to isotretinoin exposure were observed. That there are still women who are using isotretinoin during 
pregnancy despite the implementation of the PPP is of major concern. Especially since the majority of 
isotretinoin exposed women (60%) were already pregnant at the time of first isotretinoin prescription 
and it seems that pregnancy was not always excluded before isotretinoin dispensing (box 1). These 
exposed pregnancies could probably have been prevented when appropriate pregnancy testing 
would have been performed. Furthermore, it was earlier demonstrated that women of reproductive 
age treated with isotretinoin did not always use effective contraceptive measures because only up to 
59% of these women concomitantly used hormonal contraceptives.8, 9 Limited compliance with the 
PPP was also observed in a survey among Dutch pharmacists which indicated that in 2007 and 2011, 
44% and 49% of pharmacists, respectively, checked the use of contraception at every isotretinoin 
dispensing.14 The percentage of pharmacists that asked for negative pregnancy tests was stable with 
15% and 16%, respectively and is in line with our study which demonstrated that pregnancy is not 
always excluded before initiating isotretinoin and result in isotretinoin exposed pregnancies that could 
have been prevented. Our study showed that compliance with the recommended maximum length of 
prescription of 30 days was limited since one-third of isotretinoin dispensings exceeded 30 days which 
however decreased from 50% in 1999 to 13% in 2007. Based on these results it is clear that compliance 
with the PPP in the Netherlands between 1999 and 2007 was incomplete. These findings suggest an 
ongoing need to educate healthcare professionals and patients on the fetal risks of isotretinoin and 
the PPP, especially since isotretinoin is mostly used in young women of reproductive age. 
Previous studies on isotretinoin use during pregnancy in other Western countries showed comparable 
results indicating that limited compliance to the PPP is not restricted to the Netherlands.6, 15-17 In the 
United States (US), the most recent isotretinoin PPP, called iPLEDGE, has been implemented since 
2006 and is stricter than the EU PPP. iPLEDGE is an internet-based system that requires registration 
of all stakeholders with monthly updates on prescription, pregnancy tests, contraceptive use and 
acknowledgement of risks.17 The pregnancy rate among isotretinoin users in the US with the iPLEDGE 
PPP was estimated at 2.7 / 1,000 treatment courses and did not change compared to the previous PPP 
called SMART (System to Manage Accutane-Related Teratogenicity) while only small improvements in 
compliance with contraceptive measures were observed.17, 18 Apparently, also iPLEDGE does not bring 
complete security because further restrictive measures as in iPLEDGE do not seem to improve the 
results and may add unnecessary burden to the healthcare system since healthcare professionals and 
patients need to register and verify information on a monthly basis.4
Strengths and weaknesses of the study
A strength of this study is that we used a population-based design including virtually complete 
and detailed drug dispensing data and pregnancy outcome data of a large cohort, which enabled 
estimating nationwide isotretinoin exposure rates among pregnant women. A known limitation of 
using drug dispensing data is that it does not confirm the actual use of the drug under study and does 
not provide information on the precise time window of drug use. In addition, it is likely that women 
may change or stop their medication use when they become aware of pregnancy. However, it should 
be noted that our data show that the majority (80%) of pregnant women who filled prescriptions for 
isotretinoin came back for refills, suggesting that they really used the drug. 
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This study provides no information on spontaneous abortions that occurred until gestational age of 16 
weeks and ETOPs because these data are not captured in the PRN database and these pregnancies 
were thus not included in our cohort. This resulted in an underestimation of the number of pregnancies 
that were potentially exposed to isotretinoin in the 30 days before or during pregnancy and the 
adverse fetal and neonatal outcomes. Studies that estimated the teratogenic risk of isotretinoin 
using prospectively documented isotretinoin exposed pregnancies found much higher proportions of 
pregnancies resulting in spontaneous abortion, stillbirth or reported congenital malformations, that is, 
36% (13 of the 36 fetuses)3 and 26% (6 of the 23 fetuses)5.
Without detailed information on drug exposure preferably verified by the patient whether the drug 
was actually taken and detailed descriptions of the diagnosed fetal outcome as well as on spontaneous 
abortions, the teratogenic risk of isotretinoin could not be accurately estimated. With regard to the 
adverse fetal outcomes observed in our study, we cannot exclude that they had any other aetiology 
than isotretinoin exposure. Owing to the low number of cases it was also not possible to adjust in the 
statistical analysis for important confounding factors other than maternal age such as smoking, alcohol 
intake, previous pregnancy outcomes and exposure to other potentially teratogenic drugs. Detection 
bias may also have influenced the incidence and estimated risks of congenital anomalies since more 
detailed diagnostics might have been used in pregnancies exposed to isotretinoin compared to 
the unexposed pregnancies. Nevertheless, the results of our study are in line with the undisputed 
embryotoxicity of isotretinoin and suggestive of an increased risks of adverse fetal or neonatal events 
when isotretinoin is dispensed for use in the 30 days period before or during pregnancy. 
Implications and future research
In the Netherlands, approximately 180,000 pregnancies are reported annually.19 When extrapolating 
the 2.2 (95% CI 1.6 – 2.9) per 10,000 women potentially exposed to isotretinoin during pregnancy to a 
national level, there would be 29 to 52 isotretinoin-exposed pregnancies per year yielding unnecessary 
risks for congenital anomalies and fetal deaths. Therefore, it is in the interest of public health to 
implement effective PPPs and improve these measures or their compliance as much as possible to 
reduce isotretinoin use during pregnancy to the lowest possible level. 
With the present study only the period 1999 to 2007 has been evaluated. The past years in the 
Netherlands, the PPP is communicated to healthcare professionals via product information,20 national 
general practitioner standards on treatment of acne,21 drug prescription and dispensing systems,22 
the website of the Dutch Medicines Evaluation Board23 and the common (national) literature on drug 
information.24 Furthermore, research on isotretinoin use in the Netherlands and the PPP is conducted 
and published in (inter)national scientific medical journals.7-9, 14, 25-28 Consequently, data after 2007 are 
needed to judge if attention for the isotretinoin PPP during recent years has improved the carefulness 
with which isotretinoin is prescribed and dispensed.
Conclusions
Although a PPP was implemented almost 15 years ago, we showed that there are still pregnancies 
exposed to isotretinoin in the Netherlands which could have been prevented if appropriate exclusion 
of pregnancy before isotretinoin initiation would have been performed. These findings from the 
Netherlands add to the evidence that there is no full compliance to the isotretinoin PPP in many 
Western countries. Given the limited success of iPLEDGE, the question is which further measures are 
able to improve compliance.
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aBsTraCT
Objective To study the dispensing of potentially teratogenic drugs in the 12-month 
period before as well as during pregnancy in the Netherlands. 
Design Population-based study.
Setting A cohort was constructed using a linkage between the PHARMO Database 
Network and the Netherlands Perinatal Registry (PRN).
Population A total of 203,962 Dutch pregnancies reported between 1999 and 2007.
Methods Drug dispensing information was identified from the PHARMO Database 
Network for the 12-month period before conception and during pregnancy. Drugs with 
either a Swedish FASS ‘D’ classification, an Australian ADEC or American FDA ‘D’ or ‘X’ 
classification were considered potentially teratogenic (n=202).
Mean outcome measures Proportion of pregnancies that received potentially 
teratogenic drugs in the 12-month period before and during pregnancy and specific for the 
risk category X drugs and newly initiated drugs.
Results Sixteen percent of the pregnancies received a potentially teratogenic drug in the 
12-month period before and 5.07% during pregnancy. Doxycycline and paroxetine were 
most frequently received during pregnancy by 1.01% and 0.85% of women, respectively; 
0.66% of the women received a risk category X drug during pregnancy which most 
frequently consisted of triptorelin (0.25%), norethisterone (0.22%), and simvastatin (0.03%). 
Fifty-tree percent of the women who received a potentially teratogenic drug during 
pregnancy received this for the first time during the study period. These percentages were 
heterogeneous between therapeutic drug classes.
Conclusions Five percent of the pregnancies received a potentially teratogenic drug 
during pregnancy and 0.66% a drug from the risk category X. It may be possible to reduce 
these proportions in future when reasons for prescription have been explored. 
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inTrOduCTiOn
At the moment of first marketing, the safety of drugs during pregnancy is often not established 
since pregnant women are generally excluded from clinical studies. Vigilant monitoring during the 
post-marketing period is important to gain more and better knowledge on the possible risks for the 
developing embryo or fetus after maternal drug exposure. Despite the limited information on the 
effects of drugs on embryonic or fetal health, prescription drugs (excluding vitamins and minerals) 
are used in 27 – 93% of the pregnancies in developed countries.1 Even though for some drugs 
contraindications or warnings on drug use during pregnancy are in place, in pregnant women with 
certain medical conditions such as epilepsy or depression the expected treatment benefits may 
outweigh the possible harms. Furthermore, it cannot be completely avoided as a large proportion 
of pregnancies in Western Europe is unintended (42%).2 Nevertheless, unnecessary or inappropriate 
drug use during pregnancy should be avoided, especially teratogenic drugs. Teratogenic drugs, when 
used shortly before or during pregnancy, can irreversibly modify growth, structure, or function of the 
developing embryo or fetus, resulting in potential spontaneous abortion, premature delivery and 
mental and physical disabilities.3
Various studies identified concerns on the use of drugs with a teratogenic potential. Less than half 
(42%) of women of reproductive age using drugs with a teratogenic potential used concomitant 
contraceptives in the Netherlands and comparable results were observed in the United States (US).4-6 
Previous study in the US, Canada and Ireland showed that 4.2 – 7.8% of pregnant women received 
potentially teratogenic drugs.1, 7-11 In the Netherlands, in the period between 1994 and 2003, 1.1% of 
all drugs received during pregnancy were potentially harmful for the embryo/fetus.12 In view of the 
possible impact on public health, it is important to further explore the use of potentially teratogenic 
drugs among pregnant women in the Netherlands. In this population-based study, we examined the 
dispensing patterns of potentially teratogenic drugs to Dutch women in the year before and during 
pregnancy in the period between 1999 and 2007.
MeThOds
Data sources
For this population-based study, a cohort of 203,962 Dutch pregnancies was identified using a linkage 
between the PHARMO Database Network and the Netherlands Perinatal Registry (PRN) reported 
between 1 January 1999 and 31 September 2007, which correspond to 18% of all pregnancies 
included in the PRN during this period. The PHARMO Database Network is a dynamic cohort of 
participants that includes, among other information, drug-dispensing records from community 
pharmacies for more than three million individuals in the Netherlands (approximately 20% of the Dutch 
population) collected since 1991.13 The drug dispensing data contain the following information per 
prescription: the Anatomical Therapeutic Chemical (ATC) classification of the drug, dispensing date, 
regimen, quantity dispensed, and estimated length of duration of use.14 The PRN is a nationwide 
registry that contains linked and validated data from four databases: the national obstetric database 
for midwives (LVR-1), the national obstetric database for gynaecologists (LVR-2), the national obstetric 
database for general practitioners (LVR-h) and the national neonatal/paediatric database (LNR).15 The 
registry contains information about care before, during, and after delivery as well as maternal and 
neonatal characteristics and outcome of 95% of 180,000 pregnancies annually in the Netherlands 
with a gestational age of at least 16 weeks. The linking method between PHARMO and PRN has 
been described elsewhere but was generally based on the birth date of the mother and child and 
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their addresses using postal zip codes.16 To be able to define drug dispensing in the 12-month period 
before conception and during pregnancy, women needed to be registered in the community pharmacy 
database of the PHARMO Database Network for the complete study period, i.e. 12-month period 
before conception and during pregnancy. The unit of analysis was an individual pregnancy. 
Drugs of interest
The outpatient drug dispensing during the 12-month period before conception until the end of 
pregnancy was extracted from the PHARMO Database Network for all subjects included in our cohort. 
Potentially teratogenic drugs were selected using the classification systems of the US Food and Drug 
Administration (FDA), the former Australian Drug Evaluation Committee (ADEC) and the Swedish 
Catalogue of Approved Drugs (FASS).17-19 These classifications consist of four or five categories (A, 
B, C, D, X) and several subcategories to categorise the teratogenic potential of drugs (see Appendix 
I). The FDA category D includes drugs for which there is positive evidence of fetal risks, but the 
benefits may be acceptable despite the risks; category X drugs are considered contraindicated for 
use in pregnancy because of evidence on fetal risk from studies in animals or humans, or based on 
human experience. Drugs for which risks in pregnancy have not been established but for which there 
is no benefit may be classified as category X.20 In general, we selected the drugs with either a FASS 
‘D’ classification or an ADEC or FDA ‘D’ or ‘X’ classification resulting in 202 potentially teratogenic 
drugs. The drugs of interest are coded according to ATC code and are listed in Appendix II. The 
method of identification of potentially teratogenic drugs has been previously described.4 The drugs 
were divided into eleven mutually exclusive categories based on therapeutic indication: anti-infective 
& anti-parasitic agents, agents acting on the renin-angiotensin-system (RAS), anti-thrombotic 
agents, statins, dermatologicals, pituitary, hypothalamic and sex hormones, anti-neoplastic agents, 
immunomodulating agents, anti-epileptics agents, psycholeptic and psychoanaleptic agents and 
last, miscellaneous agents. Separate analyses were performed for the 39 category X drugs according 
to either ADEC or FDA classification. Reproductive hormonal drugs (ATC G03 and H01C) including 
androgens, estrogens, progestogens and gonadotropins as well as the gonadotropin releasing 
hormone (GrNH) agonists (ATC L02AE02 and L02AE04) were excluded from some analyses as these 
drugs may be dispensed to women to stimulate ovulation or used for in vitro fertilisation (IVF). The 
seven drugs with a mandatory pregnancy prevention programme in the Netherlands were analysed 
separately: thalidomide (L04AX02), lenalidomide (L04AX04), isotretinoin (D10BA01), acitretin 
(D05BB02), alitretinoin (L01XX22), bosentan (C02KX01) and ambrisentan (C02KX02). In the European 
Union (EU), alitretinoin (D11AH04) has been licensed to treat severe chronic hand eczema since April 
2009, and is therefore not considered in this study. 
Drug exposure periods
The dispensing of potentially teratogenic drugs was examined for the 12-month period before 
conception until end of pregnancy. We identified seven drug exposure periods with a duration of 
3 months each i.e. 12 – 9 months before pregnancy, 9 – 6 months before pregnancy, 6 – 3 months 
before pregnancy, 3 months before pregnancy, first trimester of pregnancy (day 1 until day 90), second 
trimester of pregnancy (day 91 until day 180), and third trimester of pregnancy (day 181 until delivery). 
The start of pregnancy was based on the last menstrual period or ultrasound, as recorded in the PRN 
database and truncated to full weeks.
Analysis
Per 3-month period, we counted the number of pregnancies that received drugs of interest. Dispensing 
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rates per 1000 pregnancies and the 95% confidence intervals (95% CI) around them were calculated 
by dividing the number of pregnancies during which a potentially teratogenic drug was filled by 
the total number of pregnancies included in our study. This was done per 3-month period for all 
teratogenic drugs, drug categories and category X drugs according to ADEC or FDA classification 
system and 95% CI were calculated. Dispensings were only counted in the 3-month period in which 
they were dispensed. A sensitivity analysis was performed to account for possible misclassification 
of drug use during pregnancy. We calculated the duration and end date of the dispensing for drugs 
initially dispensed before conception. When the end date occurred after the conception date we also 
counted the dispensing during pregnancy. Analyses restricted to newly initiated drugs were performed 
to assess the initiation of potentially teratogenic drugs during the study period. A drug dispensing 
was considered a newly initiated drug if the particular women did not receive that drug earlier in the 
12-month period before or during pregnancy. Descriptive statistics were performed using SAS version 
9.2 (SAS Institute, Cary, North Carolina, US).
resulTs
A total of 203,962 pregnancies in the Netherlands between 1 January 1999 and 1 September 2007 
were included in our study. The mean maternal age at conception was 30.33 years (SD 4.65) and mean 
duration of pregnancy was 39 weeks and 3 days (SD 19 days). Demographics of the pregnancies are 
presented in Table 1.
During 156,389 of the 203,962 pregnancies (76.68%) any prescription drug was filled within the 
12-month period before conception and 137,155 women (67.25%) received any prescription drug 
during pregnancy. Potentially teratogenic drugs were dispensed to 31,996 pregnant women (15.69%) 
in the year before conception and to 10,343 women (5.07%) during pregnancy (Table 2). As visualised 
in Figure 1, the proportion of pregnant women who received a potentially teratogenic drug decreased 
after conception. In 7.09% of the pregnancies a potentially teratogenic drugs was filled within 3 months 
before pregnancy; in the first, second and last trimester, percentages decreased to 3.72%, 1.59% and 
1.65%, respectively. Excluding reproductive hormones, ovulation stimulants and other fertility drugs, in 
the 12-month period before conception 22,805 pregnancies (11.18%) received a potentially teratogenic 
drug and 6,921 (3.39%) received it during pregnancy. Furthermore, the peak during the 3-months 
period before pregnancy – observed when these drugs were included – disappeared. A similar pattern 
was observed for category X drugs, which 7,159 women (3.51%) received in the 12-month period 
before conception and 1,350 women (0.66%) received during pregnancy. After excluding reproductive 
hormones, ovulation stimulants and other fertility drugs these numbers decreased to 952 pregnancies 
(0.47%) and 268 pregnancies (0.13%), respectively. 
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* During pregnancy; SD=standard deviation. CI=confidence interval.
Table 1: Demographics and characteristics of pregnancies included in the PHARMO-PRN cohort
Pregnancies
(n=203,962)
66,807; 32.8% (32.5 – 33.0)
137,155; 67.3% (67.0 – 67.4)
10,343; 5.1% (5.0 – 5.2)
1,350; 0.7% (0.6 – 0.7)
30.33 (4.65)
30.45 (4.42)
30.27 (4.76)
31.22 (4.84)
31.81 (4.85)
39 weeks, 3 days (19 days)
39 weeks, 3 days (19 days)
39 weeks, 3 days (18 days)
39 weeks, 0 day (21 days)
38 weeks, 6 days (24 days)
17,834
23,981
24,871
26,073
26,354
26,775
26,097
25,837
6,140
Pregnancies that received drugs during pregnancy (n; %, 95% CI) 
Pregnancies that received no prescription drugs 
Pregnancies that received a prescription drug
Pregnancies that received a potentially teratogenic drug
Pregnancies that received a category X drug
Maternal age at conception in years (Mean (±SD))
Overall
Pregnancies that received no prescription drugs * 
Pregnancies that received a prescription drug *
Pregnancies that received a potentially teratogenic drug *
Pregnancies that received a category X drug *
Duration of pregnancy (Mean (±SD))
Overall
Pregnancies that received no prescription drugs * 
Pregnancies that received a prescription drug *
Pregnancies that received a potentially teratogenic drug *
Pregnancies that received a category X drug *
Year of conception
1999
2000
2001
2002
2003
2004
2005
2006
2007
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Figure 1: Pregnancies that received a potentially teratogenic drug or a category X drug per 1000 pregnancies
Figure 2: Pregnancies that received a potentially teratogenic drug per drug category per 1000 pregnancies 8
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Drug categories
Within the 12-month period before conception, pregnant women most frequently received a potentially 
teratogenic drug classified as ‘anti-infective and anti-parasitic agents’ (8.30% of the pregnancies), 
followed by ‘pituitary, hypothalamic and sex hormones’ (5.12%), ‘immunomodulating agents’ (1.91%) 
and ‘psycholeptic and psychoanaleptic agents’ (1.78%). During pregnancy these percentages 
decreased: ‘anti-infective and anti-parasitic agents’ (1.78%), ‘pituitary, hypothalamic and sex hormones’ 
(1.65%), ‘psycholeptic & psychoanaleptic agents’ (0.91%) and ‘immunomodulating agents’ (0.44%). 
Figure 2 presents the number of pregnant women who received a potentially teratogenic drug per 
drug class and per period of interest. Except for the ‘anti-epileptics’ and ‘anti-neoplastics’ included in 
our study, fewer potentially teratogenic drugs were received during pregnancy as compared with the 
period before pregnancy. 
Individual drugs
Of the 202 potentially teratogenic drugs, 100 were dispensed at least once in the 12-month period 
before or during pregnancy and 92 were received during pregnancy. Information for the 20 potentially 
teratogenic drugs most frequently received during pregnancy is provided in Table 2. Doxycycline and 
paroxetine were most frequently received in the 12-month period before conception (by 54.51 and 
17.25 pregnancies per 1000 pregnancies, respectively) as well as during pregnancy (by 10.08 and 8.54 
pregnancies per 1000 pregnancies, respectively). Figure 3 shows that the number of pregnancies per 
1000 pregnant women who received potentially teratogenic drugs declined after conception, except 
for carbamazepine, which remained stable over the complete study period. Peaks in the 3-month 
period before conception were observed for 28 potentially teratogenic drugs including five of the 
ten most frequently received drugs, i.e. triptorelin, progesterone, follitropin  , medrogestron – IM, 
norethisterone. The category X drugs most frequently received during pregnancy are presented in Table 
3 and included triptorelin (2.49 per 1000 pregnancies), norethisterone (2.17 per 1000 pregnancies) and 
simvastatin (0.31 per 1000 pregnancies). 
With regard to the drugs with a pregnancy prevention programme, isotretinoin was dispensed to 
101 pregnant women (0.50 per 1000 pregnancies) before conception, of whom 26 received the drug 
in the 3-month period before pregnancy. Forty pregnancies (46 in the sensitivity analysis) received 
isotretinoin during pregnancy i.e. 20 in the first trimester, 20 in the second trimester and 26 in the 
third trimester. Thirty-three of the 40 pregnant women received isotretinoin more than once during 
pregnancy. Acitretin was dispensed to six pregnancies in the 12-month period before conception 
and four received acitretin during pregnancy. We did not identify pregnant women who received 
ambristentan, bosentan, thalidomide, lenalidomide and alitretinoin during the study period. 
Sensitivity analysis
In the sensitivity analysis the percentage of pregnant women who received potentially teratogenic 
increased from 5.07% to 6.14% when including pregnancies with a dispensing before conception with 
a duration of use extending beyond conception date. For category X drugs the percentage increased 
from 0.66% to 1.19%. As presented in Table 3, similar patterns were observed for the individual 
teratogenic drugs. The four drugs that increased the most were triptorelin (from 0.25% to 0.60%), 
follitropin  (from 0.35% to 0.59%), progesterone (from 0.82% to 1.07%) and paroxetine (from 0.85% 
to 1.01%). 
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Any potentially 
teratogenic drug
Doxycycline 
Paroxetine 
Progesterone 
Fluconazole
Follitropin  
Triptorelin
(GrNH agonist, 
category X drug)
Norethisterone 
(category X drug)
Medrogestron - IM 
Carbamazepine 
Valproic acid 
Dydrogesteron 
Minocycline 
Leuprorelin 
(GrNH agonist) 
Acenocoumarol 
Lynestrenol 
Azathioprine
Tretinoin 
Lamotrigine
Lithium
Hydrokinine 
N/A
J01AA02
N06AB05
G03DA04
J02AC01
G03GA05
L02AE04
G03DC02
G03DA02
N03AF01
N03AG01
G03DB01
J01AA08
L02AE02
B01AA07
G03DC03
L04AX01
D10AD01
N03AX09
N05AN01
M09AA01
Table 2: Dispensing rates per 1000 pregnancies for the potentially teratogenic drugs most frequently received 
during pregnancy 
Potentially 
teratogenic drug
ATC code In the 12-month period 
before conception 
(95% CI)
During pregnancy 
(95% CI)
156.87 (155.30 – 158.46)
54.51 (53.53 – 55.50)
17.25 (16.69 – 17.82)
16.16 (15.62 – 16.71)
25.87 (25.19 – 26.57)
9.71 (9.29 – 10.14)
13.57 (13.07 – 14.08)
15.53 (15.00 – 16.08)
12.33 (11.86 – 12.82)
1.56 (1.40 – 1.74)
1.58 (1.41 – 1.76)
4.35 (4.08 – 4.65)
3.72 (3.46 – 3.99)
4.12 (3.85 – 4.41)
1.26 (1.11 – 1.42)
4.95 (4.65 – 5.26)
0.97 (0.84 – 1.11)
1.87 (1.69 – 2.07)
0.57 (0.48 – 0.68)
0.61 (0.51 – 0.73)
1.17 (1.03 – 1.33)
During pregnancy in 
sensitivity analysis* 
(95% CI)
61.35 (60.31 – 62.40)
10.99 (10.53 – 11.44)
10.07 (9.64 – 10.50)
10.67 (10.23 – 11.12)
7.15 (6.78 – 7.51)
5.85 (5.52 – 6.19)
6.04 (5.70 – 6.37)
2.53 (2.31 – 2.75)
2.04 (1.84 – 2.24)
1.29 (1.14 – 1.45)
1.24 (1.08 – 1.39)
1.23 (1.07 – 1.38)
1.30 (1.14 – 1.46)
1.70 (1.52 – 1.87)
1.08 (0.94 – 1.22)
1.05 (0.91 – 1.19)
0.83 (0.70 – 0.95)
0.67 (0.56 – 0.79)
0.60 (0.50 – 0.71)
0.57 (0.47 – 0.67)
0.62 (0.51 – 0.73)
50.71 (49.76 – 51.67)
10.08 (9.65 – 10.52)
8.54 (8.15 – 8.95)
8.23 (7.85 – 8.63)
6.35 (6.02 – 6.71)
3.54 (3.28 – 3.80)
2.49 (2.28 – 2.71)
2.17 (1.97 – 2.38)
1.55 (1.39 – 1.73)
1.24 (1.09 – 1.40)
1.11 (0.98 – 1.26)
1.03 (0.90 – 1.18)
1.03 (0.90 – 1.18)
0.96 (0.83 – 1.10)
0.89 (0.77 – 1.02)
0.86 (0.74 – 0.99)
0.75 (0.63 – 0.87)
0.56 (0.47 – 0.67)
0.55 (0.45 – 0.66)
0.54 (0.45 – 0.65)
0.53 (0.44 – 0.64)
GrNH=gonadotropin-releasing hormone. CI=confidence interval.
*Including drugs dispensed before conception with a duration of use extending beyond conception date
8
132
Figure 3: Pregnancies per 1000 pregnancies that received the most frequently received potentially teratogenic 
drugs per study period
Any category X drug
Triptorelin 
(GrNH agonist)
Norethisterone
Simvastatin 
Atorvastatin 
Cetrorelix 
Misoprostol 
Nafarelin
Isotretinoin 
N/A
L02AE04
G03DC02
C10AA01
C10AA05
H01CC02
A02BB01
H01CA02
D10BA01
Table 3: Dispensing rates per 1000 pregnancies for the category X drugs most frequently received during 
pregnancy
Category X drug ATC code In the 12-month period 
before conception 
(95% CI)
During pregnancy 
(95% CI)
35.10 (34.31 – 35.90)
13.57 (13.07 – 14.08)
15.53 (15.00 – 16.08)
0.78 (0.70 – 0.91)
0.91 (0.78 – 1.05)
0.60 (0.50 – 0.71)
1.77 (1.59 – 1.95)
1.29 (1.15 – 1.46)
0.50 (0.41 – 0.60)
During pregnancy in 
sensitivity analysis* 
(95% CI)
11.87 (11.40 – 12.34)
6.04 (5.70 – 6.37)
2.53 (2.31 – 2.75)
0.46 (0.37 – 0.55)
0.48 (0.39 – 0.58)
0.35 (0.27 – 0.43)
0.34 (0.26 – 0.42)
0.63 (0.52 – 0.74)
0.23 (0.16 – 0.29)
6.62 (6.27 – 6.98)
2.49 (2.28 – 2.71)
2.17 (1.97 – 2.38)
0.31 (0.24 – 0.40)
0.25 (0.19 – 0.33)
0.25 (0.19 – 0.33)
0.24 (0.18 – 0.32)
0.21 (0.15 – 0.28)
0.20 (0.14 – 0.26)
GrNH=gonadotropin-releasing hormone. CI=confidence interval.
*Drug dispensed before conception which covered a period of use that overlapped pregnancy were considered
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Newly initiated drugs
In the periods before conception 60-70% of the pregnant women who received a potentially teratogenic 
drug received this for the first time during the study period (see Figure 4). These proportions decreased 
to 40.63% (15 of the 37 per 1000 pregnancies) in the first trimester of pregnancy, 35.87% (6 of the 
16 per 1000 pregnancies) and 36.43% (6 of the 17 per 1000 pregnancies) in respectively the second 
and third trimester. Comparable proportions were observed for newly initiated category X drugs. Of 
the 5,463 pregnancies that received a newly initiated potentially teratogenic drug during pregnancy, 
which corresponds to 52.82% of all pregnancies that received a drug under study during pregnancy, 
the majority received doxycycline (3,039 pregnancies, 1.49% of all pregnancies) or fluconazol (1,678 
pregnancies, 0.82% of all pregnancies). Of the 1,350 pregnancies that received a category X drug 
during pregnancy, 48% (649 pregnancies, 0.31% of all pregnancies) received this for the first time. 
The majority of the category X drugs newly initiated during pregnancy concerned triptorelin (131 
pregnancies) and norethisterone (367 pregnancies). As presented in Figure 4, stratification per drug 
class showed heterogeneous proportions per drug class. The majority of the dispensed potentially 
teratogenic drugs classified as ‘miscellaneous agents’ (>80%) and ‘anti-infective and anti-parasitic 
agents’ (90 – 60%) were newly initiated. ‘Psycholeptic and psychoanaleptic agents’, ‘anti-epileptic 
agents’, ‘statins’ or ‘agents acting on the renin angiotensin system’ were less frequently newly initiated 
with 30 – 35% before pregnancy and 10% during pregnancy.
Figure 4: Among the exposed pregnancies, the percentage that received newly initiated drugs per exposure 
period and drug class
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Change over time
Figure 5 illustrates the number of women that received potentially teratogenic drugs during pregnancy 
(first, second and third trimester) per year in the period 1999 – 2007. No changes in dispensing trend of 
potentially teratogenic drugs were observed over time with regard to the dispensing of any potentially 
teratogenic drugs, category X drugs and neither per drug classes. 
Figure 5: Pregnancies per 1000 pregnancies that received potentially teratogenic drugs during pregnancy per 
calendar year and drug classes
disCussiOn
Main findings
Between 1999 and 2007 in the Netherlands 77% of the pregnant women received a prescription drug 
in the 12-month period before pregnancy and 67% during pregnancy. Potentially teratogenic drugs 
were received by 16% of the pregnant women in the 12 months before conception and 5% of all 
women received these drugs during pregnancy. A small proportion, 0.7%, of the women received a 
category X drug during pregnancy. For 53% of the women who received potentially teratogenic drugs 
during pregnancy this considered newly initiated drugs. The decrease in the number of women who 
received potentially teratogenic drugs during pregnancy as compared to the period before conception 
was observed for the majority of potentially teratogenic drugs, which may be due to awareness of 
prescribers and patients of the potential fetal risks and the contraindications for use during pregnancy. 
However, still 5% of all pregnant women received a drug with teratogenic potential, the majority 
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during the first trimester, which is the most sensitive period for the developing fetus including the 
period of organogenesis.21 In this early stage, women might not be aware of the pregnancy, resulting 
in fetal exposure to potentially teratogenic drugs. 
Strengths and limitations
A strength of our study is the availability of detailed drug dispensing data from a year before 
conception until the end of pregnancy for a large cohort of more than 200,000 pregnancies which 
can be generalised to the Dutch population. Furthermore, the conception date could be obtained 
from the PRN database based on the last menstrual period or ultrasound, start and end dates of the 
3-month study periods could be determined very accurately, and consequently the drug dispensing in 
those periods as well as the sensitivity analysis. A limitation of our study is that potentially teratogenic 
drugs used in hospital such as certain anti-neoplastic and immunodulating agents, are not captured in 
the community pharmacy dispensing data nor are over-the-counter medications. However, prescribed 
drugs by specialists in the outpatient setting are captured. Information on pregnancies that ended 
before a gestational age of 16 weeks, including spontaneous abortions and elective terminations of 
pregnancy, was not included in our study as the PRN database only contains information of pregnancies 
≥ 16 weeks of gestation. This might have led to an underestimation of drug dispensing among the 
target population. The used classification systems to identify drugs with a teratogenic potential have 
shortcomings, e.g. the alphabetical order may incorrectly suggests a progression in risks from A to 
X, and categories do not always distinguish between differences in frequency, severity and type 
of fetal risk.20 The evidence of teratogenic effect of some drugs remains uncertain, which suggests 
some misclassification of the potentially teratogenic drugs in our study, for instance for triptorelin 
and the anticoagulants. According to Van Gelder et al.,22 75 of the 202 potentially teratogenic drugs 
included in our study and 16 of the 39 category X drugs are known to have teratogenic mechanism. 
The uncertainty about teratogenic effects may also impact on the frequency of prescribing of the drugs 
under study. Nevertheless, although the classification systems have been criticised, they are useful for 
drug utilisation research in pregnancy.23 
Interpretation
The 5.1% of the pregnant women who received a potentially teratogenic drug in our study is 
comparable to the findings of studies in other populations which ranged between 4.2 and 7.8%.7-11, 24 
Other Dutch studies also found that a considerable proportion of pregnant women received potentially 
teratogenic drugs.12, 25 The study of Van Gelder et al.25 among 32,016 Dutch pregnancies during the 
period from 1998 to 2009 showed that 18%, 21% and 33% of the pregnant women received drugs 
with potential teratogenic mechanisms in respectively the first, second or third trimester of pregnancy. 
Iron preparations, class III anti-arrhythmic drugs and tetracyclines contributed substantially to these 
high percentages, which were not all included in our study. These higher proportions compared to our 
study (overall 5.1%) can be explained by the different drugs that were examined.
Among the pregnancies that received a potentially teratogenic drug, the decreasing trend in 
percentages of pregnancies that received newly initiated drugs from before conception till the third 
trimester was expected considering the time factor in this analysis and the closed cohort. We observed 
variation in these proportions per therapeutic drug class which for some classes could be expected 
considering the indications of the drugs. Anti-infectives, the most frequently dispensed potentially 
teratogenic drugs in our study, are often for occasional, short term use what could explain the high 
proportions of pregnancies with newly initiated anti-infectives and in particular doxycycline. On the 
contrary, the anti-epileptics, statins, psycholeptic & psychonanaleptic agents and agents acting on 
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the renin angiotensin system have more chronic indications, which potentially lead to less treatment 
initiation during pregnancy (as observed for paroxetine, which was frequently dispensed but not 
often newly initiated), which is reassuring. For some drug classes as well as individual drugs the 
high proportions of newly initiated dispensings can be misleading as these correspond to a very 
low absolute number of pregnant women who received those drugs, i.e. for miscellaneous agents, 
dermatologicals and category X drugs (see Figure 2). Furthermore, the category X drugs newly 
initiated during pregnancy were mainly triptorelin and norethisterone, which are drugs used in fertility 
treatment and pregnancies in women receiving these drugs can therefore be expected, but initiating 
these therapies after conception seems inappropriate.
In the sensitivity analysis the proportion of pregnancy in which the mother received a potentially 
teratogenic drug increased from 5.1% to 6.1% when including pregnancies with a dispensing before 
conception with a duration of use extending beyond conception date. We observed that this increase 
which was mainly driven by frequently dispensed drugs used in assisted reproductive technology such 
as IVF: triptorelin, follitropin  and progesterone. These drugs, as expected by their indication, were 
most frequently received in the 3-month period before conception which explains, together with the 
overall high frequency of dispensing, the impact within the sensitivity analysis. As it can be expected 
that women only use these drugs until the IVF procedure and potential conception, our sensitivity 
analysis mainly adds untaken drugs to the analysis, resulting in an overestimation of the actual drug 
use. 
Overall, potentially teratogenic drugs classified as reproductive hormones or GrNH agonists (triptorelin 
and leuprorelin) contributed substantially to the pregnancies during which a potentially teratogenic 
drug was received (30%). As expected by their indication, these drugs were mainly received before 
pregnancy. The obvious peak in the number of women that received potentially teratogenic drugs 
in the 3-month period before conception was most probably the result of the GrNH agonists and 
other fertility agents used in IVF including progesterone and follitropin . When triptorelin and 
leuprorelin were received during pregnancy, this was mainly (in 85% and 86%, respectively) during 
the first trimester of pregnancy as expected, when the women might not be aware of the pregnancy. 
Antibiotics are often used during pregnancy and in our study ‘anti-infectives and anti-parasitic agents’ 
were also the most commonly received potentially teratogenic drugs before and during pregnancy.26 
Doxycycline, an antibiotic that is contraindicated during pregnancy because of the known effects on 
bone and tooth development in the fetus, was most frequently received during pregnancy (in 10 per 
1000 pregnancies).27 Paroxetine, a selective serotonin reuptake inhibiting antidepressant, is the second 
most frequently dispensed potentially teratogenic drug during pregnancy in our study. In 2005, the 
European regulatory authorities highlighted the possible association between maternal paroxetine 
exposure in the first trimester of pregnancy and cardiovascular malformations in the developing fetus 
via a direct healthcare professional communication.28 Although some studies observed increased risks 
on congenital heart defects after paroxetine use in early pregnancy, the absolute risk for the hearth 
defects remains small.29-31 The risks on congenital malformations have been studied for other selective 
serotonin reuptake inhibitors, with often inconclusive results.32-36 Discontinuation of antidepressants in 
pregnant women may not always be appropriate and the consequences of untreated major depression 
might impact the mother and the unborn child and the treatment of depression may outweigh the 
potential fetal harm. Therefore, the most appropriate therapy should be determined at individual 
patient level considering the potential beneficial and harmful effects of the treatment. In general, as 
with other chronic medical conditions such as epilepsy or diabetes mellitus, drugs with teratogenic 
potential should only be used during pregnancy after a balanced decision. 
The category X drugs received during pregnancy mainly concerned triptorelin, a fertility agent, 
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and norethisterone, a drug with several indications: dysfunctional uterine bleeding, endometriosis, 
polymenorrhoea, menorrhagia, metropathia, haemorrhagia, postponement of menstruation and 
premenstrual syndrome. These drugs may be classified in category X due to their lack of benefit of 
use during pregnancy. Furthermore, triptorelin can also be used for preoperative reduction of myoma 
size to reduce the symptoms of bleeding and pain in women with symptomatic uterine myomas. This 
patient population should not be or become pregnant when an uterine surgery is planned which 
may also explain the category X of this drug, rather than a potential teratogenic effect, especially 
since evidence of harmful effects of triptorelin on the fetus is not available. Next to these, statins 
were the most frequently received category X drugs during pregnancy (0.07% of the pregnancies). 
Statins are labelled category X due to potential effects on the development of the fetus as observed 
in animal studies, plus the hypothesis that treatment of dyslipidemia offers no benefit for pregnant 
women. However, studies in animals and human show conflicting evidence on the teratogenic effects 
of statins.37 The potential risks of statin use during pregnancy require further investigation.
Of particular concern is the dispensing of the highly teratogenic drug isotretinoin to 40 pregnant women 
(0.20 per 1000 pregnancies). The majority (33 of the 40) received the drug even more than once during 
pregnancy while the isotretinoin pregnancy prevention programme aims to have no isotretinoin-ex-
posed pregnancies. Although the number of observed exposed pregnancies is relatively low, it adds to 
the evidence that isotretinoin-exposed pregnancies occur despite the strict measures to prevent this. 
Isotretinoin-exposed pregnancies were also observed in a French and Canadian study.38, 39 In addition, 
previous studies identified challenges for implementation of the pregnancy prevention programme in 
the EU and US.40-42 In the Netherlands, concomitant use of contraceptives and isotretinoin is, although 
higher than the background use (48%), still relatively low among women of reproductive age (59%).43 
All these findings suggest that the current pregnancy prevention programme may not be completely 
effective. 
Conclusions
A considerable proportion of Dutch pregnancies (5%) received a potentially teratogenic drug during 
pregnancy and 0.7% a category X drug, of which in 53% of these pregnancies was newly initiated 
therapy. Drugs with teratogenic potential should be used during pregnancy only after a balanced 
decision in which potential benefits and harms are carefully weighed. It may be possible to reduce 
these proportions in future, especially since in the Netherlands only 42% of the women of reproductive 
age using potentially teratogenic drugs used concomitant contraceptive measures, which could lead 
to unnecessary teratogenic drug exposure during pregnancy.4 Future research is necessary to explore 
reasons for teratogenic drug prescription and dispensing to pregnant women in order to develop 
targeted measures to minimise unnecessary drug exposure if appropriate.
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A
B
C
Drugs which have been 
taken by a large number of 
pregnant women and women 
of childbearing age without any 
proven increase in the frequency 
of malformations or other direct 
or indirect harmful effects on the 
fetus having been observed.
Drugs which have been taken 
by only a limited number of 
pregnant women and women 
of childbearing age, without 
an increase in the frequency of 
malformation or other direct 
or indirect harmful effects on 
the human fetus having been 
observed. 
B1 Studies in animals have not 
shown evidence of an increased 
occurrence of fetal damage.
B2 Studies in animals are 
inadequate or may be lacking, 
but available data show no 
evidence of an increased 
occurrence of fetal damage.
B3 Studies in animals have 
shown evidence of an increased 
occurrence of fetal damage, 
the significance of which is 
considered uncertain in humans.
Drugs which, owing to their 
pharmacological effects, have 
caused or may be suspected
of causing, harmful effects on 
Appendix I: Overview of the definitions of the pregnancy classifications of the ADEC, FASS and FDA
Category The former Australian Drug 
Evaluation Committee (ADEC)
The Swedish Catalogue of 
Approved Drugs (FASS)
Pregnancy Classification ot the 
Food and Drug Authority (FDA)  
Medicinal products which may 
be assumed to have been 
used by a large number of 
pregnant women and women 
of child-bearing age without 
any identified disturbance 
in the reproductive process, 
e.g. an increased incidence of 
malformations or other direct 
or indirect harmful effect on the 
fetus. 
Medicinal products which may 
be assumed to have been used 
by only a limited number of 
pregnant women and women 
of child-bearing age, without 
any identified disturbance 
in the reproductive process 
having been noted so far, 
e.g. an increased incidence of 
malformations or other direct 
or indirect harmful effect on the 
fetus. 
B1 reproduction toxicity studies 
have not given evidence of an 
increased incidence of fetal 
damage or other deleterious 
effects on the reproductive 
process
B2 reproduction toxicity studies 
are inadequate or lacking, but 
available data do not indicate 
an increased incidence of fetal 
damage or other deleterious 
effects on the reproductive 
process
B3 reproduction toxicity studies 
in animals have revealed an 
increased incidence of fetal 
damage or other deleterious 
effects on the reproductive 
process, the significance of 
which is considered uncertain 
in man.
Medicinal products which by 
their pharmacological effects 
have caused, or must be 
suspected of causing, 
Adequate and well-controlled 
studies in pregnant women have 
failed to demonstrate a risk to 
the fetus in the first trimester 
of pregnancy (and there is 
no evidence of risk in later 
trimesters).
Animal reproduction studies 
have failed to demonstrate 
a risk to the fetus and there 
are no adequate and well-
controlled studies in pregnant 
women OR Animal reproduction 
studies have shown an adverse 
effect, but adequate and 
well-controlled studies in 
pregnant women have failed 
to demonstrate a risk to the 
fetus during the first trimester 
of pregnancy (and there is 
no evidence of a risk in later 
trimesters)
Animal reproduction studies 
have shown an adverse effect 
on the fetus and there are no 
adequate and well-controlled
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D
X
the human fetus or neonate 
without causing malformations.
These effects may be reversible. 
Accompanying texts should be 
consulted for further details.
Drugs which have caused, are 
suspected to have caused or 
may be expected to cause, 
an increased incidence of 
human fetal malformations or 
irreversible damage. These 
drugs may also have adverse 
pharmacological effects. 
Accompanying texts should be 
consulted for further details.
Drugs which have such a high 
risk of causing permanent 
damage to the fetus that they 
should not be used in pregnancy 
or when there is a possibility of 
pregnancy.
disturbances in the reproductive 
process that may involve risk to 
the fetus without being directly 
teratogenic. If experimental 
studies in animals have indicated 
an increased occurrence of fetal 
injuries or other injurious effects 
on the reproductive process 
of uncertain significance in 
humans, these findings are to be 
stated in this category. 
Medicinal products which have 
caused an increased incidence 
of fetal malformations or other 
permanent damage in man 
or which, on the basis of e.g. 
reproduction toxicity studies, 
must be suspected of doing 
so. This category comprises 
drugs with primary teratogenic 
effects. If the product also has 
pharmacological effects that 
may directly or indirectly have a 
harmful effect on the fetus, this 
must also be stated. 
Not applicable
studies in humans, but potential 
benefits from the use of the 
drug in pregnant women may be 
acceptable despite its potential 
risk.
There is positive evidence 
of human fetal risk based on 
adverse reaction data from 
investigational or marketing 
experience or studies in humans, 
but potential benefits from the 
use of the drug in pregnant 
women may be acceptable 
despite its potential risks (for 
example, if the drug is needed 
in a life-threatening situation or 
serious disease for which safer 
drugs cannot be used or are 
ineffective).
Studies in animals or humans 
have demonstrated fetal 
abnormalities and/or there is 
positive evidence of human fetal 
risk based on adverse reaction 
data from investigational or 
marketing experience, and 
the risks of the use of the drug 
in pregnant women clearly 
outweighs any possible benefit.
Anti-infective & Anti-parasitic 
agents
P02CA03
J01GB06
P01BE52
P01BE02
P01BA01
J05AB12
J01AA01
A01AB22
J01AA02
J05AG03
J02AC01
J05AB06
Appendix II: Classification of 202 potentially teratogenic drugs into eleven different therapeutic area
Group Name ATC-code ADEC
D
D
D
D
D
D
D
D
D
D
D
D
FASS FDA
n.a.
D
n.a.
n.a.
B3
D
n.a.
n.a.
D
D
B3
D
C
D
C
C
n.a.
C
D
D
D
D
C
C
Albendazole 
Amikacin 
Artemether 
Artemether 
Chloroquine 
Cidofovir 
Demeclocycline 
Doxycycline 
Doxycycline 
Efavirenz 
Fluconazole 
Ganciclovir 
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Anti-infective & Anti-parasitic 
agents
Agents acting on the renin 
angiotensin system
Anti-thrombotic agents
Statins
P02CA03
J01GB06
P01BE52
P01BE02
P01BA01
J05AB12
J01AA01
A01AB22
J01AA02
J05AG03
J02AC01
J05AB06
J01GB03
P01BA02
J01AA08
A07AA01
J01GB05
J01GB07
J01AA06
P01BA03
P01BC01
J05AB04
J01GA01
A01AB13
J01AA07
J01AA12
J01GB01
J05AB14
J05AF03
C09AA07
C09CA06
C09AA01
C09AA08
C09AA02
C09CA02
C09DB01
C09AA09
C09CA04
C09AA03
C09CA01
C09CA08
C09AA04
C09AA06
C09AA05
C09CA07
C09AA10
C09CA03
B01AA07
B01AA04
B01AA03
C10AA05
C10AA04
Group Name ATC-code ADEC
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
n.a.
D
D
D
D
D
D
n.a.
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
n.a.
n.a.
D
D
D
FASS FDA
n.a.
D
n.a.
n.a.
B3
D
n.a.
n.a.
D
D
B3
D
D
B3
n.a.
n.a.
n.a.
D
D
n.a.
D
D
n.a.
n.a.
D
D
B3
D
n.a.
n.a.
D
D
n.a.
D
D
D
n.a.
D
D
D
n.a.
D
D
D
D
n.a.
D
n.a.
n.a.
D
D
B3
C
D
C
C
n.a.
C
D
D
D
D
C
C
D
n.a.
D
n.a.
D
D
n.a.
n.a.
C
X
D
D
D
D
D
C
C
D
D
D
n.a.
D
D
D
C
C
D
C
C
D
D
D
C
C
D
n.a.
n.a.
X
X
X
Albendazole 
Amikacin 
Artemether 
Artemether 
Chloroquine 
Cidofovir 
Demeclocycline 
Doxycycline 
Doxycycline 
Efavirenz 
Fluconazole 
Ganciclovir 
Gentamicine 
Hydroxychloroquine 
Minocycline 
Neomycin 
Neomycin 
Netilmicin 
Oxytetracycline 
Primaquine 
Quinine 
Ribavirin 
Streptomycine 
Tetracycline 
Tetracycline 
Tigecycline 
Tobramycin 
Valganciclovir 
Zalcitabine 
Benazepril 
Candesartan 
Captopril 
Cilazapril 
Enalapril 
Eprosartan 
Exforge 
Fosinopril
Irbesartan 
Lisinopril 
Losartan 
Olmesartan 
Perindopril 
Quinapril 
Ramipril 
Telmisartan 
Trandolapril 
Valsartan 
Acenocoumarol 
Fenprocoumon 
Warfarin
Atorvastatin 
Fluvastatin 
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Dermatologicals
Pituitary, hypothalamic & sex 
hormones
Anti-neoplastic agents
C10AA03
C10AA07
C10AA01
D05BB02
D10AD03
D11AX10
D10BA01
D05AX05
D06AA04
D10AD01
G02AD04
H01CC02
G03XA01
G04CB02
G03DB01
G03CA57
G04CB01
G03GA05
H01CC01
G03XA02
G02AC03
G03DC03
G03DA02
G03FA12
G03FB06
G03BB01
H01CA02
G03DB04
G03DC02
G03DA04
G03XC01
G03BA03
H01AA02
G03CX01
L01XX22
L01XX03
L01XX01
L01XC07
L01DC01
L01XX32
L01AB01
L01BC06
L01XA02
L01AD01
L01XC06
L01AA02
L01XA01
L01BB04
L01BB06
L01AA01
L01BC01
D
D
D
X
D
X
X
D
D
D
D
D
D
D
D
D
D
D
D
D
B3
D
D
D
D
D
D
D
D
D
D
D
D
D
 n.a.
D
D
D
D
C
D
D
D
D
D
D
D
D
n.a.
D
D
B3
D
B3
D
B3
D
n.a.
n.a.
n.a.
B3
n.a.
C
n.a.
n.a.
n.a.
n.a.
D
B1
C
n.a.
n.a.
D
D
B3
B3
n.a.
B3
n.a.
D
n.a.
D
D
C
B3
n.a.
n.a.
D
D
D
D
D
D
D
n.a.
B2
D
D
D
D
D
D
X
X
X
X
C
X
X
X
B
C
C
X
X
X
n.a.
X
X
n.a.
X
n.a.
X
n.a.
n.a.
X
X
n.a.
X
n.a.
X
n.a.
X
X
n.a.
n.a.
D
D
n.a.
C
n.a.
D
D
D
D
D
C
D
D
D
D
D
D
Pravastatin 
Rosuvastatin 
Simvastatin 
Aciretin 
Adapalene 
Finasteride 
Isotretinoin 
Tazaroteen 
Tetracycline 
Tretinoin 
Carboprost 
Cetrorelix*
Danazol* 
Dutasteride 
Dydrogesteron* 
Estrogens, esterified* 
Finasteride 
Follitropin alpha* 
Ganirelix* 
Gestrinon* 
Levonorgestrel 
Lynestrenol* 
Medrogestron – IM*
Medroxyprogesterone 
and estrogen* 
Medroxyprogesterone 
and estrogen* 
Mesterolon* 
Nafarelin* 
Nomegestrol* 
Norethisterone* 
Progesterone* 
Raloxifene* 
Testosterone* 
Tetracosactide
Tibolon* 
Alitretinoin
Altretamine 
Amsacrine 
Bevacizumab 
Bleomycin 
Bortezomib 
Busulfan 
Capecitabine 
Carboplatin 
Carmustine 
Cetuximab 
Chlorambucil 
Cisplatin 
Cladribine 
Clofarabine 
Cyclophosphamide 
Cytarabine
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Immunomodulating agents
L01AX04
L01DA01
L01XE06
L01DB02
L01CD02
L01DB01
L01DB03
L01XE03
L01XX11
L01CB01
L01BB05
L01BC02
L01BC05
L01XX05
L01DB06
L01AA06
L01XE01
L01XX19
L01XE07
L01AD02
L01AA03
L01BB02
L01BA01
L01DC03
L01DB07
L01BB07
L01XA03
L01CD01
L01BA04
L01XX08
L01XB01
L01BA03
L01XE05
L01AD04
L01XE04
L01BC03
L01AX03
L01CB02
L01BB03
L01AC01
L01XX17
L01XX14
L01CA01
L01CA02
L01CA03
L01CA04
L02BG01
L04AX01
L04AC02
L04AC01
L02BA03
L02AE03
Group Name ATC-code ADEC
D
D
D
D
D
D
D
C
D
D
D
D
D
n.a.
D
D
D
D
n.a.
D
D
D
D
D
D
n.a.
D
D
D
n.a.
D
D
D
n.a.
D
D
D
D
D
D
D
X
D
D
D
D
D
D
D
D
D
D
FASS FDA
D
n.a.
B3
D
D
D
D
B3
n.a.
D
D
D
D
D
D
D
B3
B3
B3
D
D
D
D
D
D
D
D
D
D
n.a.
n.a.
n.a.
C
n.a.
B3
n.a.
D
n.a.
D
n.a.
D
n.a.
D
D
D
D
n.a.
D
B2
n.a.
D
D
C
C
D
D
D
D
D
D
n.a.
D
D
D
D
n.a.
D
D
D
D
D
D
D
D
X
D
D
D
D
D
D
D
D
n.a.
D
D
D
n.a.
D
D
D
D
D
D
D
D
n.a.
D
D
D
B
C
D
D
Dacarbazine 
Dactinomycin 
Dasatinib 
Daunorubicin 
Docetaxel 
Doxorubicin 
Epirubicin 
Erlotinib 
Estramustine 
Etoposide 
Fludarabine 
Fluorouracil 
Gemcitabine 
Hydroxycarbamide 
Idarubicin 
Ifosfamide 
Imatinib 
Irinotecan 
Lapatinib 
Lomustine 
Melphalan 
Mercaptopurine 
Methotrexate 
Mitomycine 
Mitoxantrone 
Nelaribine 
Oxaliplatin 
Paclitaxel 
Pemetrexed 
Pentostatin 
Procarbazine 
Raltitrexed 
Sorafenib 
Streptozocine 
Sunitinib 
Tegafur 
Temozolomide 
Teniposide 
Thioguanine 
Thiotepa 
Topotecan 
Tretinoin 
Vinblastine 
Vincristine 
Vindesine
Vinorelbine 
Aminoglutethimide 
Azathioprine 
Basiliximab 
Daclizumab 
Fulvestrant 
Goserelin 
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Anti-epileptic agents
Psycholeptic & 
psychoanaleptic agents
Miscellaneous agents
L03AB07
L03AB08
L04AA13
L04AX04
L02BG04
L02AE02
L02AB02
L02AB01
L04AA06
M01CC01
L02BA01
L03AX11
L04AX02
L02BA02
L02AE04
N03AF01
N03AD01
N03AX09
N03AA01
N03AF02
N03AA02
N03AB02
N03AA03
N03AX03
N03AG01
N03AG04
N05CA02
N05CA03
N05AN01
N06AB05
N05CA01
N05CA06
G04BX03
C02KX02
C02KX01
V03AC02
N02CA01
N02CA02
M09AA01
C01EB17
A02BB01
A14AB01
N07BA01
A14AA08
A14AA07
A11CA01
A01AD11
D
D
D
n.a.
D
D
D
D
D
D
B3
D
D
B3
D
D
D
D
D
D
D
D
D
D
D
D
n.a.
n.a.
D
D
n.a.
n.a.
n.a.
X
D
D
C
C
D
D
X
D
D
D
D
D
D
D
D
D
D
B3
C
D
B3
D
n.a.
D
B2
D
B3
B3
D
D
B3
n.a.
D
D
D
n.a.
n.a.
D
D
n.a.
n.a.
n.a.
C
n.a.
n.a.
n.a.
D
D
n.a.
C
n.a.
n.a.
D
D
n.a.
C
n.a.
n.a.
n.a.
n.a.
C
C
X
X
D
n.a.
n.a.
X
D
D
D
n.a.
X
D
X
C
n.a.
C
n.a.
C
D
n.a.
n.a.
n.a.
D
C
D
D
n.a.
D
D
D
X
X
X
n.a.
X
X
n.a.
n.a.
X
X
C
X
n.a.
n.a.
D
Interferon Beta 1a 
Interferon Beta 1b 
Leflunomide 
Lenalilomide 
Letrozole 
Leuprorelin* 
Medrogestron IM 
Megestrol
Mycophenolic acid
Penicillamine 
Tamoxifen 
Tasonermine 
Thalidomide 
Toremifene 
Triptorelin* 
Carbamazepine 
Ethosuximide 
Lamotrigine 
Methylfenobarbital 
Oxcarbazepine 
Phenobarbital 
Phenytoin 
Primidone 
Sultiam 
Valproic acid 
Vigabatrin 
Amobarbital 
Butabarbital 
Lithium 
Paroxetine 
Pentobarbital 
Secobarbital 
Acetohydroxac acid 
Ambrisentan
Bosentan 
Deferipron 
Dihydroergotamine 
Ergotamine 
Hydrokinine 
Ivrabradine 
Misoprostol 
Nandrolone 
Nicotine 
Oxandrolone 
Prasteron 
Retinol 
Tretinoin 
*These reproductive hormones, ovulation stimulants or fertility drugs were excluded from some analyses
n.a.=not applicable
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general disCussiOn
During the last decade the risk management approach towards drugs has evolved and it is still a very 
dynamic area. Major developments started with the introduction of the risk management plan (RMP) 
in 2005. The RMP of a drug describes the planned pharmacovigilance activities and risk minimisation 
measures that have been agreed between the marketing authorisation holder (MAH) and regulatory 
authorities. Risk minimisation measures (RMMs) are interventions that aim to optimise the benefit-risk 
balance of a drug by minimising its risks during drug use in daily practice. These measures intend to 
prevent or reduce the occurrence or the severity of adverse drug reactions (ADRs).1 Routine RMMs 
are required for all drugs and include the Summary of Product Characteristics (SmPC), the patient 
information leaflet (PIL), the labelling (packaging), the pack size and the legal (prescription) status 
of a drug. While for the majority of drugs routine RMMs adequately addresses the safety concerns 
of the drug, sometimes extra measures beyond those routinely required are necessary to minimise 
the drug related risks during use in clinical practice, i.e., the additional risk minimisation measures 
(aRMMs). Examples of aRMMs are educational tools for healthcare professionals (HCPs) or patients 
and a pregnancy prevention programme (PPP). 
For each new active substance licensed in the European Union (EU) after 2005 a RMP has been agreed 
and the need and the possibilities for aRMMs have been evaluated on a case-by-case basis. From that 
time, industry and regulators have gained experience in the field of risk minimisation measures and 
also with additional risk minimisation measures. With the EU pharmacovigilance legislation in place 
since July 2012 new standards in the EU risk management approach were set and monitoring the 
effectiveness of the risk minimisation measures in real world practice became mandatory.2, 3 However, 
the knowledge on how to measure the effectiveness of aRMMs in routine care is still quite limited.
This thesis provides further insight into the quality and quantity of the additional risk minimisation 
measures required in the EU and how the effectiveness of these measures in clinical practice can 
be evaluated. In this chapter the results of the studies presented in this thesis are summarised and 
discussed, followed by a description of the lessons learned so far and future perspectives in the area 
of evaluation of effectiveness of aRMMs in clinical practice.
Main Findings
Additional risk minimisation measures in the EU
Chapter 2 provides an overview of the aRMMs required in the EU at 1 January 2010. This analysis showed 
that aRMMs were required for 58 of the 391 (15%) active substances authorised in the EU between 
1 January 1995 and 1 January 2010 through the centralised procedure. The proportion of the active 
substances with aRMMs increased from 5% to 29% of the active substances approved in the period 
before compared to the period after the RMP was introduced. In the five years after the introduction of 
RMPs, aRMMs were most frequently required for antineoplastic and immunomodulating agents. The 
main requested additional risk minimisation strategy was provision of educational materials, which was 
required for all drugs with aRMMs, always addressed to HCPs and for approximately 50% of the drugs 
with aRMMs educational material was also requested for patients. Other measures such as a controlled 
distribution system or a PPP were less frequently required, for 17% and 9% of the active substances 
included in the analysis, respectively. An important finding of this review was the limited consistency 
in required aRMMs across similar safety concerns. Exceptions were teratogenicity and hepatotoxicity, 
where in all instances a PPP and patient monitoring was required. The increase in aRMMs may point 
to an increasing awareness of MAHs and regulators to the available options of minimising risks. The 
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growing number of drugs with aRMMs as well as the hope that these indeed will lead to less safety 
issues or adverse reactions, emphasizes the need for evaluation of the effectiveness of these measures. 
Using electronic healthcare databases for the evaluation of effectiveness of aRMMs
aRMMs are aimed to minimise potential harms related to drugs and may also add an extra burden on 
the healthcare system. Ineffective measures should be modified in early stages and not unnecessary 
burden clinical practice. This shows the clear need for rapid evaluation and timely feedback on the 
intended and unintended effects of aRMMs in clinical practice to allow modification of the aRMMs in 
an early stage. Since existing electronic healthcare record databases (EHDs) present opportunities to 
rapidly investigate drug-event associations as well was drug utilisation patterns, we explored whether 
these resources can be used to evaluate the effectiveness of aRMMs in clinical practice (Chapter 3). 
Existing electronic healthcare record databases refer to already existing computerised data sources 
containing routinely collected medical information from actual care and which are commonly used for 
pharmacoepidemiology and pharmacovigilance research.4, 5 There is wide variation between EHDs and 
these can include administrative (claims) databases, routine primary care databases, but also specific 
disease and drug registries. Data included in EHDs varies per EHD but the information considered 
generally retrievable from existing EHDs include: patient demographics, information regarding drug 
prescription/dispensing, medical events which can include adverse events, symptoms/signs, diagnosis 
in primary care, specialist diagnosis, hospital discharge diagnosis, laboratory values, death, clinical 
procedures, overdoses and teratogenic events.4, 5 The key elements of the aRMMs of the 68 drugs with 
aRMMs authorised in the EU via the centralised procedure between 1 January 1995 and 1 April 2011 
were reviewed. These key elements are the core components of the aRMMs to be implemented in all 
EU member states. Of the 801 aRMM key elements reviewed (median number of key elements per drug 
was 9.5), 36% aimed provision of knowledge and 57% recommended an action (a behavioural change) 
of HCPs or patients. Considering the information generally retrievable from existing EHDs, only a 
limited proportion (22%) of the aRMM key elements are considered suitable for evaluation in existing 
EHDs. These key elements mainly aimed at behavioural changes of HCPs. It particularly concerned 
recommendations to perform regular laboratory tests or patient examinations or recommendations 
regarding drug prescription, e.g. dose recommendations, contraindications. The key elements that 
we considered not measurable in EHDs were either poorly drafted and unclear measures (11%) or 
the data necessary for evaluation was not considered available in existing EHDs. The latter included 
aRMM key elements that aimed to provide knowledge to HCPs or patients regarding the benefit-risk 
profile of a drug (34%), to introduce behavioural changes in patients (15%) or recommended actions 
that HCPs should take regarding drug administration (11%). The majority of aRMM key element was 
not considered suitable for assessment in existing EHDs and it remains a challenge to evaluate the 
effectiveness of these aRMMs in an efficient and objective way using data sources other than EHDs. 
Well-defined aRMM key elements with clear objectives leading to unambiguous actions of the target 
group should be agreed by industry and regulatory authorities. Improvement of the quality of the 
aRMMs could facilitate the assessment of effectiveness of aRMMs in routine care. 
The evaluation of implementation and effectiveness of aRMMs in clinical practice can comprise different 
levels, which are described in Chapter 4. These levels involve 1) the assessment of risk minimisation 
tool dissemination and use, 2) measuring the knowledge of HCPs or patients as well as 3) evaluation 
of the desired behaviour of HCPs or patients (e.g., prescription behaviour or compliance to patient 
monitoring). These levels evaluate the implementation and use of the aRMMs in clinical practice and 
are considered the process indicators of the aRMMs. In addition to the process indicators, 4) the actual 
risk reduction of a safety outcome to be minimised can be assessed, which is the so-called outcome 
indicator of the aRMM. This chapter also described specific challenges in measuring the effectiveness 
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of risk minimisation measures. These include appropriate data collection via EHDs or surveys, lack 
of comparators when aRMMs are implemented since initial marketing authorisation, uncertainty on 
the best outcome measures and its interpretation, and the lack of benchmarking or pre-defined 
aRMM objectives. Considering these challenges, the best feasible methodology for evaluating the 
effectiveness of aRMMs can differ per drug or type of aRMM. 
Recommended dose restrictions of citalopram
The impact of risk minimisation measures on the use of citalopram in United Kingdom (UK) and the 
Netherlands (NL) is evaluated in Chapter 5. Citalopram is an antidepressant and available in the EU 
since the early nineties. In October 2011 European regulatory authorities recommended citalopram 
dose restrictions based on new information on a dose dependent QT interval prolongation that was 
associated with this drug.6 The maximum daily dose of citalopram was reduced from 60 mg to 40 
mg and in elderly patients (aged ≥ 65) from 40 mg to 20 mg. This was communicated to HCPs with 
a Direct Healthcare Professional Communication (DHPC) while the product information of citalopram 
was updated.7-9 The following primary care databases were used: THIN (The Health Improvement 
Network from UK) and IPCI database (Interdisciplinary Processing of Clinical Information from NL), 
covering a period ranging from 1996 to 2013. We analysed the use of the following three daily dose 
categories for citalopram in the general population: low (≤ 20 mg); moderate (>20 to ≤ 40 mg); high 
(> 40 mg). New users of citalopram and those that continued using citalopram after the new dose 
recommendations were analysed separately. Over the entire study period the monthly prevalence rate 
of citalopram use was higher in UK compared with NL and independent of country and age group, 
monthly prevalence rates were highest for citalopram low dose and very low for high dose citalopram. 
With an interrupted time-series analysis using an ARIMA (autoregressive integrated moving average) 
model we observed that after the dose restrictions, the use of citalopram with moderate dosages 
significantly decreased among the elderly in UK and NL which in British elderly was also observed 
for high dose citalopram. Among the British and Dutch population younger than 65 years only the 
use of high dose citalopram significantly reduced. Independent of country and age categories, a 
large majority of patients using citalopram at 31 October 2011 continued using the same daily dose, 
including high dosages. In both countries a decrease in elderly people starting citalopram after the 
dose restrictions was observed. This latter finding is considered an additional, unintended effect of the 
risk minimisation measures. 
Risk minimisation measures and drug exposure during pregnancy
The safe use of drugs in pregnant women is of specific interest in view of the potential serious risks on 
spontaneous abortion and birth defects after drug exposure in this vulnerable population. Pregnant 
women are generally excluded from most clinical trials and knowledge about the safety of drugs during 
pregnancy is usually not established at the moment of first marketing. Proactive pharmacovigilance 
and risk management during the post-marketing period is therefore important to not only characterise, 
but also to minimise the possible risks for the developing embryo or fetus. aRMM that can be imposed 
to minimise the risk of drug exposure during pregnancy and its serious consequences is the pregnancy 
prevention programme (PPP). In Chapter 6 we explored the reasons to request PPPs in the EU and the 
elements used in these PPPs. At time of the study seven drugs in the EU had a PPP, that have been 
developed per drug on a case-by-case basis: thalidomide and lenalidomide; the vitamin A derivatives 
isotretinoin, acitretin and alitretinoin; bosentan and ambrisentan (endothelin receptor antagonists). 
The PPPs of thalidomide, lenalidomide and the vitamin A derivatives have been imposed based on an 
established or expected high teratogenic risk in humans. For bosentan and ambrisentan, the rationale 
for the imposed PPP was less clearly documented. Not all drugs with known human teratogenic risks 
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have a PPP or an absolute contraindication for use such as the antiepileptic drugs valproic acid or 
carbamazepine.10, 11 For these therapies the potential treatment benefits may outweigh the potential 
risks because discontinuation of these therapies may be harmful for both the mother and the unborn 
child. Similarities as well as differences among risk minimisation measures taken for teratogenic drugs 
exist. The seven PPPs contained similar elements including pregnancy tests before and monthly 
during drug use; contraceptive use and pregnancy prevention counselling of patients. The differences 
between PPPs concerned educational materials for different target groups, restricted drug supply, 
continuation of contraceptive use and pregnancy tests after treatment discontinuation. The latter can 
be explained by the half-life time of the drug. In addition to such drug-specific characteristics, previous 
experiences as well as the feasibility in clinical practice should be considered in the development of 
a programme. The latter can be done by involving prescribers, pharmacists and patients. It may also 
be helpful to provide regulatory guidance on standard (minimum) requirements that should always 
be part of the PPP and optional elements (depending on the target population and drug specific 
characteristics) of PPPs in the European guideline on human reproduction and lactation.12 
Isotretinoin pregnancy prevention programme
Effectiveness of the isotretinoin PPP has previously been studied and in these studies the compliance 
with the isotretinoin PPP was less than optimal.13, 14 In Chapter 7 we examined the occurrence of 
isotretinoin exposure in Dutch pregnant women despite the mandatory PPP and we analysed the 
occurrence of adverse fetal or neonatal outcomes (intrauterine deaths ≥ 16 weeks of gestation or 
live borns with major congenital malformations). A cohort of 203,962 pregnancies between 1999 and 
2007 consisting of 208,161 fetuses was constructed using a linkage between the PHARMO Database 
Network and the Netherlands Perinatal Registry (PRN). There were 45 of these pregnancies, 2.2 
(95%CI 1.6 to 2.9) per 10,000 pregnancies, exposed to isotretinoin during pregnancy. Sixty percent of 
isotretinoin exposed pregnancies women started isotretinoin while already pregnant. Adverse fetal or 
neonatal outcomes potentially related to isotretinoin were identified for 9.4% (95% CI 1.3 to 17.6) of 
the isotretinoin exposed pregnancies. The OR for adverse fetal or neonatal outcomes after isotretinoin 
exposure in 30 days before or during pregnancy was 2.3 (95% CI 0.9 to 5.7) which should be carefully 
interpreted because low numbers were involved and no adjustments for important confounding 
factors other than maternal age could be made. Furthermore, spontaneous abortions that occurred in 
the period until 16 weeks of gestation were not included in our study. It was concluded that although 
a PPP was already implemented in 1988, isotretinoin exposed pregnancies and adverse fetal and 
neonatal events potentially related to the exposure still occur. These findings from the Netherlands 
add to the evidence that there is no full compliance to the isotretinoin PPP in many Western countries. 
Given the limited success of iPLEDGE, the even stricter isotretinoin PPP implemented in the United 
States (US), the question is which measures are able to further improve compliance.
Dispensing of drugs with teratogenic potential to pregnant women
In Chapter 8 we examined the dispensing of potentially teratogenic drugs in the 12 month period 
before as well as during pregnancy in the same cohort of Dutch pregnancies as described in Chapter 
7. 202 drugs with either a Swedish Catalogue of Approved Drugs (FASS) ‘D’ classification, the 
former Australian Drug Evaluation Committee (ADEC) or US Food and Drug Administration (FDA) 
‘D’ or ‘X’ classification were considered potentially teratogenic. Category X drugs should not be 
used during pregnancy since the risks clearly outweigh the potential benefits. Sixteen percent of 
the 203,962 pregnancies received a potentially teratogenic drug in the 12 month period before and 
5.1% during pregnancy. Doxycycline and paroxetine were most frequently received during pregnancy 
by 1.01% and 0.85% of women, respectively; 0.66% of the women received a risk category X drug 
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during pregnancy which most frequently consisted of triptorelin (0.25%), norethisterone (0.22%), and 
simvastatin (0.03%). Fifty-tree percent of the women who received a potentially teratogenic drug 
during pregnancy received this for the first time during the study period. The majority of the dispensed 
potentially teratogenic drugs classified as ‘anti-infective and anti-parasitic agents’ were newly initiated 
whilst ‘Psycholeptic and psychoanaleptic agents’, ‘anti-epileptic agents’, ‘statins’ or ‘agents acting 
on the renin angiotensin system’ were less frequently newly initiated: 30 – 35% were initiated before 
pregnancy and approximately 10% during pregnancy. Heterogeneity between these percentages 
can be explained by the shorter and occasional use of anti-infectives compared to chronic use of 
antidepressants and anti-epileptics. It can be concluded that a considerable proportion of 5% of the 
pregnancies received a potentially teratogenic drug during pregnancy and 0.7% a drug from the risk 
category X. Drugs with teratogenic potential should be used during pregnancy only after a balanced 
decision in which potential benefits and harms are carefully weighed. It may be possible to reduce 
these proportions in future, especially since in the Netherlands only 42% of the women of reproductive 
age using potentially teratogenic drugs used concomitant contraceptive measures, which could lead 
to unnecessary teratogenic drug exposure during pregnancy.15 Future research is necessary to explore 
reasons for teratogenic drug prescription and dispensing to pregnant women in order to develop 
targeted measures to minimise unnecessary drug exposure if appropriate. 
KnOWledge On eFFeCTive arMMs is sTill laCKing
The growing experience with aRMMs over the years provided insight in the possibilities and challenges 
of aRMMs in clinical practice as well as evaluating the effectiveness of aRMMs. In addition to the practical 
experience obtained by regulators, industry and academics, several initiatives contributed knowledge 
to this field. With the EU pharmacovigilance legislation in place since July 2012 new standards in the 
EU risk management approach were set and Good Vigilance Practice Module XVI was developed 
to provide guidance on evaluation of risk minimisation measures.1 In addition, the report ‘Practical 
approaches to risk minimisation for medicinal products’ of the Council for International Organisations 
of Medical Sciences (CIOMS) Working Group IX has recently been published.16 Furthermore, the 
work in this thesis and other scientific publications provide useful information on how effectiveness of 
aRMMs can be evaluated and the challenges involved.
However, knowledge on effective aRMMs is still limited because only a few studies evaluating aRMMs 
or the US risk evaluation and mitigation strategies (REMS) of a specific drug have become available in 
the scientific literature. Since evaluation of the effectiveness of aRMMs became a legal obligation in 
the EU in 2012, evaluations of recent aRMMs may be still be in progress and therefore not yet available 
in the public domain. The studies that have been published often concern the implementation and 
effectiveness of the PPP or direct healthcare professional communications (DHPCs).13, 14, 17-29 Other 
studies evaluated the REMS for varenicline, the REMS for long-acting ß2-adrenergic agonist (LABA) 
and the recommended screening for latent tuberculosis (TB) prior to initiation of tumour necrosis 
factor-alpha (TNF- ) antagonists.30-33 More examples concern routine risk minimisation measures such 
as the evaluation of the effect of the paracetamol pack size reduction in UK to a maximum of 32 
tablets in pharmacies and to 16 tablets for non-pharmacy sales on the deaths due to paracetamol 
overdose.34 An Italian study evaluated the effectiveness of recommendations (new maximum daily 
dose and recommended echocardiograph before start and every 6 months) that were added to the 
SmPC for cabergoline to reduce the risk of cardiac valvulopathy in clinical practice.35 
A few systematic reviews addressed the methodologies that have been used to study the impact of 
regulatory interventions.36-39 Piening et al. and Dusetzina et al. reviewed studies evaluating the impact 
of drug safety warnings including black box warnings or dear doctor letters in the US and DHPC in 
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the EU.36, 39 Another review included also studies that evaluated risk minimisation interventions other 
than safety warnings such as the PPP or patient monitoring or examination.37 The review of Briesacher 
et al. included evaluations of FDA safety warnings, label changes and drug withdrawals that used 
methodologies applicable in administrative claim databases only, so studies using surveys or other 
primary data collection were excluded.38 Because studies on effectiveness of aRMMs or REMS are still 
very limited, the systematic reviews mainly included evaluations of risk communications such as DHPCs 
and FDA safety communications and particularly with regard to antidepressants, rosiglitazone and 
cisapride. Nevertheless, knowledge on possible methodologies to assess the impact of drug safety 
warnings is relevant to consider in the evaluation of effectiveness of aRMMs as discussed in the next 
section. 
evaluaTiOn OF eFFeCTiveness OF arMMs in CliniCal PraCTiCe:  The essenTials
The evaluation of the effectiveness of aRMMs in clinical practice basically starts with understanding the 
objective of the aRMMs. Once it is clear what the aRMM aims to achieve, the following main components 
necessary to evaluate effectiveness of aRMM should be carefully considered by regulators, industry 
and academics: the outcome measures, data sources and analytical methods to use in the evaluation. 
These essentials for evaluating the effectiveness of risk minimisation measures are discussed below 
using experiences from the studies presented in this thesis as well as in published literature.
What to achieve: objectives of the aRMMs
Understanding the objective of the aRMM is necessary to determine an outcome that could truly 
measure the effectiveness of the aRMM. Recommendations leading to unambiguous actions of the 
target group (e.g. HCPs or patient) that would prevent or reduce the risk of the event in clinical 
practice can more easily be translated into objectives and expectations of the aRMMs, which facilitate 
the implementation and effectiveness evaluation of aRMMs in clinical practice. Therefore, specific and 
clearly drafted aRMM key elements which, if possible, lead to actions should be agreed by industry 
and regulatory authorities. Sometimes several objectives could be suggested for the aRMM. For 
example for the isotretinoin PPP these include: 1) knowledge on the teratogenic risk of isotretinoin 
and on the strategies to prevent pregnancy; 2) compliance with prescription and use of contraceptives 
during isotretinoin treatment in young women; and the final objective: 3) no isotretinoin exposed 
pregnancies. Guidance on these different aspects of the risk minimisation process (Figure 1) and the 
evaluation of effectiveness are provided in the European Good Vigilance Practice Module XVI.1 This 
process starts with the fact that an aRMM should reach the target group: for instance the distribution 
of educational material to HCPs or patients. Once read, used and understood, the target group should 
be knowledgeable on serious risks of the drug and how to use it appropriately. Next, the target groups 
should implement the desired behaviour if that is recommended. All together, these aspects should 
result in a lower risk on the occurrence of a harmful event (e.g., isotretinoin exposed pregnancy) which 
is considered the final objective of the aRMMs.
Figure 1: the process of risk minimisation in four levels
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What outcome to evaluate 
The main question is which objective and corresponding outcome should be studied to evaluate 
effectiveness of aRMMs in clinical practice. Prieto et al.40 described a model that documents the 
effectiveness of risk minimisation measures evaluating process as well as outcome indicators. This dual 
evidence approach has been incorporated in the European guidance on risk minimisation measures 
and is generally in line with the risk minimisation process as indicated in Figure 1. The process 
indicators evaluate the implementation of RMMs which include evaluation of level of knowledge of 
HCPs and patients and compliance to clinical actions or behaviour of HCPs or patients. With the 
outcome indicators the effect on the occurrence or severity of the ADRs to be minimised in clinical 
practice can be determined. Another model presents five different steps to measure effectiveness 
of aRMMs and each level results in another outcome with increasing utility of information, i.e. (1) 
risk minimisation tool coverage, (2) risk minimisation tool awareness and use, (3) risk knowledge and 
comprehension, (4) behavioural modification, (5) safety outcomes.41 
The systematic reviews of studies evaluating the effects of DHPCs, FDA risk communications and some 
other risk minimisation interventions showed that the majority of evaluations assessed behavioural 
modifications such as prescription behaviour and mainly overall drug use or drug use in specific patient 
populations.36, 37, 39 The impact of the intervention on knowledge and the occurrence of adverse events 
(safety outcome) was assessed infrequently. A minority of the studies included in these reviews evaluated 
multiple process indicators or outcome indicators.37, 39 Drug exposure data (prescription behaviour) is 
frequently used as process indicator of behavioural change but may result in crude estimates of the 
effectiveness of risk minimisation measures which becomes more informative when more specific drug 
use outcomes are used by stratification for e.g. special patient populations, new users, indication, 
duration of use or prescribed dose. To reflected the prescription behaviour of HCPs of citalopram, we 
studied several process outcomes (Chapter 5): prevalent and incident use of citalopram in the general 
population, the distribution of the daily dose categories among all citalopram users as well as effect 
on use in continuing citalopram users after the recommended dose restrictions. However, there may 
still be additional relevant outcomes related to citalopram prescription that could have been studied. 
When studying process indicators it is not simply knowledge or behaviour that can be evaluated. 
Within these areas there are many possible outcomes that can be used to study effectiveness of 
aRMMs of which the most appropriate should be used. Specific and clear pre-defined objectives 
leading to actions should facilitate the determination of the most suitable process indicators. The use 
of appropriate outcome indicators (safety outcome) of interest should be considered (e.g. a surrogate 
endpoint such as an adequate biomarker as a substitute for a clinical endpoint) if such an approach 
facilitates the effectiveness evaluation.1 While the safety outcome of the isotretinoin PPP, isotretinoin 
exposed pregnancies, is an acute event and quite clear, the most appropriate outcome to study can 
be more open for discussion when it concerns a biomarker (e.g. liver function levels) or an event 
that can have different stages of severity (e.g. impaired vision towards blindness). The challenge is 
to measure the occurrence of an event that should not occur anymore. Pharmacoepidemiological 
approaches should be applied to study different type of safety outcomes including acute events or 
events that gradually develop over time. Pharmacoepidemiological studies may be less informative 
when there is still considerable uncertainty with regard to the drug-event association. When the safety 
outcome to be studied is very rare, it may be challenging to indicate a risk reduction as we would aim 
to demonstrate almost a zero risk. 
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Appropriate data sources
Effectiveness of aRMMs can be studied using different type of data sources. As an example, the 
awareness of TB risk, performance of TB screening and factors predicting TB screening among 
prescribers of TNF-  antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab) in 
multiple EU member states were studied using data from prescriber surveys.33, 42 In contrast, the data 
from a Spanish registry of patients with rheumatic diseases treated with TNF-  antagonists allowed 
assessment of automatically, longitudinal data, but in only one country.30 The type of data used 
for the evaluation of aRMMs and the possible impact on the validity of the results, time planning, 
possible outcome measures or other potential biases should be well considered by researchers, 
regulators and MAHs. Existing electronic healthcare databases (EHDs) present good opportunities to 
rapidly investigate drug-event associations and are commonly used for pharmacoepidemiology and 
pharmacovigilance research.43, 44 EHDs contain longitudinal routinely collected data reflecting actual 
care of a broad patient population. Using this data is efficient and timely feedback on the aRMM may 
be provided which allows adjustment of aRMMs in early stages. It is known that EHDs are frequently 
used to evaluate the effectiveness of risk communications and particularly to study drug prescribing 
(behavioural outcomes) and sometimes also safety outcomes.36, 37, 39 It is preferred to study these 
outcome measures using data obtained from existing EHDs because of the efficiency and validity of 
using data from EHDs as well as the higher utility of information from behavioural outcomes and safety 
outcomes compared to information on reaching the target group or knowledge. However, as observed 
in Chapter 3, only 22% of the key elements of aRMMs may potentially be measurable in EHDs because 
these data sources do not capture all data necessary data for the evaluation. Furthermore, some EHDs 
may not be appropriate since the number of subjects using the particular drug with aRMMs available 
in EHDs can be limited or grow slowly. This is particularly of concern for drugs that recently entered 
the market or are used for treating serious disease in hospital and therefore not recorded in primary 
care databases, which is likely for drug with aRMMs. These issues indicate that there is a clear need for 
approaches that go beyond the use of EHDs to allow evaluation of effectiveness of aRMMs. These can 
include surveys or qualitative assessments which are often used to evaluate whether aRMMs reached 
the target group and the achieved level of knowledge among this target group.36, 37 The use of surveys 
is the main method of data collection among the studies evaluating effectiveness of risk minimisation 
measures that are included in the EU PAS Registry.45 Some limitations of this approach are that data 
collection can be time consuming and delay the evaluation whereas insufficient aRMMs need to be 
identified in an early stage to enable prompt improvement. Furthermore, response rates to surveys 
are often low and the responses may not reflect the actual knowledge, awareness or use of aRMMs 
among the target group which may prevent drawing valid conclusions from the assessment of aRMM’s 
effectiveness.46, 47
 
Other possible data sources that may be used to evaluate the effectiveness of aRMMs in clinical 
practice are the spontaneous reporting systems as these include case reports of patients that developed 
adverse events. These systems lack however a suitable overall denominator (i.e., total exposure to the 
drug, number of patients exposed or number of drug doses administered), which inevitably hampers 
interpretation of results. Furthermore, it is known that reporting of ADRs can be influenced in different 
ways by external events.48 It may be that aRMMs increase the intention to report events to these 
systems. The use of spontaneous reports in the evaluation of aRMM may therefore not be suitable.
Analytical methods
To analyse impact of regulatory interventions issued post-marketing, data from the pre-intervention 
period can be compared against the post-intervention period, a time series analysis or other regression 
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analysis can be performed e.g. linear regression, Poisson regression, joint point regression.36 A 
requirement of such analysis is the use of longitudinal data on prescription or patient level which often 
are obtained from existing EHDs to study drug prescription patterns or safety outcomes. Briesacher et 
al. identified three analytic methods with strong internal validity suitable for evaluations of regulatory 
actions which include the interrupted time series, the regression discontinuity design, and the statistical 
method, the extended Cox model.38 While the interrupted time series analysis is frequently applied to 
evaluate the impact of DHPCs, FDA risk communications and some other regulatory interventions,36, 
38, 39 experiences with the last two approaches have not yet been available in the literature and 
experience is needed to assess the actual feasibility of these methods. All three approaches described 
by Briesacher et al. have the ability to control for other factors and can incorporate intention-to-treat 
analyses.38 Interrupted time series design is preferred to study the impact of policy changes where it is 
difficult to employ a comparison group, and account for potential biases in the effect of the intervention 
including secular trend, seasonal effects, random fluctuations and autocorrelations.49 However, for 
aRMMs required since initial marketing authorisation an interrupted time series analysis or a pre-post 
intervention analysis cannot be applied and effectiveness may be evaluated by comparing the observed 
against expected outcomes. Expected outcomes can be pre-defined reference values or benchmarks 
obtained from literature, historical data, frequencies in general population, other geographical location 
or centres where the intervention was not implemented, another drug or other target population (e.g. 
adults when the intervention is aimed at children).37 A study on use of cisapride with contraindicated 
drugs is an example where reference values were obtained from the study population.50 The observed 
co-prescribing of cisapride with potentially interacting drugs was compared to the chance of having 
a co-prescription based on background prevalence of cisapride and potentially interacting drugs (the 
expected). When it may not be feasible to involve comparators or assess changes after a certain point 
in time, the evaluation of aRMMs could be restricted to descriptive analysis using a cohort covering a 
period of time or a cross-sectional analysis. Such descriptive analysis are used in the isotretinoin study 
in Chapter 7 of this thesis in which the annual incidence of isotretinoin exposed pregnancies in the 
Netherlands between 1999 – 2007 was studied without having a comparison group. Changes after the 
implemented intervention could also not be analysed because the PPP was implemented during the 
complete study period. Information collected with surveys usually provides cross-sectional information 
on knowledge or behaviour at one point in time unless the survey is repeated over time among the 
same participants.
Selecting the most appropriate settings
In summary, several outcome measures, data sources and analytical methods can be used to study 
the effectiveness of risk minimisation measures which all have specific strengths and weaknesses and 
the most appropriate settings may depend on the type of drug, aRMM or event to be minimised. The 
challenge is developing and systematically utilizing robust methodologies for evaluation of aRMMs 
effectiveness. First, specific and clear pre-defined objectives of aRMMs are necessary to determine 
the most appropriate process and outcome indicators. Second, preference is given to behavioural 
indicators and safety outcomes that can be studied using existing EHDs. EHDs are considered valid 
and efficient resources that can provide timely feedback on the effectiveness of aRMMs. However, 
since EHDs do not capture all data necessary to study the different process and outcome indicators, 
approaches beyond the use of EHDs should be used and it is a challenge to do this in an efficient 
and proper way. The interrupted time series analysis and pre-post intervention analysis are frequently 
used statistical methods for evaluation of regulatory intervention implemented during post-marketing 
such as DHPCs. Since aRMMs are often required from initial marketing authorisation these analytical 
methods cannot always be applied and the possibilities of other comparators in the evaluation of 
aRMMs need to be explored. 
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FuTure PersPeCTives
The past 10 years after starting RMPs have led to a better understanding of the possibilities and 
challenges of aRMM implementation and the evaluation of effectiveness in clinical practice. Very clearly 
this field is still developing since there is still limited knowledge on effective aRMMs in clinical practice; 
what can be achieved with aRMMs and the best way of achieving this. Furthermore, besides measuring 
the effectiveness (benefits) of aRMMs in clinical practice, the actual burden and the additional load of 
aRMMs, should be explored. This burden may impact access to medicines, daily activities of patients 
or HCPs and human and financial resources. 
There is a need for transparency about effective aRMMs and validated tools as well as on evaluations 
of effectiveness of aRMMs. Besides sharing results of studies in scientific literature, study protocols and 
final study reports can be obtained from the publicly available EU PAS register hosted by ENCePP.45 
This E-registry includes all non-interventional PASS relating to medicines which will become more 
populated and can be used as learning opportunities. 
Role for the regulator
Without having standard requirements available, regulators should carefully review the need for 
aRMMs. This is a case-by-case assessment and the extra measures should be adequately justified, 
proportionate to the risk and feasible in clinical practice. Previously, (based on the Guideline on risk 
management systems of 2005), the MAH had to justify why aRMMs were not necessary, suggesting that 
aRMMs were needed by default.51 This approach changed with the EU pharmacovigilance legislation in 
force since July 2012 and since that time it should be justified why routine risk minimisation measures 
are not considered sufficient and why aRMMs are necessary.52 This approach as well as the increased 
knowledge on aRMMs in general may have resulted in different proposals for aRMMs as compared 
to the situation up to 2010. The legal obligation to measure the effectiveness of aRMMs might have 
contributed to this.
In one of our studies we observed that the objectives of aRMMs were not always clear. This requires 
attention of regulators because specific and clear objectives of the aRMMs are an essential starting 
point in the design of the required PASS that evaluate the effectiveness of aRMM. Next, regulators 
should carefully consider what knowledge is needed to decide on the successfulness of the measures 
and critically review how and when this can be obtained in a feasible, efficient and valid way leading 
to useful results. Finally, regulators should engage with HCPs and patients from clinical practice to 
explore what would be effective aRMMs, how to define success and to decide on when and how to 
continue or modify aRMMs in clinical practice. 
Effective aRMMs
For the drugs we evaluated in Chapter 3, educational materials were the main strategy which can 
comprise many different educational tools such as a brochure, checklist, website or a patient alert 
card. However, knowledge on the effectiveness of aRMMs in clinical practice, or more specifically, 
educational tools in addition to the SmPC, is still lacking. More research is necessary to evaluate the 
effectiveness of specific risk minimisation tools. Furthermore, the development of the most appropriate 
aRMM tools and strategies requires involvement of stakeholders from clinical practice and insights 
in local conditions. Industry and regulators should engage with patients and HCPs (e.g. physicians, 
pharmacists, etc) and explore if, when and how (not) HCPs and patients let aRMMs be integrated in 
clinical practice. Knowledge from other disciplines such as behavioural and communication science 
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could also contribute to this. It would also be relevant to identify factors associated with sustained 
responses to communication and to investigate how aRMMs can affect communication between 
HCPs and patient. There might be substantial variation in preferences of the need for, the format and 
distribution of the materials between different prescribers, pharmacists and patients populations. 
How to define success
Knowledge about the effectiveness of aRMMs is necessary to determine the success of the additional 
measures and to decide on the need for continuation and potential adjustments of the aRMMs. 
As discussed in the previous sections of this chapter, there are various possibilities to evaluate the 
effectiveness of aRMMs in which different process and outcome indicators, data sources and analytical 
methods can considered which all have their strengths and limitations. Because methodological 
challenges exist, it may still be open for discussion what type of study is necessary to define the 
successfulness of aRMMs. Other issues are: 
Acceptable levels for successful aRMM are often not defined and it is not always clear when an aRMMs 
could be labelled as successful. An option is to consider aRMM successful only when the risk of a 
particular safety outcome is completely eliminated meaning that the event (e.g. isotretinoin exposed 
pregnancy) does not occur in the patient population treated. It may however not be realistic to use such 
a ‘zero tolerance’ strategy to estimate aRMM successfulness. Even with full compliance to the aRMMs 
the event may develop in patients using that drug independently and moreover, noncompliance 
with the aRMM could be a carefully made decision of the HCP and patient. It should also be noted 
that significant changes in knowledge, behaviour or safety outcomes after aRMM implementation 
or differences between patient populations do not automatically indicate a successful aRMM. It still 
needs to be assessed whether the level of compliance to aRMMs or occurrence of the safety outcome 
is acceptable. For example, as observed in Chapter 5, the significant reduction of moderate dose 
citalopram use (>20 mg – ≤ 40 mg) daily among patients aged 65 or older may not be large enough 
because still a considerable proportion of the elderly patient population is using these daily doses 
(since longer time) when the change in SPC arrives. With regard to the assessment of acceptable levels 
of clinical knowledge among HCPs, it may be better to achieve that 75% of the prescribers respond 
correct to 8 out of 10 survey questions instead of reviewing the percentage of prescribers that have 
all survey questions correct. Regulators and industry should explore acceptable and feasible levels for 
success by involving HCPs and patients working with aRMMs in clinical practice. The most optimal and 
acceptable levels of compliance to aRMMs (i.e. process indicators) and of its final outcome measures 
(occurrence of events) in clinical practice may vary across different drugs. 
It has become more and more clear that regulatory actions cannot only have intended effects, but 
may also have unintended consequences. The need for laboratory monitoring may result in decreased 
drug use and recommendations that are targeted at specific patient population may also diffuse in 
other groups.36 Following the warning of the increased risk of suicide associated with antidepressant 
use in children and adolescents in 2004, a decrease in use of this antidepressant was also observed 
in adults.53-56 Furthermore, long-term effects of this warning suggested that the risk communication 
was followed by a decrease in antidepressant use but with an increase in suicides.56 The warning may 
has unintentionally discouraged depressed patients from seeking treatment, which may even be more 
harmful.57 For these reasons understanding the possible unintended effects of risk communication and 
risk minimisation measures is important and should be considered in decisions to be made. 
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What and when to evaluate 
The most appropriate process and outcome indicators or combinations to define successfulness 
of aRMMs should facilitate justified decisions on the continuation or modification of the aRMMs. 
However, the most appropriate outcomes to estimate effectiveness may not always be the most 
feasible outcome to study. Providing early feedback on the occurrence of rare events or events that 
develop after long-term drug exposure can be challenging since drug use shortly after drug marketing 
is limited. When feedback on the final safety outcome is not feasible, it may be easier to provide 
(preliminary) results of the process indicators only or provide results on the safety outcome in a later 
stage. There is need to explore the most appropriate point in time after aRMM implementation that 
provides early feedback as well as adequate data for evaluation. This can be done based on previous 
experiences in evaluation of effectiveness, driven by minimum patient exposure or based on providing 
sample size calculations necessary to indicate certain effects. It may be helpful to develop standard 
time schedules and frequencies to provide follow-up on the effectiveness of aRMMs to prevent 
evaluations leading to insufficient results. 
Causality and extrapolation
In addition to the difficulties with data collection of appropriate outcome measures and definitions of 
successful aRMMs, other issues that could complicate the interpretation of the study results concern the 
uncertainty in the causality between the process indicators, final safety outcomes and the implemented 
aRMM. This uncertainty is difficult to overcome with the current way of aRMM implementation and the 
study designs available to study effectiveness of interventions in routine daily care. Sometimes aRMMs 
have been implemented for a complete drug class or several generic compounds (e.g. the new oral 
anticoagulants). For these drugs it may be difficult to assess whether it is the aRMM of the single drug 
under review that is contributing to the study results or it may be the combination of aRMMs of drugs 
from the same class.
The need for aRMM is often decided on European level while the implementation of the aRMM takes 
place locally to take into account national requirements, e.g. health systems, language and health 
believes. This national phase allows better-fitting programmes. In current regulatory practice the 
effectiveness of aRMMs is often measured in only some of the EU member states, due to e.g. available 
electronic healthcare databases and sales per EU member state. Variation in clinical practice and 
implementation of aRMMs between EU member states limit extrapolation of the results on effectiveness 
of risk minimisation measures to all EU member states. However, the heterogeneity between member 
states also provide opportunities to study differences in aRMM implementation and the effect of this. 
Does this finally lead to aRMM (dis)continuation and modification
When to stop and how long to continue with aRMMs is an area that deserves attention and requires 
involvement of different stakeholders. The results of the evaluations of the effectiveness of aRMM 
could lead to various conclusions on continuation or modification of the aRMMs. When results show 
sufficient effectiveness, the aRMM may be continued, or even discontinued when the measure has 
become standard care. When the effectiveness of aRMMs is considered limited, the aRMM may not 
be continued or possibilities to improve the effectiveness may be identified. Reasons for failure and 
improvement of aRMMs can sometimes be identified using the process indicators measured within the 
evaluation or with root cause analysis by involving stakeholders from clinical practice. 
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COnClusiOn
Evaluating effectiveness of aRMM is recognised to be a relatively young but evolving area with no 
universally agreed standards and approaches. Knowledge and experience on how the effectiveness 
can be evaluated and the challenges involved have been gained. Specific and clear objectives of 
aRMMs are necessary and the most appropriate and feasible outcomes to estimate intended 
and unintended effects of aRMMs in clinical practice should be determined. Since knowledge on 
effective aRMMs is still very limited there is a need to continuously share experiences on effective risk 
minimisation and methodologies to evaluate the effectiveness of the measures. Furthermore, more 
research is necessary to better understand what can be achieved with aRMMs in clinical practice 
and when aRMMs can be considered successful. This is needed for an adequate assessment of the 
need for aRMMs and selection of the most appropriate tools as well as to facilitate the decision on 
the (dis)continuation or modification of aRMMs implemented in clinical practice. Industry, regulators 
and stakeholders from clinical practice should engage and advantage should be taken from relevant 
methods in drug utilisation research, pharmacoepidemiology and other disciplines such as behavioural 
and communication sciences. 
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Het College ter Beoordeling van Geneesmiddelen (CBG) beoordeelt en bewaakt de werkzaamheid, 
risico’s en kwaliteit van geneesmiddelen voor mens en dier. Het CBG neemt een positie in 
binnen de Europese geneesmiddelen registratieautoriteiten. Wanneer op basis van een klinisch 
onderzoeksprogramma de werkzaamheid-schadelijkheid balans van een geneesmiddel positief is 
bevonden, kan er een handelsvergunning verstrekt worden en mag het geneesmiddel toetreden 
tot de markt. Het is echter van belang om, nadat een geneesmiddel op de markt beschikbaar is, 
de kennis over de werkzaamheid en schadelijkheid van een geneesmiddel verder uit te breiden 
met ervaringen uit de klinische praktijk. Daarom worden de werkzaamheid-schadelijkheid balans 
en vastgestelde voorwaarden voor geneesmiddelgebruik continue geëvalueerd en zo nodig 
aangepast. Farmacovigilantie speelt hierin een belangrijke rol. De Wereldgezondheidsorganisatie 
(WHO) definieert farmacovigilantie als de wetenschap en activiteiten gerelateerd tot het opsporen, 
beoordelen, begrijpen en voorkomen van bijwerkingen of andere problemen die verbanden houden 
met gebruik van geneesmiddelen.
De afgelopen 10 jaar heeft farmacovigilantie zich ontwikkeld tot een aandachtsgebied waarin het 
minimaliseren van risico’s gerelateerd aan een geneesmiddel een prominentere rol heeft gekregen. 
De grote veranderingen startten met de introductie van het risico management plan (RMP) in 2005. 
Het RMP van een geneesmiddel beschrijft de geplande farmacovigilantie en risico minimalisatie 
maatregelen die zijn overeengekomen tussen de vergunninghouder van een geneesmiddel 
(farmaceutische industrie) en de Europese registratieautoriteiten. 
Risico minimalisatie maatregelen (RMM) zijn interventies die de balans werkzaamheid-schadelijk-
heid van een geneesmiddel optimaliseren tijdens geneesmiddelgebruik in de dagelijkse praktijk. 
Deze maatregelen hebben als doel nadelige effecten (bijwerkingen, medicatie fouten) van een 
geneesmiddel te voorkomen, de kans op deze effecten te verkleinen, of de ernst van een nadelig 
effect te verlagen, mocht dit optreden. Routine RMM worden vastgesteld voor alle geneesmiddelen 
en omvatten de Samenvatting van Product Kenmerken (SmPC), de patiënten bijsluiter (PIL), het uiterlijk 
van de verpakking, de verpakkingsgrootte en de voorschrijfstatus van het geneesmiddel. Hoewel 
routine RMM voldoende zijn voor de meeste geneesmiddelen, kunnen extra maatregelen soms nodig 
zijn om de veiligheidsissues van een geneesmiddel te beperken. Deze worden aanvullende risico 
minimalisatie maatregelen (aRMM) genoemd en worden vastgesteld in de handelsvergunning als 
voorwaarde voor gebruik van een geneesmiddel in de praktijk. Voorbeelden van deze aanvullende 
maatregelen zijn voorlichtingsmaterialen voor artsen, apothekers of patiënten, of een zwangerschap-
spreventie programma (ZPP).
Voor elk geneesmiddel met een nieuw actief bestanddeel dat een handelsvergunning in de Europese 
Unie (EU) heeft verkregen na 2005 is een RMP vastgesteld. Per geneesmiddel is er beoordeeld of 
aRMM nodig zijn en welke mogelijkheden voor aRMM er zijn. Vanaf 2005 doen de vergunninghouders 
en de registratieautoriteiten dus ervaring op in het veld van risico minimalisatie maatregelen en 
de aanvullende maatregelen. Met ingang van de Europese wetgeving in 2012 is het meten van de 
effectiviteit van de risico minimalisatie maatregelen in klinische praktijk verplicht. Echter, de kennis 
over hoe de effectiviteit van aRMM in dagelijkse praktijk gemeten kan worden is nog erg beperkt.
Dit proefschrift geeft inzicht in de kwaliteit en kwantiteit van de aanvullende risico minimalisatie 
maatregelen die van kracht zijn in de EU en hoe de effectiviteit van deze maatregelen in de dagelijkse 
praktijk geëvalueerd kan worden. Er wordt dieper in gegaan op de risico minimalisatie maatregelen 
van teratogene geneesmiddelen (in het bijzonder het ZPP) en blootstelling aan geneesmiddelen met 
teratogene eigenschappen tijdens de zwangerschap.
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Aanvullende risico minimalisatie maatregelen (aRMM) in de EU
Hoofdstuk 2 geeft een overzicht van de aRMM vastgesteld in de EU tot 1 januari 2010. Van de 
geneesmiddelen geregistreerd voordat het RMP van kracht was had 5% aRMM en van de 
geneesmiddelen geregistreerd na de introductie van het RMP (2005) had 15% aRMM. Dit betroffen 
voornamelijk oncologische geneesmiddelen en geneesmiddelen die het afweersysteem beïnvloeden. 
Het meest gevraagde type aRMM was voorlichtingsmateriaal voor artsen, apothekers of andere 
zorgverleners. In 50% van de gevallen werd er ook voorlichtingsmateriaal voor de patiënt gevraagd. 
Een gecontroleerd distributie systeem of een ZPP was minder vaak gevraagd, respectievelijk voor 17% 
en 9% van de geneesmiddelen met aRMM. Er bleek weinig consistentie te zijn in de veiligheidsissues 
waar de aRMM voor zijn vastgesteld. Zowel het groeiend aantal geneesmiddelen met aRMM als de 
hoop dat deze maatregelen ook daadwerkelijk tot minder bijwerkingen of andere veiligheidsissues 
zouden leiden, benadrukt de noodzaak tot het evalueren van de effectiviteit van deze maatregelen. 
Het gebruik van bestaande databanken van elektronische patiëntendossiers om de 
effectiviteit van aRMM te evalueren
aRMM hebben als doel de schadelijke effecten van een geneesmiddel te beperken, maar deze 
extra maatregelen kunnen de klinische praktijk ook belasten. Ineffectieve aRMM dienen daarom in 
een zo vroeg stadium geïdentificeerd en aangepast te worden. Dit geeft aan dat er behoefte is aan 
een efficiënte methode om de effectiviteit van de aRMM te beoordelen. Bestaande databanken 
van elektronische patiëntendossiers, zoals geanonimiseerde patiëntendossiers van de huisarts of 
apotheek uitgifte gegevens van receptgeneesmiddelen die routinematig worden verzameld, bieden 
mogelijkheden om relatief snel associaties tussen een geneesmiddel en een bijwerking te bestuderen. 
Ook kunnen op populatieniveau patronen in geneesmiddelgebruik in klinische praktijk bestudeerd 
worden. In Hoofdstuk 3 is onderzocht of deze databanken ook geschikt kunnen zijn om de effectiviteit 
van aRMM te evalueren. Gezien de informatie beschikbaar in bestaande databanken van elektronische 
patiëntendossiers, schatten wij dat 22% van de hoofdelementen van de aRMM meetbaar zijn in 
deze gegevensbronnen. Voornamelijk elementen gerelateerd aan het voorschrijfgedrag van artsen 
(zoals dosering, duur, contra-indicatie) en intensiever monitoren van de patiënt (zoals bloedwaarde 
testen) zijn meetbaar bevonden. Het blijft een uitdaging om de effectiviteit van de andere aRMM 
op een efficiënte en objectieve manier te evalueren waarbij andere gegevens dan die beschikbaar 
in bestaande databanken van elektronische patiëntendossiers gebruikt moeten worden. Goed 
gedefinieerde aRMM hoofdelementen met heldere doelen die leiden tot eenduidige acties van de 
doelgroepen (zorgverleners of patiënten) zullen door vergunninghouders en registratieautoriteiten 
moeten worden gedefinieerd om de evaluatie van aRMM te faciliteren. 
De verschillende stappen binnen een evaluatie van de effectiviteit van aRMM in de dagelijkse klinische 
praktijk zijn beschreven in Hoofdstuk 4. Deze stappen omvatten 1) beoordeling van de distributie 
en gebruik van de risico minimalisatie tool, 2) meten van de verkregen kennis onder zorgverleners 
of patiënten, 3) evalueren van het gewenste gedrag van zorgverleners of patiënten (bijvoorbeeld 
het voorschrijfgedrag van de arts of het intensief monitoren van de patiënt). Deze stappen evalueren 
de implementatie en gebruik van de aRMM in de dagelijkse praktijk en worden ook wel ‘proces 
indicatoren’ genoemd. Naast de proces indicatoren kan 4) de actuele risico verlaging van een 
veiligheidsissue gemeten worden, dat ook wel de ‘uitkomst indicator’ van de aRMM wordt genoemd 
(zie Figuur 1). Mogelijke uitdagingen in het meten van de effectiviteit van aRMM staan ook beschreven 
in dit hoofdstuk en omvatten geschikte dataverzameling, beperkte mogelijkheid tot vergelijken 
van groepen, onzekerheid over de beste uitkomstmaat en de interpretatie, en gebrek aan vooraf 
vastgestelde doelen. Gezien deze uitdagingen kan de best uitvoerbare methode om de effectiviteit 
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van aRMM te evalueren verschillen per geneesmiddel of soort aRMM.
In Hoofdstuk 5 is de effectiviteit van de risico minimalisatie maatregelen van een specifiek 
geneesmiddel bestudeerd. In oktober 2011 werd bekend dat het gebruik van hoge doseringen 
citalopram (een antidepressiva) kan leiden tot verlenging van het QT interval, wat zich kan uiten in 
(fatale) hartritmestoornissen. De aanbevolen maximale dagelijkse dosering werd toen verlaagd 
van 60 mg naar 40 mg en in ouderen (≥ 65 jaar) van 40 mg naar 20 mg. Deze risico informatie is 
gecommuniceerd aan artsen via een brief, een zogenaamde DHPC (Direct Healthcare Professional 
Communication). Het gebruik van citalopram tussen 1996 en 2013 en het mogelijke effect van de 
DHPC en aanbevolen doseringsverlaging zijn geanalyseerd. Hiervoor is gebruik gemaakt van de 
Nederlandse Interdisciplinary Processing of Clinical Information (IPCI) databank en het Britse The Health 
Improvement Network (THIN); beide longitudinale databanken van elektronische patiëntendossiers 
van huisartsen. We zagen dat zowel in Nederland als in het Verenigd Koninkrijk dat de lage dosering 
(≤ 20 mg dagelijks) citalopram het meest werd voorgeschreven en het gebruik van hoge dosering (> 
40 mg dagelijks) citalopram erg beperkt was over de gehele studieperiode. In beide landen daalde 
het gebruik van gematigde dosering (> 20 mg tot ≤ 40 mg dagelijks) citalopram significant in ouderen, 
nadat in 2011 de maximale aanbevolen dosering werd aangepast. Het gebruik van de hoge dosering 
daalde alleen significant in patiënten jonger dan 65 jaar. In beide landen waren er na oktober 2011 
significant minder ouderen gestart met citalopram gebruik, dat wordt gezien als een extra, onbedoeld 
effect van de risico minimalisatie maatregelen.
Risico minimalisatie maatregelen en blootstelling aan geneesmiddelen tijdens de 
zwangerschap
Blootstelling aan geneesmiddelen met teratogene eigenschappen tijdens zwangerschap kan 
schadelijke effecten veroorzaken, zoals een spontane abortus of aangeboren afwijkingen bij het kind. 
Het zwangerschapspreventie programma (ZPP) is een aRMM dat ingezet kan worden om blootstelling 
aan een bepaald geneesmiddel tijdens de zwangerschap te voorkomen. In Hoofdstuk 6 zijn de 
ZPP’s van de zeven geneesmiddelen met elkaar vergeleken. De ZPP’s van thalidomide, lenalidomide 
en de vitamine A derivaten (isotretinoine, alitretinoine, acitretine) zijn opgelegd gebaseerd op 
een vastgesteld of verwacht hoog teratogeen risico in mensen. De achterliggende reden voor het 
ZPP van de endothelin receptor antagonisten (bosentan en ambrisentan) is minder overtuigend. 
Overeenkomsten tussen de zeven ZPP’s omvatten de zwangerschapstesten voorafgaand aan en 
tijdens het gebruik van het geneesmiddel, gebruik van anticonceptie voorafgaand, tijdens en na de 
behandeling, en patiëntenvoorlichting. Verschillen tussen de ZPP’s omvatten het voorlichtingsmateri-
aal voor verschillende soorten zorgverleners, beperkte geneesmiddel uitgifte (uitgeven binnen zeven 
dagen na voorschrijven, maximale duur van voorschrift van 30 dagen), de periode waarna er gestopt 
mag worden met anticonceptie en het uitvoeren van zwangerschapstesten. Naast geneesmiddel 
specifieke eigenschappen dienen voorgaande ervaringen en toepasbaarheid in klinische praktijk te 
worden overwogen tijdens de ontwikkeling van het ZPP. Het is belangrijk om voorschrijvers, apothekers 
en patiënten hierin te betrekken. 
In Hoofdstuk 7 is de effectiviteit van het isotretinoine ZPP geëvalueerd door isotretinoine blootstelling 
in Nederlandse zwangere vrouwen tussen 1999 en 2007 te bestuderen. Met een link tussen de PHARMO 
database (bevat apotheek uitgifte gegevens van receptgeneesmiddelen van drie miljoen mensen 
in Nederland) en het geboorteregister (PRN) zijn ruim 200,000 zwangerschappen geïdentificeerd. 
We zagen dat 45 zwangerschappen, 2,2 (95% betrouwbaarheidsinterval (BI) 1,6 – 2,9) per 10.000 
zwangerschappen, zijn blootgesteld aan isotretinoine tijdens de zwangerschap. Zestig procent van 
deze zwangerschappen was al zwanger op het moment dat de isotretinoine behandeling van start 
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Figuur 1: Het risico minimalisatie proces in vier stappen
ging, wat aangeeft dat er mogelijk is afgeweken van het ZPP. Afwijkende zwangerschapsuitkomsten 
zoals een doodgeboren kind of aangeboren afwijkingen bij een kind waren gerapporteerd voor 9,4% 
(95% BI 1,3 – 17,6) van de isotretinoine blootstelde zwangerschappen. De odds ratio voor afwijkende 
zwangerschapsuitkomsten na isotretinoine bloostelling in de 30 dagen voorafgaand aan conceptie en 
tijdens de zwangerschap was 2,3 (95% BI 0,9 – 5,7). Dit betekent dat er 2,3 x zoveel kans is op een 
afwijkende zwangerschapsuitkomst, als er tijdens de zwangerschap isotretinoine werd gebruikt. Deze 
uitkomst moet voorzichtig geïnterpreteerd worden gezien de lage getallen in de analyse. Op basis 
van deze studie hebben we geconcludeerd dat hoewel een ZPP is geïmplementeerd sinds 1988, er 
nog steeds isotretinoine blootgestelde zwangerschappen voorkomen in Nederland. Ook afwijkende 
zwangerschapsuitkomsten mogelijk gerelateerd aan de blootstelling komen nog steeds voor. Deze 
bevindingen dragen bij aan het bewijs dat er geen volledige trouw is met het isotretinoine ZPP in 
diverse Westerse landen. Gegeven het beperkte succes van iPLEDGE, het zelfs striktere ZPP in de 
Verenigde Staten, is het de vraag welke maatregelen nodig zijn om de compliantie te vergroten.
Door gebruik te maken van hetzelfde cohort zwangerschappen als in Hoofdstuk 7, is in Hoofdstuk 
8 de uitgifte van geneesmiddelen met potentiële teratogene eigenschappen aan zwangere vrouwen 
bestudeerd. De resultaten laten zien dat in 5% van de Nederlandse zwangerschappen de vrouw een 
geneesmiddel met teratogene potentie ontvangt via de apotheek. In 0,7% van alle zwangerschappen 
betreft dit een categorie X geneesmiddel; een geneesmiddel dat niet gebruikt dient te worden tijdens 
de zwangerschap, omdat de mogelijke risico’s duidelijke opwegen tegen de mogelijke voordelen van 
het geneesmiddel. Geneesmiddelen met potentiële teratogene eigenschappen dienen alleen tijdens 
de zwangerschap gebruikt te worden na een weloverwogen besluit waarin de mogelijke nadelige en 
voordelige effecten afgewogen zijn. In de toekomst kan het percentage zwangere vrouwen dat een 
geneesmiddel met potentiële teratogene effecten ontvangt wellicht verlaagd worden als oorzaken en 
redenen van gebruik van deze geneesmiddelen in kaart worden gebracht.
Meten van effectiviteit van aRMM in de dagelijkse praktijk: wat is essentieel?
aRMM hebben als doel de kans op een nadelig effect van een geneesmiddel te verkleinen of de ernst 
van de dit nadelige effect te verlagen. Dit proefschrift bediscussieerd de meest essentiële onderdelen 
die nodig zijn om de effectiviteit van aRMM in de dagelijkse klinische praktijk te evalueren. Om te 
beginnen moet het duidelijk zijn wat het doel van de aRMM is om vervolgens de meest geschikte 
uitkomstmaat, gegevensbronnen en analytische methoden vast te kunnen stellen. Er zijn verschillende 
stappen in het risico minimalisatie proces waar de effecten gemeten kunnen worden (zie Figuur 1). De 
implementatie van de aRMM in de klinische praktijk kan uitgedrukt worden in proces indicatoren: is 
het voorlichtingsmateriaal ontvangen, gelezen, begrepen, is er een verandering in kennis en leidt dit 
vervolgens tot het gewenste gedrag van de voorschrijver of patiënt. Dit zou uiteindelijk moeten leiden 
tot een verminderde kans op een bijwerking (de uitkomst indicator).
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De keuze van deze verschillende uitkomstmaten (kennis niveau, voorschrijfgedrag, aantal voorgevallen 
bijwerkingen) om effectiviteit van de aRMM uit te drukken hangt af van het vooraf vastgestelde doel 
van de aRMM en de mogelijkheden tot het meten van die bepaalde uitkomstmaat. Vervolgens zijn 
er diverse gegevensbronnen die gebruikt kunnen worden waarin grofweg onderscheid gemaakt 
kan worden tussen het gebruik van bestaande databanken van elektronische patiëntendossiers (o.a. 
geanonimiseerde patiëntendossiers van huisartsen, apotheek uitgifte gegevens) of nieuwe data 
verzameling door middel van een vragenlijst of interviews. De voorkeur gaat uit naar het gebruik 
van bestaande databanken van elektronische patiëntendossiers gezien deze valide data bevat om 
gedragsindicatoren en uitkomst indicatoren te bestuderen. Bovendien is het gebruik van deze 
gegevensbronnen efficiënt, zodat er tijdig terugkoppeling betreffende de effectiviteit van de aRMM 
gegeven kan worden. Echter, niet alle benodigde gegevens om diverse proces en uitkomst indicatoren 
te bestuderen zijn altijd aanwezig in deze bestaande databanken. Het blijft van belang om gegevens 
verzameld buiten de beschikbare bestaande databanken van elektronische patiëntendossiers te 
gebruiken om effectiviteit van aRMM te meten hoewel het een uitdaging is dit op een efficiënte en 
goede manier te doen. De meest gebruikte analytische methoden om de effecten van interventies 
van registratieautoriteiten geïmplementeerd enige periode, nadat een geneesmiddel op de markt is 
gekomen te evalueren zijn de zogenoemde ‘interrupted time series analysis’ en de voor-na interventie 
analyse. Gezien aRMM vaak verplicht zijn vanaf het eerste moment dat desbetreffende geneesmiddel 
op de markt is, kunnen deze methoden niet altijd worden toegepast en zullen er andere mogelijke 
vergelijkingen gemaakt moeten worden om veranderingen of verschillen aan te kunnen tonen.
Toekomstperspectieven
Het evalueren van de effectiviteit van aRMM is een relatief nieuw onderzoeksveld waarvoor geen 
universeel overeengekomen standaarden en methoden beschikbaar zijn. De afgelopen jaren zijn de 
kennis en ervaringen over hoe de effectiviteit van aRMM geëvalueerd kan worden en de uitdagingen 
die hierin meespelen erg gegroeid. Het is van groot belang dat er aRMM met specifieke en duidelijke 
doelen worden vastgesteld en daarna dienen de meest geschikte en uitvoerbare uitkomstmaten, die 
de gewenste en ongewenste effecten van de aRMM in klinische praktijk weergeven, bestudeerd te 
worden. De kennis over effectieve aRMM is nog steeds beperkt en het is daarom van belang kennis 
en ervaringen over effectieve risico minimalisatie en de methodologie om dit te meten met elkaar te 
blijven delen. Daarnaast is er onderzoek nodig om te begrijpen wat er bereikt kan worden met aRMM 
in de praktijk en wanneer aRMM succesvol geacht zouden kunnen worden. Dit is belangrijk tijdens 
het beoordelen of aRMM nodig zijn, welk type aRMM er ingezet moet worden en het ondersteunen 
van de beslissing of aRMM gestopt of aangepast moet worden. De vergunninghouders en registra-
tieautoriteiten moeten samenwerken met belanghebbenden uit de klinische praktijk (voorschrijvers, 
apothekers, patiënten) en het is aanbevolen gebruik te maken van relevante methoden bekend uit het 
‘drug utilisation’ onderzoek, de farmacoepidemiologie en andere disciplines zoals gedrags- en com-
municatiewetenschappen.
9

aPPEndicEs
a
176 appendices
177dankwoord
danKWOOrd
De afgelopen vijf jaar heb ik gewerkt aan mijn promotieonderzoek en nu is het proefschrift eindelijk 
klaar! Er zijn een heleboel mensen die hebben bijgedragen aan het tot stand komen van dit proefschrift 
en die wil ik nu bedanken. 
Ten eerste mijn promotor prof.dr. Miriam Sturkenboom. Beste Miriam, ik wil je bedanken voor de 
mogelijkheid die jij mij hebt gegeven om dit onderzoek uit te voeren, de vrijheid die ik hierin kreeg en 
te mogen putten uit de enorme kennis die je hebt. Je wist altijd deskundig commentaar te leveren en 
richting aan de ideeën te geven. Na onze overleggen ging ik altijd vol vertrouwen aan de slag.
Mijn copromotoren dr. Sabine Straus en dr. Gianluca Trifìro. Met jullie als experts binnen de pharma-
coepidemiologie en farmacovigilantie kon ik mij geen beter koppel wensen. Beste Sabine, ik heb 
grote bewondering voor jou en je aanstekelijke enthousiasme binnen ons onderzoek. Je had altijd tijd 
en zin om mee te denken over welke vraag dan ook. Ook in de regulatoire wereld nam je me overal 
mee naar toe wat ik heel erg waardeer. Bedankt voor deze enorme betrokkenheid, je altijd snelle 
kritische blik en de mental support. Dear Gianluca, many thanks for all your help and sharing all your 
epi knowledge with me and off course the fun. Although you were not always physically around, I knew 
I could count on you! 
Dank aan prof.dr. Bruno Stricker, prof.dr. Bert Leufkens en prof.dr. Régine Steegers – Theunissen voor 
het plaats nemen in de kleine commissie. Beste Bruno, ik heb genoten en veel geleerd van onze 
samenwerking. Bedankt voor je heldere kijk op het onderzoek en het vertrouwen wat je geeft. Beste 
Bert, bedankt dat ik dit onderzoek vanuit het CBG heb mogen doen. Ik hoop dat we dit kunnen 
voortzetten bij het CBG. Dank aan prof.dr. Lolkje de Jong, dr. Patricia van den Bemt en dr. Peter Mol 
voor het plaats nemen in de grote commissie. Beste Lolkje, bedankt voor de samenwerking aan het 
PPP stuk.
Mijn dank aan alle coauteurs. Dear Swapu, it was a pleasure working with you. Thanks for sharing your 
knowledge and the enthusiastic discussions. Ik heb met veel plezier samengewerkt met het PHARMO 
Instituut en voelde me altijd welkom als ik toch nog een analyse moest doen. Leanne, bedankt voor 
al je enthousiasme tijdens de PHARMO-PRN studies. Zonder jou was ik nooit wegwijs geworden in de 
SAS programmeer wereld wat ik vervolgens nog veel heb kunnen toepassen. Rikje, bedankt voor je 
hulp en goed input. Zonder jou ideeën en kennis waren de studies nooit gestart. 
Het onderzoek bij het Erasmus MC combineerde ik met werk bij het CBG. Dit vereiste planningsvermogen 
en flexibiliteit maar uiteindelijk lukte dit vaak wel aardig. Ook mocht ik hierdoor van extra veel collega’s 
en uitstapjes genieten. Met dank aan de collega’s van de Medische Informatica en pharmaco-epi 
groep kijk ik terug op een periode waarin ik heel veel heb geleerd en waarin we veel met elkaar 
hebben beleefd en vriendschappen zijn ontstaan. Naast alle koffiemomenten, borrels en uitjes waren 
de congressen natuurlijk een hoogtepunt! 
Leonoor, ik ben heel blij dat jij mijn paranimf bent. Jij weet als geen ander hoe het is om 
promotieonderzoek te combineren met CBG werk. Sinds het grote bedspring feest in Chicago hebben 
we veel lol gemaakt. Lang leve Whats-app en Lync wat ook best leuk is, maar het is jammer dat ik je 
niet vaker kan zien. Bedankt dat ik me altijd welkom voel bij jullie Kersen! 
Mijn dank aan de beste kamergenootjes ever. Marjolein en Gwen, jullie waren er altijd en daarom 
voelde ik me altijd extreem welkom op onze kamer. Bedankt voor de gezelligheid en de mogelijkheid 
om stoom af te blazen tijdens het hele avontuur. 
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Iedereen van de IPCI groep wil ik bedanken voor de goede tijd. Sandra, jij stond altijd voor mij 
klaar, bedankt daarvoor. Je wist altijd alles en was zo behulpzaam met administratieve zaken dat 
ik er misschien wel een beetje lui van werd. Bedankt voor alle lol en gastvrijheid, dit gaan we nog 
voortzetten. Vera, ik vind het heel leuk hoe jij als ping pong bal door het leven gaat. Bedankt voor al je 
interesse, oprechtheid en alle lol. Ik hoop dat we in de toekomst nog wat activiteiten gaan ondernemen. 
Nico jij was eigenlijk overal, Erasmus, CBG en mijn vaste maatje tijdens de NIHES cursussen. Super! 
Preci je zorgt altijd erg goed voor mij. Bedankt voor al je baksels, dat was echt wel een reden om nog 
vaker richting Rotterdam te gaan, ga zo door! Aafke, ik heb genoten met jou in Montréal en heb leuke 
herinneringen aan het beklimmen van die berg op slippers. Daniel bedankt daarvoor! Tineke bedankt 
voor al je interesse en humor, het was heel gezellig! Kartini ik heb genoten van de zondagen dat we 
beiden in Rotterdam te vinden waren. We hebben veel gelachen en frustraties gedeeld. Jouw mooie 
verhalen en relativeringsvermogen doen het altijd goed, helemaal tijdens de terugweg. Bedankt voor 
al die keren dat ik met je mee naar huis mocht rijden. Gelukkig zie ik je nog bij het CBG. Desirée 
bedankt voor het regelen van alle regeldingen rondom deze promotie. Mees en Kris, bedankt voor al 
jullie support wat betreft computers, Jerboa en ander IT en borrel zaken.
Mijn dank aan alle collega’s van de afdeling geneesmiddelenbewaking en FT-2 van het CBG. Ik heb 
ontzettend veel van jullie mogen leren en ik heb het naar mijn zin met jullie. Joris ik wil jou bedanken 
voor het vertrouwen en de tijd die je me gegeven hebt het afgelopen jaar. Deze vrijheid was precies 
wat ik nodig had om alles af te kunnen maken. Fakhredin, bedankt voor al je hulp met de eerste twee 
studies. Jou kennis is een duidelijk startpunt geweest van mijn onderzoek wat uiteindelijk tot een 
heel proefschrift heeft geleid. Bedankt! Mijn collega’s van GMB-FT2 Menno, Marjolein, Fakhredin, 
Anouk, Quirine, Alexandra en Marieke wil ik bedanken voor al hun steun de laatste maanden, de 
leuke samenwerking en de gezelligheid die er altijd is. Ook buiten werktijd. Ik ben blij dat we collega’s 
blijven. 
Veel herkenning vond ik bij andere de onderzoekers van de afdeling Sandra, Nico, Ruben, Niels, 
Alexandra, Kartini en Renate. Fijn dat ik mijn ervaringen met jullie kon delen tijdens het onderzoek, 
beoordelen en de borrels. Ruben en Niels, ik weet niet hoor, maar het is altijd leuk als jullie er zijn 
op een congres, bij het CBG, in de kroeg of op de fiets/ijsbaan en grappen maken. Bedankt voor de 
gezellige tijd en vriendschap. Ineke, bedankt voor de samenwerking aan het PPP stuk. Carlijn, bedankt 
voor al je enthousiasme en de fietstochten naar Utrecht afgelopen zomer.
Naast alle collega’s wil ik ook mijn vrienden uit Limmen e.o., Amsterdam en alle familie bedanken voor 
de interesse en steun voornamelijk afgelopen jaar. Meiden van FC Bolo en van voormalig D’Enterij 
Dames 3 jullie zorgden altijd voor genoeg afleiding na het werk met een hoop gelach. Ciska bedankt 
voor je ongelofelijke gastvrijheid in de tijd dat ik dagelijks in Rotterdam moest zijn en bij jou kon 
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